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Introduction and outline of the thesis
Heart failure is a major and increasing health problem. Heart failure is primarily a disorder of the 
elderly. In Europe, at least 10 million people suffer from heart failure and half of those patients will 
die in four years time1. The prevalence of heart failure increases rapidly with age to 10% in persons 
over 80 years2. Particularly in the elderly, the accuracy of diagnosis of heart failure by clinical means is 
inadequate1. Furthermore, radiographic methods are not accurate in the diagnosis of heart failure3. 
Yet, the importance of early diagnosis is enormous, given the fact that both mortality and symptoms 
can be reduced with carefully tailored therapy4, 5. 
Many definitions of heart failure have been used in the literature but none of them is entirely 
satisfactory. Heart failure can be defined as the state in which the heart is unable to pump blood at 
the rate needed by the metabolising tissues or can do so only with elevated filling pressures6. This 
definition may also not be perfect, but left ventricular filling pressure, or pulmonary capillary wedge 
pressure (PCWP), is an objective straight forward variable and not subject to personal judgement. 
Therefore, assessment of left ventricular filling pressure or PCWP is of great importance for diagnosing 
heart failure. Elevated PCWP greatly supports the diagnosis of heart failure, whereas normal PCWP 
strongly opposes the diagnosis of heart failure1. A major disadvantage of PCWP however, is that it has 
to be assessed invasively, which is not without risk7, 8. Furthermore, the assessment of PCWP is also 
not eligible for the follow up of heart failure patients, due to the invasive character of it.
The availability of a simple, safe, repeatable, and non-invasive technique for determining left 
ventricular filling pressure could greatly contribute to the early detection and improved treatment 
of heart failure. In 1943, the presence of an abnormal blood pressure response to Valsalva manoeuvre 
in patients with congestive heart failure was reported9. In the last two decades, correlation between 
cardiac filling pressures, i.e. PCWP, and the blood pressure response to the Valsalva manoeuvre has 
been described10-12. However, these studies were small and not restricted to the elderly, in whom 
the prevalence of heart failure is highest. Furthermore, the blood pressure response to the Valsalva 
manoeuvre was only examined scarcely in patients with atrial fibrillation and cardiac valvular disease, 
disorders that are highly prevalent in the elderly13, 14.
The general aim of this thesis was to study whether the blood pressure response to the Valsalva 
manoeuvre can be used to assess PCWP in elderly subjects.
Outline of the thesis
The physiology of the blood pressure response to the Valsalva manoeuvre, the various factors 
influencing the blood pressure response, its relation with heart failure, and the clinical utility and 
limitations in diagnosing and monitoring heart failure are reviewed in chapter 2.
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In chapter 3, the recruitment of healthy elderly subjects to participate in a study protocol, which 
included right-sided cardiac catheterisation, is described. Given the invasive character of the study, it 
was anticipated that recruitment of healthy elderly volunteers would be difficult. Therefore, we aimed 
to determine the feasibility of recruiting healthy elderly subjects for a study requiring participants 
to undergo right-sided cardiac catheterisation. Secondly, we aimed to identify the factors important 
for successful recruitment of the volunteers and what factors contributed to the completion of the 
study. In addition, we evaluated the role of nursing care for successful participation.
In order to be able to assess stroke volume during the Valsalva manoeuvre, we studied whether 
Finapres pulse wave analysis with Modelflow was a reliable non-invasive method to assess cardiac 
output by comparing non-invasive Modelflow cardiac output with thermodilution cardiac output, 
in healthy elderly subjects. This study is described in chapter 4.
A non-invasive method to increase PCWP temporarily might help us to get insight in the 
physiological blood pressure response to the Valsalva manoeuvre. Furthermore, it gives us the 
opportunity to study whether changes in PCWP can be monitored using the blood pressure 
response to the Valsalva manoeuvre. In chapter 5, a study investigating whether a temporary increase 
in PCWP could be achieved safely in healthy elderly subjects, with lower body positive pressure using 
anti-gravity garment inflation, was described.
Only little is known about normal values of PCWP in the elderly15, 16. Normal values of the 
blood pressure response to the Valsalva manoeuvre subjects have never been reported. Therefore, 
we sought to obtain normal values of PCWP and of the blood pressure response to the Valsalva 
manoeuvre in healthy elderly subjects. In addition, we studied whether elevated PCWP, which was 
effectuated by anti-gravity garment inflation, could be diagnosed in these subjects by using the 
blood pressure response to the Valsalva manoeuvre. This study is described in chapter 6.
A method to diagnose heart failure should not only be applicable in the elderly, but should also 
be applicable in common cardiac disorders such as atrial fibrillation and valvular heart disease. The 
study described in chapter 7 sought to assess whether elevated PCWP can be detected in a large 
heterogeneous group of elderly cardiac patients with various cardiac disorders, including atrial 
fibrillation and valvular heart disease, and healthy elderly controls.
Chapter 8 describes the ability of the blood pressure response to the Valsalva manoeuvre to assess 
pulmonary capillary wedge pressure sequentially, in a group of seven elderly cardiac patients.
The blood pressure response to the Valsalva manoeuvre is related to cardiac filling pressures, 
which are elevated in heart failure. Since elevated cardiac filling pressures are related to increased 
mortality, the blood pressure response to the Valsalva manoeuvre could have prognostic significance 
itself. In the study described in chapter 9, we examined the relationship between the blood pressure 
response to the Valsalva manoeuvre and mortality in a heterogeneous group of elderly cardiac 
patients undergoing right-sided cardiac catheterisation.
Chapter 10 summarises and discusses the findings of the studies mentioned above and a Dutch 
translation of the summary and discussion is given in chapter 11.
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Abstract
Especially in elderly patients, physical examination and radiographic methods are not always 
accurate in the diagnosis of heart failure. In heart failure, both mortality and symptoms can be 
reduced with carefully tailored drug therapy, which emphasises the importance of early diagnosis. 
Assessment of left ventricular filling pressure or pulmonary capillary wedge pressure (PCWP) is 
essential to diagnose heart failure. An abnormal blood pressure response to Valsalva manoeuvre in 
patients with heart failure has been described extensively. Furthermore, the blood pressure response 
to the Valsalva has been reported to correlate with PCWP and left ventricular end diastolic pressure. 
In this report, the physiology of the blood pressure response to the Valsalva manoeuvre, the various 
factors influencing the blood pressure response, its relation with heart failure, and the clinical utility 
and limitations in diagnosing and monitoring heart failure are reviewed.
Introduction
The diagnosis of heart failure relies on clinical judgment, based on history, physical examination 
and appropriate examinations1. However, especially in elderly patients, physical examination and 
radiographic methods are not always accurate in the diagnosis of heart failure1, 2. Therefore, heart 
failure can be missed easily in the elderly, in whom the prevalence of heart failure is highest. Both 
mortality and symptoms can be reduced with carefully tailored drug therapy3, 4, which emphasises 
the importance of early diagnosis.
While echocardiography is the method for assessment of cardiac function and therefore an 
important tool in the diagnosis of heart failure1, cardiac dysfunction and heart failure are not synonyms. 
Based on the definition of heart failure as the state in which the heart is unable to pump blood at the 
rate needed by the metabolising tissues or can do so only with elevated filling pressures5, assessment 
of left ventricular filling pressure or pulmonary capillary wedge pressure (PCWP) seems mandatory 
to diagnose heart failure. After all, elevated PCWP greatly supports the diagnosis of heart failure, 
whereas normal PCWP strongly opposes the diagnosis of heart failure1. However, PCWP can only be 
assessed invasively through pulmonary artery catheterisation, which is not without risks6, 7. Several 
echocardiographic approaches to assess PCWP have been proposed, but it is not clear if any of these 
methods provides the precision and accuracy needed for the evaluation of patients8. Also natriuretic 
peptides have been reported to be promising in the diagnosis of heart failure, with the opinion of 
independent cardiologists, based on clinical symptoms, as gold standard9. However, the correlation 
between PCWP and natriuretic peptides has been reported to be poor10, as was the diagnostic accuracy 
to detect elevated PCWP11.
In this report, we will review a method of assessing filling pressures and diagnosing heart failure, 
which has been reported frequently since 1943, namely the blood pressure response to a Valsalva 
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manoeuvre12. Several reports have described the presence of an abnormal blood pressure response 
to Valsalva manoeuvre in patients with congestive heart failure12-16. Furthermore, the blood pressure 
response to the Valsalva has been reported to correlate with PCWP and left ventricular end diastolic 
pressure17-25. With the availability of non-invasive continuous blood pressure measurement devices
17, 26, the blood pressure response to the Valsalva manoeuvre can be assessed easily and completely 
non-invasive. In addition, beat-to-beat blood pressure devices, such as Finapres, are available in an 
easy to use version for daily clinical practice at relatively low cost. Therefore, the blood pressure 
response to the Valsalva manoeuvre may be a very useful, and patient friendly diagnostic tool to 
detect heart failure. In addition, the manoeuvre can be repeated easily and could thus be used to 
guide therapy in heart failure patients17.
The present review is focused on the blood pressure response to the Valsalva manoeuvre in 
relation to heart failure. We will review the reports on the physiology of the blood pressure response 
to a Valsalva manoeuvre, and the various factors influencing the blood pressure response to the 
Valsalva manoeuvre. We will review and discuss the studies on the relationship of the blood pressure 
response to the Valsalva manoeuvre and cardiac filling pressures and heart failure and review its 
clinical utility and limitations in diagnosing and monitoring heart failure.
The Valsalva manoeuvre
The Valsalva manoeuvre, initially described by Antonio Maria Valsalva in his work De aure humana 
tractatus in 170427, was actually intended as a technique for expelling pus from the middle ear by 
expiration against a closed nose and mouth28. Several decades later in 1761, Morgagni published his 
book De sedibus et causis morborum per anatomen indagatis 29 including a previously unpublished 
passage of his master Valsalva: “If the glottis be closed after a deep inspiration, and a strenuous 
and prolonged expiratory effort be then made, such pressure can be exerted upon the heart and 
intrathoracic vessels that the movement and flow of the blood are temporarily arrested”30.
Physiology of the blood pressure response to a Valsalva manoeuvre
The Valsalva manoeuvre consists of sustained intrathoracic pressure, build-up by forced expiration 
against a closed glottis or closed nose and mouth. For research purposes, a mouthpiece connected to 
a pressure transducer is mostly used. A small air-leak in the mouthpiece forces the subject to continue 
blowing, which prevents closure in the glottis. An intra-oral pressure of 30 to 40 mmHg, maintained 
for at least 10 seconds, is usually applied for research goals. A standard Valsalva manoeuvre is an 
active manoeuvre with forceful contraction of the expiratory thoracic and abdominal muscles.
20
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A normal blood pressure response to the Valsalva manoeuvre can be divided into four phases
14, 16, 31-34. Phase I starts as straining commences. Both systolic and diastolic blood pressure rise abruptly 
due to reflection of the increased intra-thoracic and intra-abdominal pressure to the left heart and 
the aorta. Pulse pressure remains unchanged. The stroke volume rises because of compression of the 
left heart and the aorta, which propels the blood into the peripheral arteries. Due to the rise of blood 
pressure, a reflex bradycardia is seen.
Phase II is accompanied by a decrease in blood pressure, pulse pressure and tachycardia. The 
blood pressure decrease can be explained by a decrease in venous return to the thoracic cavity 
due to the increased intra-thoracic pressure13. The decrease in blood pressure stops after 6 to 8 
seconds after beginning of straining and blood pressure remains at a plateau thereafter. In young 
healthy subjects, arterial pressure increases in the last part of phase II, resulting in a U-shaped blood 
pressure curve. This rise of arterial blood pressure at the end of phase II is thought to be a result of 
sympathetic reflex activity35, and is enhanced by venoconstriction with a rise in peripheral venous 
pressure followed by a secondary rise in right atrial and pulmonary arterial pressures16.
Phase III begins immediately after straining, when blood pressure falls steeply due to the sudden 
decrease in pressure in the thorax. The heart rate increases during a few cycles. Phase IV is characterised 
by a blood pressure overshoot as a result of an augmented stoke volume following an increase in 
venous return after strain release. This is accompanied by peripheral arterial vasoconstriction due to 
sympathetic reflex activity and bradycardia caused by reflex parasympathetic activity35, 36. Figure 1 
shows a normal blood pressure response to a Valsalva manoeuvre.
Figure 1  Registration of a normal blood pressure response to the Valsalva manoeuvre. The upper registration is Finapres 
blood pressure. The four typical phases can clearly be distinguished (see text for explanation). The lower registration is the 
expiratory pressure during the Valsalva manoeuvre.
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Factors influencing the blood pressure response to a Valsalva 
manoeuvre
Many factors, such as age, autonomic function, position, respiration, medication, etc have been 
reported to influence the Valsalva manoeuvre. We will discuss the most important factors.
Age
Age and increasing blood pressure are associated with a non-linear decline in cardiac baroreceptor 
sensitivity, derived from heart rate response during phase IV in the Valsalva manoeuvre. The greatest 
decline occurs in the third and fourth decade with little change after 40 years of age37. The ratio of 
the heart rate in phase IV and phase II) showed a weak but statistically significant correlation with 
age (r=-0.37)38. In a study in healthy subjects, older individuals showed a greater decrease in pulse 
pressure during phase II and a similar diastolic pressure overshoot during phase IV than younger 
individuals, suggesting a lesser baroreflex-mediated vasoconstriction response39. Thus, the blood 
pressure response seems to be affected by age. Therefore, since heart failure is a disease of old age, 
studies examining the relation between Valsalva response and cardiac filling pressures should take 
age into account and include elderly subjects.
Autonomic function
A normal baroreflex function is essential for the reflex tachycardia during Valsalva phase II preventing 
an excessive decrease in blood pressure. In addition, blood pressure overshoot and bradycardia 
during phase IV rely on intact baroreflex function. When cardiac autonomic effectors are blocked 
chemically by the combination of propranolol and atropine, the reflex tachycardia during phase 
II of the Valsalva manoeuvre is blocked and the fall in blood pressure is magnified40. In patients 
with spinal cord transection,41 with diabetic neuropathy42-44, or other conditions that impair the 
autonomic system, the heart rate response to the Valsalva manoeuvre is diminished, and the phase 
II fall in arterial blood pressure is exaggerated45. The overshoot in phase IV is absent and the reflex 
bradycardia is lacking in diabetic patients with clinical evidence of autonomic neuropathy46.
Depth of inspiration preceding straining, expiratory pressure and strain duration
The decrease in blood pressure and the accompanying tachycardia in phase II and the hypertension 
and bradycardia in phase IV increase with increasing strain pressure and with increasing duration of 
straining34, 40. Furthermore, the depth of the inspiration preceding the Valsalva manoeuvre affects 
the blood flow into the lungs; in all phases of the Valsalva manoeuvre, blood pressure is lower after 
a deeper inspiration34.
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Postural position
In order to detect subclinical heart failure, the Valsalva manoeuvre should be performed in a 
supine position, because in patients with mild cardiac disease a normal response to the Valsalva 
manoeuvre in standing position became abnormal in supine position, and even more abnormal 
when the legs were elevated16. This was explained by a volume shift from the lower body to the 
thoraco-abdominal space, providing filling of the left ventricle during the manoeuvre. Because of 
both reflex and mechanical factors, leaning forwards during the Valsalva manoeuvre was reported to 
provide circulatory stability during straining, while in order to test autonomic function, the Valsalva 
manoeuvre is preferably performed in a leaning backward position47, 48.
Medication
Beta-blockers
Contradictory findings of beta-blockers on the Valsalva manoeuvre have been reported. While 
resting heart rate was lower with beta-blockers, removal of beta-adrenergic activity did not influence 
the direction and magnitude of heart rate response to changes in arterial blood pressure in healthy 
men49, 50. However, timolol, a beta-adrenoreceptor blocking drug, caused a significant decrease in 
tachycardia in phase II and a decrease in blood pressure overshoot with diminished bradycardia 
in phase IV in patients with hypertension51, 52. An absence of decrease in blood pressure during 
phase II, a pattern is also seen in patients with congestive heart failure, was noted after intravenous 
administration of timolol. Overriding alpha-receptor activity, and not congestive heart failure might 
be the explanation for this phenomenon, because there were no clinical signs of heart failure in these 
patients51. Thus, beta-blocking drugs appear to have substantial influence on the cardiovascular 
response to a Valsalva manoeuvre, particularly on phase IV blood pressure overshoot and reflex 
bradycardia, while the reflex heart rate change in response to blood pressure changes stays intact.
Angiotensin converting enzyme (ACE) inhibitors
In healthy young men, captopril caused less tachycardia in phase III and did not modify phase IV 
overshoot when comparing to placebo53, leaving unclear, whether this was a direct effect on the 
Valsalva manoeuvre or caused by reduction of left ventricular filling pressures. In normotensive 
subjects, enalapril, lisinopril, captopril, perindopril, and cilazapril did not produce significant 
changes in the Valsalva ratio, and there were no effects on the sympathetically mediated blood 
pressure overshoot54, 55. Thus, baroreflex function appears to be unaltered following ACE inhibition. 
In hypertensive patients, perindopril caused lowering of systolic blood pressure during all phases of 
the Valsalva manoeuvre56.
Calcium channel blockers
In hypertensive patients, calcium-channel blockers from the dihydropyridin group have been 
reported to reduce blood pressure in all phases of the Valsalva manoeuvre, while the relative 
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blood pressure variation during the phase of the Valsalva manoeuvre and the changes in heart rate 
remained unchanged57, 58. 
Diuretics
Several investigators administered furosemide to induce a decrease in central blood volume and 
to decrease left ventricular filling pressures, which affected the blood pressure response to the 
Valsalva manoeuvre17, 59, 60. Also indapamide caused a significant larger decrease in blood pressure 
during phase II of the manoeuvre with a significant higher heart rate compared to placebo therapy61. 
However, it remains unclear whether diuretic therapy influences autonomic reflexes itself apart from 
effects on intravascular volume.
Adrenergic agents
Norepinephrine, an arterial vasoconstrictor, causes elevation of the central venous pressure. This 
may explain why, during a Valsalva manoeuvre, the decline of arterial pressure in phase II is later and 
less pronounced after norepinephrine administration. Consequently, also the overshoot in phase IV 
is less pronounced35.
Although opposite effects of identical drugs have been reported, we can conclude that cardiovascular 
drugs, and especially beta-blockers may influence the Valsalva manoeuvre significantly. This should 
be kept in mind when investigating the relationship of blood pressure response to the Valsalva 
manoeuvre and congestive heart failure.
Pulmonary emphysema
In patients with pulmonary emphysema, the peripheral pulse almost completely disappeared during 
the Valsalva straining phase and the time for the pulse pressure to return to baseline level was 
prolonged62. Several explanations for these findings were proposed: emphysema-induced elevated 
pressures in the pulmonary vessels could render the right ventricle unable to maintain output during 
straining; secondly, the veins of emphysema patients might be less reactive and less able to increase 
pressure in response to a Valsalva manoeuvre; thirdly, barrel chest deformities may expose more 
surface of the caval vein to high intra-thoracic pressures during a Valsalva manoeuvre, and thereby 
make it more susceptible to collapse.
The blood pressure response to the Valsalva manoeuvre, filling 
pressures and heart failure: pathophysiology
In 1943, it was reported that pulse pressure drops during the Valsalva manoeuvre, followed by an 
increase in pulse pressure after strain release12. However, in a case of decompensate heart failure due 
24
Chapter 2 The Valsalva manoeuvre as a non-invasive instrument for diagnosis of heart failure: a review
25
to aortic regurgitation, there was no decrease in blood pressure during the Valsalva manoeuvre. This 
phenomenon was described again in a larger group of healthy subjects and heart failure patients14, 15. 
While healthy subjects showed a decrease of pulse pressure, subjects with heart failure showed no 
change of pulse pressure during the Valsalva manoeuvre and the overshoot was also absent. In the 
most severely ill patients with the highest venous pressures, the pulse pressure even increased during 
the Valsalva manoeuvre14. The absence of decrease of blood pressure was explained by elevation of 
venous pressure leading to maintenance of filling of the heart, in spite of the increase in intrathoracic 
pressure12. A study of circulation times during the Valsalva manoeuvre using intravenous radioactive 
phosphate supported this explanation13. In normal subjects, circulation time was increased during 
the expiratory effort of a Valsalva manoeuvre, while in heart failure patients, circulation time was 
only slightly retarded. Furthermore, in a normal subject, radio-opaque contrast was stagnated in 
the veins outside the thoracic cavity during straining, while in a heart failure patient, the contrast 
continued to flow freely towards the right atrium13.
However, in another report, an abnormal response was considered to be caused not solely by 
a venous blockage effect, but by both left and right-sided heart failure16. The difference between a 
normal and abnormal blood pressure response to the Valsalva manoeuvre was considered to depend 
on the slope and the position on the (Starling) ventricular function curve. On this ventricular 
function curve, left ventricular stroke work, of which pulse pressure and mean arterial pressure are 
approximate indices, is plotted against left ventricular filling pressure. With high filling pressures, 
i.e. at the flattened part of this curve, a fall in filling pressure will affect stroke work only minimally. 
The slope of the Starling curve is dependent on the severity of the heart disease. In patients with 
elevated left ventricular filling pressures, a decrease in filling pressure due to straining will not result 
in a decrease in arterial blood pressure. In severe mitral stenosis, the relationship of pressure to flow 
across the mitral valve becomes flat and a decrease in the pressure gradient due to straining will also 
not result in a decreased flow across the valve and blood pressure will not decrease.
In heart failure, the autonomic system is altered, with an increase in sympathetic activity, 
associated with increased plasma noradrenalin, and a reduction in vagal activity63. Since it has been 
demonstrated that infusion of noradrenalin results in a attenuated decrease in blood pressure 
during the Valsalva manoeuvre35, the absence of decrease in blood pressure in heart failure may 
be explained by alteration of the autonomic system. However, while severe vasoconstriction can 
result in an intermediate abnormal response, it is not the sole cause of an abnormal blood pressure 
response to the Valsalva manoeuvre16.
The degree of abnormality of the blood pressure response did not appear to correlate with the 
type of heart disease, but seemed to vary with the severity of congestion as judged by clinical criteria15. 
The pattern of blood pressure response to the Valsalva manoeuvre in patients with valvular heart 
disease was not correlated with the severity of obstruction at the valvular orifice, but with the degree 
of elevation of right ventricular end diastolic or right atrial pressure. Furthermore, an abnormal blood 
pressure response has been reported to correlate with various cardiac related function tests such as 
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vital capacity, circulation time, clinical functional class and cardiac enlargement, and furthermore 
to elevated PCWP and pulmonary congestion16. Figure 2 shows a “square wave” blood pressure 
response, with an absence of decrease of blood pressure, to a Valsalva manoeuvre in a subject with 
congestive heart failure.
Figure 2  Registration of an abnormal blood pressure response, which is seen in heart failure. The upper registration is 
Finapres blood pressure. The absence of decrease in blood pressure during phase results in a typical “square wave” response. 
The lower registration is the expiratory pressure during the Valsalva manoeuvre.
Quantitative relationship between the blood pressure response to the Valsalva 
manoeuvre and cardiac filling pressures
Throughout the years, several studies have been reported describing a relationship between the 
decrease of blood pressure during the Valsalva manoeuvre and left ventricular end-diastolic pressure 
and PCWP17-25. The methods used to measure the blood pressure response to the Valsalva manoeuvre 
were not uniform nor was the strength of correlation between the blood pressure response to the 
Valsalva manoeuvre and cardiac filling pressure.
Invasive assessment of the blood pressure response to the Valsalva manoeuvre
The decrease of pulse pressure, which was measured in the aorta, during the strain phase of the 
Valsalva manoeuvre, correlated with left ventricular end-diastolic pressure (r=0.71) and PCWP 
(r=0.77) in patients for elective cardiac catheterisation20. In patients on mechanical ventilation, 
blood pressure was measured in the radial artery, and the ratio of systolic blood pressure of the last 
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beat during the manoeuvre divided by the systolic blood pressure before the manoeuvre correlated 
linearly with the PCWP (r=0.87)22.
In only one report, the blood pressure response to the Valsalva did not correlate with left 
ventricular end-diastolic pressure23. Blood pressure was measured in the aorta and the pulse 
amplitude ratio, the minimal pulse pressure divided by maximum pulse pressure during the strain 
phase of the Valsalva manoeuvre did however, correlate, though not very strongly, with mean right 
atrial pressure.
Non-invasive assessment of the blood pressure response to the Valsalva 
manoeuvre
Vericor, a plethysmographic device, was used to measure blood pressure non-invasively at a finger 
in clinically stable and unstable patients17. The ratio of the minimal amplitude to the maximal 
amplitude (systolic pressure) of the blood pressure response to a Valsalva manoeuvre was called 
the pulse amplitude ratio. Pulse amplitude ratio correlated linearly and strongly with mean PCWP 
(r=0.89 for stable patients and r=0.92 for unstable patients). Drug induced changes in PCWP were 
also clearly correlated to changes in the pulse amplitude ratio. Using the same method, a sensitivity 
and specificity of predicting PCWP higher than 18 mmHg of 91% and 100%, respectively, has been 
found in male severe heart failure patients18. Furthermore, a strong correlation with left ventricular 
end diastolic pressure (r=0.86) has been reported19. In another study, blood pressure was also 
measured non-invasively at a finger with a device called Finapres, in stable patients undergoing 
right-sided cardiac catheterisation. The ratio of pulse pressure of the last two and the first three 
beats of the strain did correlate with PCWP (r=0.87)25. Comparable results were found when using 
a non-invasive device to assess the response to the Valsalva manoeuvre using pulse densitography 
at the ear21.
In another report, blood pressure was measured sphygmanometrically. A Valsalva manoeuvre was 
defined normal if systolic blood pressure decreased below control level24. PCWP and left ventricular 
end diastolic pressure were significantly higher in patients with an abnormal Valsalva manoeuvre. 
Sensitivity and specificity of the Valsalva manoeuvre of detecting a PCWP or end-diastolic pressure 
higher than 15 mmHg was 100% and 91%, respectively. Interestingly, there was no difference in left 
ventricular ejection fraction in patients with a normal and those with an abnormal response.
Clinical utility
In most of the reports describing the relation between the blood pressure response to the Valsalva 
manoeuvre and cardiac filling pressures, patients with arrhythmias were excluded19, 22, 24, 25, and only 
four patients were reported to have atrial fibrillation17, 21. In the general population, the prevalence 
of atrial fibrillation in the elderly is around 6%64 while in heart failure patients, the prevalence varies 
from 10% in NYHA class II to 50% in NYHA class IV patients64. Exclusion of patients with atrial 
fibrillation would therefore be a serious limitation of a tool for diagnosing heart failure. Furthermore, 
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in studies on the quantitative relationship of the blood pressure response to the Valsalva manoeuvre, 
only eleven patients, nine with aortic valve stenosis25 and two with mitral stenosis20, 23, were reported 
to suffer from cardiac valve abnormalities. The prevalence of valvular heart disease is high; in 
randomly selected subjects from 55 to 86 years old, the prevalence of severe aortic valve calcification 
was reported 13%, and of (mild) aortic regurgitation it was 29%65. Therefore, further research is 
needed on the relationship of the blood pressure response to the Valsalva manoeuvre and cardiac 
filling pressures, especially in the elderly and without exclusion of those with atrial fibrillation and 
with valvular heart disease.
Reproducibility
Reproducibility of the Valsalva manoeuvre has been reported only scarcely. Analysis of two successive 
Valsalva manoeuvres in a small group of healthy subjects and non-cardiac patients, revealed a 
coefficient of variation of 11% for phase II pulse pressure change66. A maximum difference of 18% of 
any parameter was reported in a study on repeated Valsalva manoeuvres in patients, undergoing right-
sided cardiac catheterisation21. Recently, the coefficient of variation of the decrease in pulse pressure in 
three subsequent Valsalva manoeuvres of 14% has been reported in 28 healthy elderly subjects67.
Prognostic significance of an abnormal Valsalva manoeuvre
An abnormal blood pressure response to the Valsalva manoeuvre is correlated with heart failure, and 
signifies elevated filling pressures and congestion. However, only little is known about the prognostic 
implications of an abnormal blood pressure response to the Valsalva manoeuvre in patients with 
heart failure, nor about the implications of normalisation of this response for prognosis68, 69.
In haemodialysis patients, it was suggested that the Valsalva manoeuvre might identify patients 
at risk of acute congestive heart failure. In those patients who experienced an episode of acute heart 
failure, the decrease of blood pressure during the Valsalva manoeuvre was significantly smaller than 
in the other patients, while no differences in clinical assessment were found68.
In survivors of first myocardial infarction, absence of decrease in blood pressure during a bedside 
Valsalva manoeuvre, which was performed 6 weeks post infarction, was related to a low radionuclide 
ejection fraction and was highly predictive of future sudden cardiac death69. Therefore, the absence 
of a decrease in blood pressure during a Valsalva manoeuvre may be predictive of both development 
of acute heart failure in the near future as well as long-term cardiac mortality. Further investigations 
will have to substantiate these findings.
Safety of the Valsalva manoeuvre
There have been serious doubts concerning the safety of the Valsalva manoeuvre throughout 
the years. Long ago, death as a complication resulting from excessive straining or life threatening 
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arrhythmias due to the Valsalva manoeuvre were reported70, 71. Indeed, the Valsalva manoeuvre can 
produce syncope even in normal subjects. Syncope could be induced in the majority of healthy 
volunteers through a sequence of hyperventilation, orthostasis, and the Valsalva manoeuvre72. In 
patients with ischemic heart disease, the use of a Valsalva manoeuvre is discouraged because of a 
supposed accompanying fall in coronary blood flow73. On the other hand, the Valsalva manoeuvre 
was reported as a non-pharmacological method to relief angina pectoris, presumably caused by 
decline in left ventricular end-diastolic pressure with sustained diastolic coronary blood flow, 
suggesting that the Valsalva manoeuvre reduces determinants of cardiac oxygen demand, rather 
relieving acute ischaemia than aggravating it74-76. Furthermore, in more than 2100 patients with severe 
heart disease, no myocardial ischaemia or any form of hemodynamic, dysrhythmic, or conduction-
system instability nor neurological symptoms were observed during carefully monitored single or 
repeated Valsalva manoeuvres17.
Conclusions
During the last five decades, a multitude of reports has described a relationship between the blood 
pressure response to the Valsalva manoeuvre and cardiac filling pressures. Already in 1943, it was 
stated that the vast amount of experimentation and study devoted to the Valsalva manoeuvre had 
lead to conflicting and bewildering results, due to the fact that many different persons experimented 
with many totally different techniques, usually upon different groups of subjects30. Even nowadays, 
the Valsalva manoeuvre is still surrounded with a lot of controversies. 
In broad outlines, a normal blood pressure response with the typical four phases in healthy 
subjects and a square wave response in patients with clinically manifest heart failure has been 
reported consistently. According to most studies, the square wave response is due to an increased 
intrathoracic volume, though studies conflict regarding the correlation of this response with increases 
in right-sided or left-sided intra-cardiac pressures. All reports are, however, consistent in the fact that 
a square wave blood pressure response to the Valsalva manoeuvre is seen in severely ill patients and is 
a sign of severely impaired circulation. It is unclear whether an intermediate response to the Valsalva 
manoeuvre has clinical and perhaps prognostic implications. Furthermore, the intra-individual and 
intra-individual variability of the blood pressure response to the Valsalva manoeuvre could hamper 
exact estimation of cardiac filling pressures. Finally, the manoeuvre is influenced by a multitude 
of variables such as patient age, the use of cardiovascular drugs, and the presence of pulmonary 
emphysema or autonomic dysfunction. These difficulties might trouble a correct interpretation of 
the Valsalva blood pressure response. Further research is clearly needed to investigate the utility of 
the Valsalva manoeuvre in diagnosing and monitoring heart failure, with particular attention to the 
factors mentioned before.
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Abstract
Background and aims: Heart failure is primarily a disorder of the elderly. To investigate a non-
invasive method to diagnose heart failure in the elderly, right-sided catheterisation was needed in 
healthy elderly subjects. We studied the feasibility of recruitment of healthy elderly subjects for this 
invasive investigation and aimed to identify the factors important for recruitment and for successful 
participation.
Methods: Healthy subjects, aged ≥65 years, were invited by advertisement in a local newspaper 
to participate in an invasive study, preceded by extensive medical examination. An experienced 
research nurse provided coaching and care on an individual basis. Motivation to participate, 
satisfaction, and the expected and perceived burden were assessed with a questionnaire before and 
after catheterisation.
Results: From 180 subjects responding, 53 were invited for screening of whom 38 were included. 
Cardiovascular examination was the most important reason for participation. The questionnaire 
showed considerable satisfaction about the information and care given and about participating in 
the study in general.
Conclusions: Recruitment of healthy elderly subjects for an invasive cardiovascular study is feasible. 
Individual coaching contributed to the satisfaction experienced. The appointment of an experienced 
research nurse appears important for successful recruitment and participation of healthy elderly 
subjects in an invasive cardiovascular study.
Introduction
Heart failure is a major and increasing health problem. It is estimated that in the United States and 
Western Europe together about 15 million patients suffer from heart failure1, 2. The prevalence of 
heart failure increases rapidly with age and is primarily a disorder of the elderly3, 4. The prognosis of 
patients with heart failure is poor5, however, the prognosis can be improved with early diagnosis and 
treatment6, 7, which emphasises the importance of early diagnosis.
Especially in the elderly, physical examination and radiographic methods are not very sensitive 
for detection of heart failure and the diagnosis can be missed easily8, 9. The availability of a simple, 
safe, repeatable, and non-invasive bedside technique for determining left ventricular filling pressures 
could greatly contribute to the early detection and improved treatment of heart failure.
In heart failure, pulmonary capillary wedge pressure (PCWP), which is a measure of left 
ventricular filling pressure, is elevated. PCWP is normally assessed by right-sided catheterisation 
which is not without risks of morbidity and mortality10, 11. Therefore, a non-invasive method to assess 
PCWP is preferable. The blood pressure (BP) response during performance of a Valsalva manoeuvre 
is related to PCWP12-14. Since BP can be measured non-invasively at a finger15, this BP response can be 
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used to diagnose heart failure non-invasively. However, the relationship between PCWP and the BP 
response to the Valsalva manoeuvre has never been studied specifically in the elderly in whom the 
prevalence of heart failure is highest. Furthermore, necessary reference values acquired from healthy 
elderly subjects are absent. Therefore, we wanted to investigate the relationship between PCWP and 
the BP response to the Valsalva manoeuvre not only in elderly cardiac patients but in healthy elderly 
subjects as well.
Given the invasive character of the study, it was anticipated that recruitment of healthy 
elderly volunteers would be difficult. Therefore, this study aimed to determine the feasibility of 
recruiting healthy elderly subjects for a study requiring participants to undergo right-sided cardiac 
catheterisation. Secondly, we aimed to identify the factors important for successful recruitment 
of the volunteers and what factors contributed to the completion of the study. In addition, we 
evaluated the role of nursing care for successful participation.
Methods
Recruitment
To recruit healthy elderly subjects over the age of 65, an advertisement in a local newspaper 
(circulation 203,000) requested participation in an invasive study. The advertisement presented 
the logo of the University Medical Center Nijmegen and the Netherlands Heart Foundation and 
mentioned an extensive medical examination prior to inclusion in the study. The allowance was set 
at Euro 112.50 and costs of travel and parking were reimbursed. Subjects responded by telephone 
and a brief medical history was taken. The study was briefly explained after which the subjects 
were invited to the outpatient clinic of the Department of Geriatric Medicine. At the first visit, 
the research protocol was thoroughly explained by the research fellow (J.J.R.) and written study 
information was given (see Appendix). The risk of possible complications of the catheterisation was 
mentioned explicitly and repeatedly.
During the entire study, a research nurse (A.B.) with extensive experience in geriatric nursing and 
specialist training in care for the elderly, was seconded to the study. Based on the experience of the 
research nurse, all subjects were screened for evident cognitive disorders. At the end of the first visit, 
the research nurse verified the subject’s understanding of the protocol and the risks involved. The 
understanding of the protocol was verified by asking whether all information given by the research 
fellow was clear. The subject was explicitly given the opportunity to ask questions. Furthermore, 
the research nurse asked questions to verify the understanding; the subjects were asked to repeat 
essential information (e.g. risks) in their own words. The subjects underwent a screening programme 
consisting of medical history, physical examination, electrocardiography, blood laboratory analysis, 
bedside spirometry, bicycle stress-electrocardiography, and echocardiography. Table 1 shows the 
screening programme in detail. Exclusion criteria were: history or signs of myocardial infarction, stable 
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or unstable angina pectoris, rhythm or conduction abnormalities, cardiomyopathy, congestive heart 
failure, moderate or severe valve stenosis or regurgitation, left ventricular hypertrophy (all according 
to ACC/AHA Practice Guidelines); history of hypertension, defined as systolic blood pressure (BP) in 
rest >140 mmHg and/or diastolic BP >90 mmHg or use of anti-hypertensive medication16, and any 
other serious disease or the use of medication with cardiovascular effects. A history or symptoms 
of neurological disorders (like Morbus Parkinson), diabetes mellitus, and chronic obstructive 
pulmonary disease were also exclusion criteria because these diseases may influence the BP response 
to the Valsalva manoeuvre. Subjects who were found to be ineligible to participate in this study 
were given an extensive explanation about the reason for exclusion. A letter informed the General 
Practitioner of each subject about the findings of the screening programme. All subjects gave written 
informed consent. The Ethics Committee for Research on Human Subjects of the University Medical 
Center Nijmegen approved the investigation under the condition that an experienced cardiologist 
(W.R.M.A.) would perform all catheterisations. The principles outlined in the Declaration of Helsinki 
were followed17.
Protocol
Prior to the catheterisation, the subjects were asked to refrain from caffeine and nicotine from 
midnight. In the catheterisation-laboratory, an anti-Gravity (anti-G) garment was applied. This anti-
Gravity garment consists of inflatable trousers and was used to increase PWCP temporarily18, later on 
in the protocol. A pulmonary artery catheter was inserted through an antecubital vein under local 
anaesthesia, and positioned in the left or right pulmonary artery. Because of the anti-G garment 
covering the upper legs and lower abdomen, the antecubital approach was chosen instead of the 
femoral approach. The following hemodynamic variables were measured: right atrial pressure, right 
ventricular pressure, pulmonary artery pressure, PCWP, and cardiac output. With the catheter left 
in non-occlusive position in the pulmonary artery, the subject was transported to the coronary 
care unit (CCU). After a five-minute rest period in supine position, PCWP was measured before, 
immediately after, and at four minutes after inflation of the anti-G garment. Just after each PCWP-
measurement, the subject was asked to perform a Valsalva manoeuvre. After deflation of the anti-G 
garment, the subject was placed in semi-recumbent position. Following a five-minute rest period, an 
identical procedure was performed as in the supine position. 
At the end of the protocol, the catheter was removed from the arm and a compress was applied. 
The catheterisation and the measurements lasted from 8:30 to 10:30. Two hours after removal of the 
catheter, the subject was discharged from hospital. The entire protocol took 4 hours.
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Table 1  Screening programme in detail
Medical history
Including: activities of daily living (ADL)
use of medication
use of alcohol
allergies
Complete physical examination
Including: blood pressure in supine and standing position
length
weight
Electrocardiogram
Including: rhythm
signs of previous myocardial infarction
conduction
ventricular hypertrophy
Blood tests
Including: haemoglobin
hematocrit
leukocytes
thrombocytes
International Normalised Ratio (INR)
sodium
potassium
aspartate aminotransferase (ASAT)
alanine aminotransferase (ALAT)
lactate dehydrogenase (LDH)
alkalic phosphatase
gamma glutamyl transferase
creatinin
ureum
glucose
Bedside spirometry
Including: forced expiratory volume 1 sec  (FEV1)
vital capacity (VC)
Bicycle stress-electrocardiography
Including: maximum level of exercise
maximum heart rate
maximum systolic/diastolic blood pressure
angina pectoris
reason of termination of test
rhythm
conduction
repolarisation
Echocardiography
Including: peak velocity early diastolic rapid filling wave (E)
peak velocity late diastolic atrial contraction wave (A)
E/A ratio
deceleration time
end systolic volume
end diastolic volume
ejection fraction (Simpson)
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Coaching
The geriatric experience of the research nurse was considered necessary in view of the specific 
demands of working with elderly volunteers as earlier studies have shown19, 20. The demands in this 
study included assessing the understanding in the subjects of the protocol and the risks, giving 
information custom-made to the individual and providing individual support by physical presence 
during the procedures.
The telephone calls were handled by the research nurse or the research fellow based on availability. 
The initial eligibility for the study was established in this conversation. The research nurse was 
present at the initial visit, the screening procedure, and the cardiac catheterisation. At the initial visit, 
the research nurse assessed the cognitive capability of the subjects to comprehend the implications 
of participating in the study and made sure that the procedure and the risks involved were fully 
understood. During every next visit to the clinic for the screening procedures, she repeated the 
extensive information about the study, the procedure and the risks, and checked for understanding. 
This was adapted to the knowledge and cognitive competence of each individual subject. All subjects 
were explicitly invited to ask questions at every contact. Their right to withdraw from the study at 
any time without giving a reason was emphasised. During the cardiac catheterisation, the research 
nurse stayed by the side of the subject to provide reassurance and to explain the proceedings as they 
progressed. At the CCU, the research nurse instructed the subject about the Valsalva manoeuvre 
and made sure the subject was as comfortable as possible. After the procedure, the subject stayed 
in the CCU for two hours under observation of the research nurse in order to guard against possible 
complications and to evaluate the subject’s experience of the procedure. Before discharge, verbal 
and written instructions were given in case a post-procedural haemorrhage or other complications 
occurred. In the evening following the protocol and the day afterwards, a follow-up telephone 
call was made by the research nurse to check on late post-procedural complications such as a 
haematoma or a painful arm.
The research nurse was easily accessible for questions throughout the entire study. In case of 
absence of the research nurse, a telephone-answering machine was stand-by and all calls were 
returned within 24 hours. In case of difficulties, transportation to and from the clinic was arranged. 
During the whole study, the appointments in the clinic were adapted to the personal needs and 
wishes of the individual subject. 
Questionnaire
Before and after cardiac catheterisation, the satisfaction with participation in the study and the 
expected and experienced burden was collected by using an anonymous 15-item questionnaire. 
The key-questions and possible responses are presented in Table 2. The pre- and post questionnaires 
were handed to the subject by the research nurse, after the last test of the screening programme and 
after discharge from the CCU respectively. An addressed and postage-paid envelope was supplied for 
returning the questionnaires.
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Table 2  Key questions from the questionnaire
Translation in English of the original questionnaire
Pre-test questions
Why do you take part in this study? (more than one answer possible)
 curiosity, interest in science
 contribution to the advancement of science 
 the extensive cardiovascular examination
 because the study is sponsored by the National Heart Foundation (NHF)
 contribution to the improvement of health care
 the allowance
How did you experience the burden of the screening procedure?
(physical examination, bicycle stress-electrocardiography, 
echocardiography)
 very intrusive
 moderately intrusive
 somewhat intrusive
 not intrusive
How do you estimate the burden of the heart catheterisation?  very intrusive
 moderately intrusive
 somewhat intrusive
 not intrusive
Would you advise others to participate in this study?  yes
 no
 don’t know
The information given by the physician was:  more than sufficient
 sufficient
 insufficient
The information given by the nurse was:  more than sufficient
 sufficient
 insufficient
Post-test questions
The information given before the catheterisation by the physician proved 
to be:
 more than sufficient
 sufficient
 insufficient
The information given before the catheterisation by the nurse proved 
to be:
 more than sufficient
 sufficient
 insufficient
How do you rate the burden of the catheterisation?  very intrusive
 moderately intrusive
 somewhat intrusive
 not intrusive
Did the entire study impose:  less of a burden than expected
 more of a burden than expected
 the same burden as expected
Would you participate again in this study?  yes
 no
 do not know
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Would you advise others to participate?  yes
 no
 do not know
The pain experienced during the catheterisation was: nothing                                                       a lot 
0----1----2----3----4----5----6----7----8----9----10
Data handling and analysis
The anonymous pre- and post-test questionnaires were coded to make a paired comparison possible. 
In order to test for pre- and post-test individual differences, the Sign-Test was used. A two-sided 
p-value ≤0.05 was considered to be significant. Values are expressed as mean±SD.
Results
Recruitment
Within a period of two days, 180 subjects responded to the advertisement by telephone. The flow 
chart in Figure 1 shows the enrolment of healthy elderly subjects in the study protocol. By phone 
a brief medical history was taken and 35 subjects were excluded from participation based on the 
use of cardiovascular medication. After being informed about the possible risks of the cardiac 
catheterisation, 13 subjects decided not to participate in the study. We aimed at a number of 30 
subjects actually undergoing catheterisation. We expected that of 50 subjects 20 subjects would be 
excluded. Therefore, of the remaining 132 subjects, the first 52 consecutive eligible subjects were 
invited to the outpatient clinic of the Department of Geriatric Medicine. The data of most of the 
remaining respondents (n=80) were, with their permission, kept in a database for future research. 
After the screening programme, 14 subjects were excluded, 38 elderly subjects (37 Caucasians and 
one Asian, mean age 70±4, range 65 - 81 years) were eligible and included in this study. After inclusion, 
one female subject, aged 67 years, withdrew from the study because of fear of the catheterisation. 
Scheduled for catheterisation were 37 subjects: 24 males and 13 females. In five female subjects, 
insertion of the catheter was not possible due to spasms of the antecubital vein. The entire protocol 
was completed by 32 subjects.
Two minor complications occurred. In one female subject, a supra-ventricular tachycardia 
occurred during introduction of the catheter into the heart, which ended after intravenous 
verapamil. She recognised the palpitations from the past, yet they always had been diagnosed as 
hyperventilation. One other female subject developed phlebitis at the antecubital vein three days 
after the catheterisation, which recovered completely after oral flucloxacillin.
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Figure 1  Flow diagram of enrolment of subjects. Between brackets numbers of (male/female); γgt, gamma-glutamyl-
transferase.
Responded to
advertisement
n=180 (134/46)
Included
n=38 (24/14)
Completed protocol
n=32 (24/8)
Excluded
n=14 (9/5)
Hypertension n=3 (1/2)
Left/right bundle branch block n=5 (3/2)
Ectopic atrial rhythm n=1 (1/0)
Previous myocardial infarction n=2 (1/1)
Positive stress-electrocardiography n=2 (2/0)
Alcohol abuse with elevated γgt n=1 (1/0) 
Did not complete protocol
n=6 (0/6)
Withdrew n=1 (0/1)
Failed insertion of catheter n=5 (0/5)
Invited to screening
n=52 (33/19)
Not invited to screening
n=128 (101/27)
Withdrew n=13 (10/3)
Use of cardiovascular medication n=35 (30/5)
Included in database for future use n=80 (61/19)
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Results of the questionnaire
All subjects in whom insertion of the catheter was attempted at the catheterisation laboratory 
were asked to complete both the pre-test and post-test questionnaire, regardless whether the 
entire protocol was completed. The pre-test questionnaire was returned by 95% and the post-
test questionnaire by 97% of all 37 subjects. The reasons to participate in the study are presented 
in Figure 2; the expected and the experienced burden of the catheterisation are shown in Figure 
3. The individual paired scoring of the burden showed no significant difference before and after 
catheterisation (p=0.30). Of all subjects, 80% found the procedure less burdensome than expected 
and 20% as expected. Given the opportunity, 69% would participate again in this study, 23% 
answered that they would consider participating again and 8% of the subjects would not because 
they now had the information they wanted to acquire (i.e. their physical well being).
The individual paired scoring of the question “Would you advise others to participate?” showed 
no significant difference before and after catheterisation (p=1.0) Before catheterisation, 80% of the 
subjects said that when asked, they would advise other healthy elderly volunteers to participate 
and 20% did not know what to advise. After catheterisation 83% said they would advise others to 
participate, 3% said they would not, and 14% did not know. The satisfaction with the information 
given by the research fellow and by the research nurse was asked and judged as more than sufficient 
by over 80% of the subjects. The burden of the screening procedure was rated as somewhat (3%) to 
not intrusive (97%). After the catheterisation, the subject was asked to score the pain experienced 
during the procedure on a zero (no pain) to ten (severe pain) scale. The mean pain score was 
1.12±1.55 (mean±SD); 50% of all subjects experienced no pain (score 0); the highest score was 6, 
mentioned by 3% of all subjects.
Figure 2   Reasons to participate in the study mentioned by the subjects in the questionnaire. More than one answer was 
possible.
Allowance
Improvement of healthcare
Sponsoring by NHF 
Cardiovascular examination
Contribution to science  
Interest in science 
number of subjects 
0            5 10 15 20 25 30
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Figure 3  Expected and experienced intrusiveness of the catheterisation. The black columns represent the expectation 
before catheterisation. The white columns represent the experienced intrusiveness as stated after the catheterisation.
Discussion
The main finding of this study is that it was very feasible to recruit the number of healthy elderly 
subjects needed for a cardiovascular study requiring right-sided cardiac catheterisation. The large 
number of respondents within a two-week period following an advertisement exceeded our 
expectations.
To our knowledge, this was the first time a study required elderly volunteers to undergo an 
invasive procedure such as a cardiac catheterisation. Several large (non-invasive) studies, like the 
Cardiovascular Health Study (CHS) and the Systolic Hypertension in the Elderly Program (SHEP-
study), reported on the experiences with recruitment and participation of elderly in cardiovascular 
research20-22. In the SHEP-study, different recruitment strategies were used in order to obtain the 
large number of participants (4,800) necessary. These strategies included extensive public relations 
measures, mass mailing campaigns, mass screening and chart review in clinics. The CHS showed 
that addressing the personal needs of the elderly was important for recruitment: e.g. providing free 
transportation, allowing relatives and friends to participate, and arranging replacement care for ill 
family members.
The results regarding motivation in our study were comparable to those of the CHS in which 
the most common reasons for participation were related to personal health and altruistic motives 
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such as improving the health of others or contributing to medical science20. Similarly in the SHEP-
study, where they surveyed older subjects’ reasons to join a clinical trial, the most important reasons 
for participation were contribution to science (96%), improvement of health of others (96%) and 
improvement of their own health (93%)19. Van Gelderen et al. confirmed these findings by stating 
that, contrary to young volunteers, older subjects participated because of the medical examination 
and the benefit it might result in for others23. 
Other investigators studying the factors influencing the willingness of subjects over 60 to 
participate in medical research, found that the more intrusive a study, the least subjects are inclined 
to participate without an allowance24. We learned, however, that an allowance of Euro 112.50 
played no significant role for elderly volunteers as reason to participate. The same investigators also 
found that the opportunity to learn had a positive effect on the participation in a study24. This is in 
agreement with the interest in medical science mentioned by a third of our subjects.
Therefore, the recruitment of healthy elderly volunteers must focus on attractive reasons for 
subjects to participate such as a contribution to one’s health, altruistic motives, an opportunity to 
participate in the world of science, and to be an essential part of scientific cardiovascular research. 
To acknowledge the last two motives, we kept subjects regularly informed about the progress of 
the study. To satisfy the concern about their own health, all subjects received a copy of the letter to 
their General Practitioner with the results of the physical examination. We found that this was much 
appreciated by the subjects.
The importance of giving participants in a study extensive information and a personal approach 
was found by van Gelderen et al., who stated that it kept subjects motivated during the study23. 
A study that identified the patients’ perspective of cardiac catheterisation showed that personal 
attention and distraction during catheterisation decreases stress and anxiety25. The low score on the 
pain scale and the fact that 80% experienced the procedure as less burdensome than expected and 
20% just as expected beforehand, illustrates that the invasive procedure did not surprise the subjects 
in a negative way. The overall satisfaction with participation is reflected in the results of the questions 
about the given information, their advice to others and whether they would participate again.
We believe that the custom-made individual care and coaching provided by the research nurse 
before, during, and after the catheterisation resulted in the positive way the subjects experienced 
the procedure. The continual individual attention the research nurse gave contributed to the 
considerable satisfaction and pleasure in the participation and the low perception of pain and 
burden. It kept subjects committed to the study, and therefore probably accounts for the very low 
dropout-rate.
Remains to be seen if our findings also are valid for research in other medical fields whereby 
e.g. gastric-intestinal screening would be required for inclusion. It is very well possible that it was 
specifically the prospect of receiving a cardiovascular check-up that enticed healthy elderly to 
participate in this medical research study.
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More men than women completed the protocol: more men responded to the advertisement and 
since respondents were invited to the screening in order of response, more men than women were 
included; in addition, due to spasms of the antecubital veins, the insertion of the catheter failed in 
36% of the women. We have no clear explanation on why so many women had vein spasms.
A limitation of the study is that the questionnaire, which was made especially for use in this 
study, could not be validated beforehand. Therefore, the answers to the questions given by the 
subjects and the analysis may not be applicable to other invasive studies. In this study however, the 
questionnaire provided a good overall impression of the burden experienced by the volunteers and 
the satisfaction about their participation. We acknowledge the fact that the outcome of this study 
could be culturally determined and that the subjects responding to an advertisement in a newspaper 
do not represent a cross-section of the elderly population. 
In conclusion, we demonstrated that it is possible to recruit healthy elderly volunteers for 
cardiovascular research that includes cardiac catheterisation. The cardiovascular screening was the 
main motive for participation; the allowance played no significant role. Custom-made information, 
coaching and care throughout the entire study by a specialised research nurse resulted in satisfaction 
and commitment of the volunteers. We therefore recommend that in any invasive cardiovascular 
study on elderly volunteers, a research nurse is appointed for the recruitment, screening, and 
implementation.
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Appendix
Translation in English of the written study information in Dutch.
Information about the research project entitled “The relationship between the Valsalva test 
(forced expiratory effort) and heart function in healthy elderly persons”
You have been asked to participate in a research programme to determine whether the 
Valsalva test (forced expiratory effort) can be used to measure certain heart functions. This 
brochure gives additional written information about this research.
Introduction
The heart pumps blood through your body. If the heart does not work well, then insufficient 
blood is pumped out of the exit of the heart and blood gathers at the entrance to the heart. 
This is called heart failure. As a result, the pressure in the veins in the lungs rises, which can 
lead to shortness of breath in people with a heart that works poorly. Too high a pressure 
in the pulmonary veins can at present only be measured by inserting a very small tube (a 
catheter) into a vein so that it reaches the heart. Our research aims to find out whether there 
is another, simpler method to measure the pressure in the pulmonary veins. We call this 
method the “Valsalva test”. 
How does the Valsalva test work?
We want to measure the way in which your blood pressure changes as you blow out through 
your lips against some form of resistance. We measure the blood pressure by placing a small 
blood pressure cuff around one of your fingers. You then blow through a tube with a small 
opening at the far end. You can see on a screen how hard you need to blow. You will have to 
blow into the tube for 12 to 15 seconds.
What does the research involve?
First, we have to find out whether you can participate in the research. You will be invited 
for a consult with the doctor who is doing this research and he will carry out a physical 
examination. Your blood will be tested and an electrocardiogram will be performed. You will 
return to the outpatient clinic for a second appointment during which an echocardiography, 
(making images of the heart using ultra-sound) and a bicycle trainer fitness test to determine 
your endurance and the function of the heart. After about one week, you will receive the 
results of these examinations and you will be informed whether you can participate in the 
examination in the research programme.
You will then be invited to participate in the actual research examination itself. This will take 
one morning. The results of the Valsalva test need to be compared with the actual pressure 
in the lung veins. This means that a special kind of heart catheterisation (called a right-sided 
heart catheterisation) will have to be done. 
The catheterisation will take place in the cardiac catheterisation laboratory of the University 
Medical Center Nijmegen. We will only be measuring the pressure in the pulmonary veins 
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and the right side of the heart. You will be asked to lie on a narrow table and you will be 
attached to a monitor in order to observe your heart rhythm. To ensure that the work will be 
sterile, you will be covered with sterile blue sheets. The spot on the arm where the catheter 
(tube) will be inserted into a vein will be disinfected and a local anaesthetic applied. An 
experienced cardiologist will then insert a small peel-off introducer into the vein to enable 
the tube to be moved up to the heart. It will not be necessary to use radiographic contrast 
fluid. The pressure in the pulmonary veins will be measured. This will not be noticeable.
After this, the introducer will be removed but the catheter will be left in place. Then, you will 
be transported to the coronary care unit. There, a blood pressure cuff will be placed around 
your finger and you will be asked to blow through a tube for 12 to 15 seconds (the Valsalva 
test). This will be repeated twice.
During the catheterisation you will wear a “pilot’s pressure suit” (actually, only the leggings). 
This suit can be inflated with air and we can vary the blood pressure in the heart by adjusting 
the amount of inflation. You will notice the pilot suit has been inflated because of a slight 
pressure on your legs.
After the examination, the catheter will be removed. The entry point into the vein will have 
pressure applied for ten minutes. After this, a compress will be placed around your arm and 
this should be worn for several hours.
The examination will be concluded in the early afternoon and you can return home after 
this.
Risks involved
The Valsalva-test, blowing into a tube against a resistance, is without risk. Risks involved 
in the right heart catheterisation are: bleeding, haematoma, damage to the vein, and heart 
rhythm disturbances. The risks are small.
Your rights
A special committee, which reviews and evaluates all research in the University Medical 
Center Nijmegen, has approved this research programme. Before the examinations take 
place, you will have a consultation with a doctor who will explain the examinations, 
which you will undergo. A member of your family or a friend may accompany you to this 
consultation and you may ask questions at this time. You decide yourself whether you wish 
to participate in the research programme. You will have at least one day to decide whether 
you want to participate in the research programme. You may stop participating in the 
programme at any time, and you do not need to give any reason for this decision. If any 
damage arises from the examinations you may hold the hospital responsible. The hospital 
is insured for such events.
Allowance
All travel costs and costs of parking your car in the hospital car park will be reimbursed, 
even if the examination of the first day determine that you cannot participate further in the 
research programme. An allowance of Euro 112.50 will be paid for participation in the actual 
research (the catheterisation).
52
Chapter 3
Location of the examinations
The examinations will be carried out at the department of Cardiology of the University 
Medical Center Nijmegen in Nijmegen, The Netherlands. The heart catheterisation will 
be done by an experienced cardiologist in the presence of the doctor responsible for 
the research programme and the research nurse. The research programme is under the 
responsibility of Professor F.W.A. Verheugt, MD, PhD, Cardiologist, W.R.M. Aengevaeren, 
MD, PhD, Cardiologist and Head of the cardiac catheterisation laboratory, and R.W.M.M. 
Jansen, MD, PhD, Geriatrician.
Questions
If you have any questions about this research programme, please contact one of the 
following persons:
A. Bos, RN, Research Nurse
J. Remmen, MD, Research Fellow
R. Jansen, MD, PhD, Geriatrician
University Medical Center Nijmegen
Chapter 4
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Abstract
Non-invasive continuous monitoring of cardiac output could be very useful in clinical care and in 
research settings, particularly in elderly subjects. We studied whether Finapres arterial pulse wave 
analysis with Modelflow® is a reliable non-invasive method for the assessment of cardiac output in 
healthy elderly subjects. We compared Modelflow® cardiac output (MFCO) with thermodilution 
cardiac output (TDCO) in 28 healthy subjects, aged 70±4 years (mean±SD). TDCO was measured 
during right-sided heart catheterisation, while MFCO was calculated with Modelflow® software 
from non-invasive arterial Finapres blood pressure, which was measured simultaneously. The two 
methods were compared using a paired t-test, by Pearson correlation, and Bland-Altman analysis. 
TDCO was 6.4±1.1 l/min (mean±SD) and MFCO was 4.7±1.3 l/min, p<0.001. There was no significant 
correlation between MFCO and TDCO (r=0.28, p=0.13). Mean difference (bias) was -1.7 l/min (SE 
0.27 l/min), with an SD (precision) of 1.5 l/min. The 95% limits of agreement were -4.6 l/min to +1.1 
l/min. In conclusion, non-invasive Modelflow® cardiac output differed significantly from and showed 
no significant correlation with invasively determined thermodilution cardiac output in the normal 
range. Although simple, non-invasive and patient friendly, the Modelflow® method is inaccurate for 
assessment of cardiac output without invasive calibration.
Introduction
A non-invasive method for the continuous assessment of cardiac output could be useful in clinical 
care and in research settings. It could monitor the (first dose) effects of drug therapy and guide 
treatment of hypertension and heart failure, especially in the elderly, in whom the prevalence of 
these diseases is high1.
A promising method for the assessment of cardiac output non-invasively is the arterial pulse 
wave analysis, the main principle of Modelflow®2-5. This model is incorporated in the Beatscope® 
software programme, and calculates cardiac output from arterial pressure waves, which can be 
acquired invasively with an intra-arterial catheter or non-invasively with Finapres6-11. Finapres also 
exists in a portable Portapres® version, which enables long-term ambulatory monitoring of cardiac 
output8.
We aimed to study whether Finapres pulse wave analysis with Modelflow® is a reliable non-
invasive method for the assessment of cardiac output, by comparing non-invasive Modelflow® 
cardiac output (MFCO) measurements with thermodilution cardiac output (TDCO) measurements 
in healthy elderly subjects.
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Methods
In an ongoing study, we are investigating the relationship between pulmonary capillary wedge 
pressure and the arterial blood pressure (BP) response to the Valsalva manoeuvre in elderly subjects. 
To this purpose, we have performed right-sided heart catheterisation in healthy elderly subjects, 
which has given us the opportunity to compare simultaneously assessed TDCO and MFCO.
Subjects
Volunteers were recruited by means of an advertisement in a local newspaper, requesting 
participation in an invasive study. A brief medical history was taken by telephone. Suitable volunteers 
were invited to the outpatient clinic to undergo a screening programme consisting of medical 
history, physical examination, electrocardiography, blood laboratory analysis, bedside spirometry, 
bicycle stress-electrocardiography, and echocardiography. Inclusion criteria for participation were 
age ≥65 years and ability to give informed consent. Exclusion criteria were: history or signs of 
myocardial infarction, stable or unstable angina pectoris, rhythm or conduction abnormalities, 
cardiomyopathy, congestive heart failure, moderate or severe valve stenosis or regurgitation, left 
ventricular hypertrophy (all according to ACC/AHA Practice Guidelines), history of hypertension 
(defined as systolic blood pressure (BP) in rest >140 mmHg and/or diastolic BP >90 mmHg or use of 
anti-hypertensive medication1; onetime limits of normal BP were 160/90 mmHg at screening), any 
other serious disease, and use of medication with cardiovascular effects. All subjects gave written 
informed consent. The study was approved by the Ethics Committee for Research on Human 
Subjects of the University Medical Center Nijmegen, The Netherlands, and conformed with the 
principles outlined in the Declaration of Helsinki12.
Materials and measurements
TDCO was determined by right-sided heart catheterisation, using a 7.5 French Swan Ganz CCO/VIP 
139HF75 catheter (Baxter, Irvine, USA), connected to a Baxter COM-1 or a Baxter COM-2 computer. 
To determine TDCO, 10 ml of 0.9% NaCl solution at room temperature was manually injected 
through the proximal port of the Swan-Ganz catheter in approximately two seconds. Injections were 
performed at least three times, at random points in the respiratory cycle. Each thermodilution curve 
was checked visually for shape and appearance time before acceptance. If one TDCO value diverged 
more than 10% from the other two, one to three additional injections were performed, and values in 
the upper and lower range were discarded, after which the mean of the remaining three values was 
taken as the TDCO.
Non-invasive continuous arterial BP and heart rate were measured beat-to-beat with Finapres 
(Ohmeda 2300, Englewood, USA) on the index or middle finger on the opposite side to the 
catheterised arm. MFCO was calculated offline from the Finapres BP waveform by the Modelflow® 
programme that is incorporated in the software programme BeatScope, version1.0 (TNO-TPD 
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Biomedical Instrumentation, Amsterdam, The Netherlands). Modelflow® is a three-element model 
that uses arterial input impedance, including continuous correction for variations in the diameter, 
the compliance of the aorta, and total peripheral resistance, describing the relation between aortic 
flow and pressure and computing stroke volume2. The parameters age, sex, height, and weight are 
required for the model and are entered prior to the measurements. MFCO (in l/min) is computed by 
multiplying stroke volume and heart rate2-5.
In order to evaluate a possible effect of the bolus injection on MFCO, we compared MFCO 
calculated from 15 beats just before the first injection and from 15 beats just after injection, and we 
repeated this for the third injection.
Protocol
Subjects refrained from caffeine and nicotine for at least 12 hours prior to the experiment. In the 
catheterisation laboratory, the subject assumed a supine position at the catheterisation table and 
the Finapres was applied; subsequently, an experienced cardiologist (W.R.M.A.) inserted an eight 
French peel-off-sheet into the basilic or cephalic vein, using the Seldinger technique under local 
anaesthesia with lidocaine 2%. A Swan-Ganz catheter was positioned in the left or right pulmonary 
artery under fluoroscopic guidance. In supine position, cardiac output was subsequently assessed by 
means of bolus thermodilution.
Continuous Finapres BP waves were recorded and stored from the moment of insertion of the 
Swan Ganz catheter until the end of the protocol. Offline assessment of MFCO was derived from 
uninterrupted Finapres BP waves starting 15 seconds prior to the first thermodilution injection and 
ending 30 seconds after the last injection. Accordingly, all cardiac cycles from which TDCO was 
derived were also used for derivation of MFCO. However, Modelflow® utilised the cycles between the 
injections as well, and those cycles were not used for TDCO. Therefore, not all cardiac cycles used for 
both methods were identical, neither was the number of cardiac cycles.
At the end of the protocol, the Swan-Ganz catheter was removed from the arm and a compress 
was applied. Within two hours after removal of the catheter, the subject was released from the 
hospital.
Data analysis and statistics
Data were recorded using a personal computer and sampled with the MID TestOrganizer, version 
5.3 (Department of Biomedical Engineering, University Medical Center, Nijmegen, The Netherlands). 
Statistical analysis was performed with SPSS 10.0 for Windows (SPSS Inc, 2000, Chicago, USA). Values 
are expressed as mean±SD. A two-sided p-value ≤0.05 was considered to be significant.
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Variability of TDCO was expressed as the within-subject standard deviation, calculated as the 
square root of the mean variance of the three measurements that were used for comparison with 
MFCO for all subjects13. The coefficient of variation was the within-subject standard deviation 
expressed as percentage of the group mean TDCO. We divided each period of Finapres curves 
into portions of 60 beats, which enabled us to calculate the within subject standard deviation and 
coefficient of variation of MFCO.
Agreement between TDCO and MFCO values was judged by computing Pearson’s correlation 
coefficient and by plotting the difference of MFCO and TDCO against their mean14. The mean 
difference (bias) and SD (precision) between MFCO and TDCO were computed and tested using a 
paired t-test. Mean difference±1.96 SD were known as the 95% limits of agreement.
We considered a mean difference ≥1.0 l/min between MFCO and TDCO (20% of a mean CO of 
5.0 l/min) as clinically important and assumed a standard deviation of 1.0 l/min for both TDCO and 
MFCO. We calculated that a sample size of 25 subjects would be sufficient to detect a difference 
between MFCO and TDCO of 1.0 l/min at a power of 95%, using a paired t-test.
Results
Patient enrolment
The flow diagram in Figure 1 shows the enrolment of healthy elderly subjects in the study protocol. 
More men (78%) than women (22%) completed the protocol: more men (74%) responded to the 
advertisement and since respondents were invited to the screening in order of response, more men 
(63%) than women (37%) were included. In addition, due to spasms of the antecubital veins, the 
insertion of the catheter failed in five women. The data of the 28 elderly subjects who completed 
the study protocol were suitable for analysis. Subject characteristics are presented in Table 1. None 
of the subjects used medication. BP was assessed sphygmanometrically; minimum, maximum and 
median BP values were 110, 170, and 150 mmHg respectively for systolic BP and 75, 90, and 85 mmHg 
respectively for diastolic BP.  One subject with systolic BP of 170 mmHg was not excluded because later 
on BP was 150/70 mmHg. At the bicycle stress electrocardiography, all subjects performed well and 
exceeded the predicted age- and sex-adjusted maximal heart rate and workload. Echocardiographic 
findings were in the normal, age adjusted range15. All cardiac output measurements were performed 
between 22 March 2000 and 24 November 2000.
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Figure 1  Flow diagram of enrolment of subjects. Between brackets numbers of (male/female); γgt, gamma-glutamyl-
transferase; SVT, supra-ventricular tachycardia.
Responded to
advertisement
n=180 (134/46)
Included
n=38 (24/14)
Completed protocol
n=28 (22/6) 
Excluded n=14 (9/5):
Hypertension n=3 (1/2)
Left/right bundle branch block n=5 (3/2)
Ectopic atrial rhythm n=1 (1/0)
Previous myocardial infarction n=2 (1/1)
Positive stress-electrocardiography n=2 (2/0)
Alcohol abuse with elevated γ gt n=1 (1/0)
Failed insertion of catheter n=5 (0/5)
Did not complete protocol n=10 (2/8):
Withdrew n=1 (0/1)
Catheter induced SVT n=1 (0/1)
Failure of cardiac output computer n=3 (2/1)
Invited to screening
n=52 (33/19)
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Table 1  Subject characteristics at screening 
Parameter Value 
Male/female 22/6
Age (years) 70 ± 4
Systolic blood pressure (mmHg) 143 ± 16
Diastolic blood pressure (mmHg) 83 ± 3
Heart rate (min-1) 64 ± 6
Length (cm) 175 ± 9
Body surface area (m2) 1.93 ± 0.2
Weight (kg) 78 ± 12
Body mass index (kg/m2) 25 ± 3
Bicycle stress-electrocardiography
 Maximum heart rate (% of predicted)
 Maximum workload (% of predicted)
105 ± 9
141 ± 18
Echocardiography
 Peak Velocity early diastolic rapid filling wave (E, m/s)
 Peak Velocity late diastolic atrial contraction wave (A, m/s)
 E/A ratio
 Deceleration time (ms)
 End systolic volume (ml)
 End diastolic volume (ml)
 Ejection fraction (Simpson, %)
0.62 ± 0.15
0.75 ± 0.15
0.84 ± 0.15
233 ± 50
58 ± 16
127 ± 41
53 ± 7
Data are expressed as mean±SD (n=28).
Cardiac output measurements
In the 28 subjects, the mean (±SD) recording time of Finapres BP used for Modelflow analysis was of 
197±76 (range 96 – 456) seconds. From the monitor, all Finapres signals appeared of good quality. 
The mean number of cardiac cycles per subject, used for MFCO, was 229±102 (range 88 – 536). 
Finapres heart rate was 69±8 beats/min; systolic BP was 163±21 mmHg; diastolic BP 82±11 mmHg 
and mean arterial BP 108±13 mmHg. From these Finapres signals, MFCO was calculated; mean 
MFCO was 4.7±1.3 l/min. The within subject standard deviation of MFCO was 0.17 l/min and the 
coefficient of variation was 3.6%.
For TDCO measurements, at least three injections were performed in each subject. In 12 out 
of 28 subjects (42%), more than three injections were made due to diverging values or unreliable 
temperature curves: in 5 subjects 4 injections were made, in 3 subjects 5 injections, and in 4 subjects 
6 injections. Group mean TDCO was 6.4±1.1 l/min. The within-subject standard deviation was 0.30 
l/min and the coefficient of variation was 4.7%.
The mean difference of MFCO calculated from 15 beats just before and just after the first bolus 
injection was 0.058 l/min, (not significant; 95% CI: -0.005 to 0.121 l/min). For the third injection, the 
difference was 0.062 l/min, (not significant; 95% CI: -0.005 to 0.131 l/min).
Figure 2 shows MFCO plotted against TDCO assessed simultaneously in each subject. There 
was no significant correlation between MFCO and TDCO (r=0.29, p=0.13). The mean difference 
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(MFCO – TDCO) expressed as percentage of TDCO was -32% (95% CI: - 43% to -22%). The difference 
between MFCO and TDCO plotted against their mean is shown in Figure 3. MFCO and TDCO 
differed significantly (p<0.001). The bias was -1.7 l/min (SE 0.27 l/min), with a precision of 1.5 l/min. 
The 95% limits of agreement were -4.6 l/min to +1.1 l/min.
Figure 2  Modelflow cardiac output (MFCO) plotted against thermodilution cardiac output (TDCO) for each subject. The 
broken line is the line of equality, and the solid line is the regression line.
Figure 3  Difference of Modelflow cardiac output (MFCO) and thermodilution cardiac output (TDCO) plotted against their 
mean. Broken lines represent the 95% limits of agreement.
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Discussion
The main findings of the present study in healthy elderly subjects are that MFCO values differed 
significantly from TDCO values, and that there was no significant correlation between MFCO and 
TDCO. Modelflow® mostly underestimated cardiac output compared with TDCO. In addition, Bland-
Altman plots showed that the error between the two methods was not confined to a certain range 
of cardiac output. The range between the 95% limits of agreement was large, from -4.6 to +1.1 l/min, 
more than 5 l/min. Taking into account a mean TDCO in our subjects of approximately 6 l/min, this 
range is unacceptable large from a daily clinical perspective. Therefore, Modelflow® seems inaccurate 
for non-invasive assessment of cardiac output.
To our knowledge, this has been the first study comparing MFCO with invasive TDCO in healthy 
elderly subjects. In combination with the portable Finapres (Portapres), Modelflow® could enable 
continuous, long-term, and ambulant non-invasive monitoring of cardiac output. Especially in 
the elderly, it could be of great use for diagnosis and guidance of treatment of heart failure and 
hypertension, if it were an accurate method for non-invasive assessment of cardiac output. Within 
that framework, our findings are disappointing.
Several factors could account for our findings. One of them might be the fact that we did not 
calibrate Modelflow® with an invasively assessed cardiac output value. Based on data from a study 
on the elastic properties of human aortas obtained at autopsy16, Modelflow® uses the maximal cross-
sectional area of the aorta at high pressure. However, the patient’s true aorta area deviates from the 
mean value that is used by Modelflow®. Accurate measurement of the aortic diameter or a dilution 
estimate of cardiac output was reported to improve accuracy2. In several studies, a calibration factor 
(initial TDCO divided by initial MFCO) was multiplied by MFCO, after which 95% limits of agreement 
with thermodilution cardiac output were small2, 4, 5, 17. In only one study were the pre-calibration 95% 
limits of agreement reported5. In that study in septic patients on an intensive care unit, 95% limits 
of agreement were -6.5 l/min to +2.6 l/min, even larger than in our study, although with a range of 
cardiac output of 4.1 to 18.2 l/min. Because of its invasive nature, calibration by using right-sided 
catheterisation means that the Modelflow® method is not strictly non-invasive and limits its use. If 
the Modelflow® method were also accurate without invasive calibration, this could make it a truly 
non-invasive and far more easy to use method. For this reason, we decided to assess Modelflow® 
cardiac output without initial invasive calibration.
The advanced age of our subjects seems not to be an explanation for the large difference between 
MFCO and TDCO values. As mentioned above, Modelflow® uses data derived from a study on 45 
human thoracic and 20 abdominal aortas. The age of the patients at autopsy ranged from 30 to 
88 years; 54% of the patients were over 65 years old16. Whether our results can be extrapolated to 
younger subjects remains unanswered, but it is unlikely that age is responsible for the differences 
found in the present study.
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Unlike our present study, most other studies have used intra-arterial BP curves for Modelflow® 
analysis. Since Finapres recordings were reported to be even better for Modelflow® analysis than intra-
arterial BP curves4, the use of Finapres instead of intra-arterial BP is also unlikely to be responsible for 
the large difference between MFCO and TDCO values in the present study. 
The bolus thermodilution method, achieved by right-sided heart catheterisation, has been 
accepted as the gold standard for measurement of cardiac output18, 19, and was therefore used in this 
study for comparison to the Modelflow® method. Large variability of TDCO could, at least partially, 
account for the difference between MFCO and TDCO. For TDCO, a standard deviation of the mean 
of three injections has been described from 3.5% to 11%, and when the injectate used was colder the 
standard deviation became smaller19, 20. In our study, using room-temperature injectate, we achieved 
a very small in-subject standard deviation of less than 5%. It is therefore unlikely that the variability in 
our TDCO was a main cause of the difference between MFCO and TDCO. We recognise the fact that 
variability is a measure of reproducibility more than of accuracy. The small variability of our TDCO 
values is probably due to a number of reasons: values diverging more than 10% from the other two 
were discarded; all subjects were healthy without any cardiac abnormality; the range of measured 
cardiac output was relatively small; and all measurements were performed by the same experienced 
cardiologist. The variability of MFCO was even smaller than that of TDCO and this cannot explain 
the large differences between the values derived from the two methods either.
MFCO values measured before and after bolus injection did not differ significantly. Therefore, 
bolus injection of 10 ml ambient-temperature saline solution appeared to have little or no influence 
on MFCO, and also cannot explain our findings.
In several reports, invasive calibration was not performed for Modelflow® assessment of cardiac 
output, and therefore cardiac output was not expressed as an absolute value but solely as (relative) 
change in cardiac output21-26. In other reports, however, MFCO has also been expressed as absolute 
values27-29. Based on our findings, we believe that absolute MFCO values, determined without 
invasive calibration, should be interpreted cautiously and should not be used to guide clinical 
treatment. Additionally, change in MFCO expressed as absolute values might not correctly reflect 
change in true cardiac output either. Relative change in MFCO might give a correct reflection of 
relative change in cardiac output, since the calibration factor is then present in both the numerator 
and the denominator. To assess the ability of Modelflow® to detect relative changes in cardiac output 
without previous invasive calibration, further studies are needed comparing relative changes in 
MFCO with relative changes in TDCO.
The present study was subject to certain limitations. First, we compared absolute MFCO values 
with TDCO values at just one time point, and not at different times with different values of cardiac 
output. Therefore, we could not assess the ability of Modelflow® to detect changes in cardiac 
output. Furthermore, our findings are restricted to the normal physiological range of cardiac output. 
Whether these findings can be extrapolated to pathologically low or high cardiac output ranges 
remains unanswered.
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In conclusion, in healthy elderly subjects, non-invasive MFCO values differed significantly from 
and showed no significant correlation with invasively determined TDCO values in the normal range. 
Therefore, although the Modelflow® method is easy to use, non-invasive and patient-friendly, it is 
inaccurate for the assessment of cardiac output without invasive calibration.
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Abstract
In a study on non-invasive assessment of pulmonary capillary wedge pressure (PCWP), we sought 
a method to increase PCWP non-invasively. We hypothesised that inflation of an anti-G garment 
was suitable to increase PCWP non-invasively in healthy elderly subjects. In 20 subjects, aged 70±4 
years (mean±SD), before, immediately after, and 4 minutes after anti-G garment inflation to 52 
mmHg, PCWP and mean pulmonary artery pressure (MPAP) were measured with a Swan-Ganz 
catheter, and mean arterial blood pressure (MAP) with Finapres, in supine and semi-recumbent 
position. Supine, PCWP (mmHg, mean±SD) increased from 9.9±2.1 to 15.5±3.9** immediately after 
inflation and 13.4±3.7** at 4 minutes; semi-recumbent from 8.9±2.0 to17.5±3.3** and 14.7±2.9** 
(*p<0.05, ** p<0.001 vs. before inflation). MPAP (mmHg) increased after inflation: supine 16.9±2.3 
to 22.3±4.6** and 20.6±3.9** and semi-recumbent 15.7±2.8 to 24.3±5.1** and 22.5±3.5**, suggesting 
that increased preload was the primary effect of anti-G garment inflation. Supine, MAP (mmHg) 
increased from 96.0±11.3 to 101.4±13.4** and 100.5±12.7* and semi-recumbent from 102.0±8.9 
to 108.3±11.4** and 106.0±11.3*, suggesting an effect of increased afterload as well. The latter was 
supported by an increase in total peripheral resistance (d s cm-5) from 1346±299 to 1441±384 after 
four minutes (p=0.057) and from 1461±341 to 1532±406 (p=0.054), supine and semi-recumbent 
respectively, while cardiac output remained unchanged. Complications did not occur. We conclude 
that in healthy elderly subjects, anti-G garment inflation is a safe, non-invasive, method to induce 
a significant increase in PCWP. Our findings justify its application in future studies in which non-
invasive temporary increase in PCWP is required.
Introduction
The prognosis of patients with heart failure is poor1 but can be improved with early diagnosis and 
treatment2, which emphasises the importance of early diagnosis. Especially in the elderly, physical 
examination and radiographic methods are not very sensitive means for detection of heart failure3, 
4. Heart failure can be defined as the pathophysiological state in which the heart is unable to pump 
blood at a rate needed by the metabolising tissues or can do so only from elevated filling pressure5. 
Mean pulmonary capillary wedge pressure (PCWP) provides a clinically useful estimate of mean 
left atrial pressure and left ventricular filling pressure and can be used to diagnose heart failure6. 
However, PCWP can only be assessed invasively through pulmonary artery catheterisation, which 
is not without risks of morbidity and mortality7, 8. A non-invasive method for estimation of PCWP 
would be useful for detection of heart failure and to guide its treatment.
Previous reports demonstrated a relationship between the level of mean PCWP and the arterial 
blood pressure (BP) response during a Valsalva manoeuvre, i.e. sustained straining against an airway 
resistance9-11. In extension to these reports, we investigated the relationship of PCWP and the BP 
70
Chapter 5 Lower body positive pressure by anti-G garment inflation
71
response to the Valsalva manoeuvre in healthy elderly subjects12, in order to get insight in the 
physiological BP response to the Valsalva manoeuvre and to obtain normal values. A non-invasive 
method to increase PCWP temporarily might help us to study this relationship. Furthermore, it gives 
us the opportunity to study whether changes in PCWP can be monitored using the BP response 
to the Valsalva manoeuvre. Consequently, we initially sought a safe and non-invasive method to 
increase PCWP temporarily. Possibly, this could be achieved by application of lower body positive 
pressure by means of anti-gravity (anti-G) garment inflation. Anti-G garments are used to prevent 
loss of consciousness in high-performance fighter-aircraft pilots but have also been used as a tool for 
changing hemodynamics for research and clinical purposes13-16. The specific effect of anti-G garment 
inflation on PCWP remains unclear. An increase in PCWP after inflation has been described, but only 
in intensive care patients17, 18 and never in healthy subjects.
Therefore, the aim of this study was to investigate in healthy elderly subjects whether a temporary 
increase in PCWP could be achieved safely with lower body positive pressure using anti-G garment 
inflation. We also investigated the circulatory effects of anti-G garment inflation in different postural 
positions.
Methods
Primary and secondary outcome
The primary outcome variable was PCWP before, immediately after, and at four minutes after 
inflation of an anti-G garment in both supine and semi-recumbent position. Secondary outcome 
variables were pulmonary artery pressure (PAP), arterial blood pressure (BP), cardiac output, and 
peripheral resistance before and after inflation of the anti-G garment in supine and semi-recumbent 
(legs placed horizontally and upper body in a 45 degree angle) position. The safety endpoint 
consisted of complaints or clinical signs of acute congestive heart failure or any other complication 
during or after inflation.
Subjects
Volunteers were recruited by means of an advertisement in a local newspaper, requesting participation 
in an invasive study. By telephone, a brief medical history was taken. Suitable volunteers were invited 
to the outpatient clinic to undergo a screening programme consisting of medical history, physical 
examination, electrocardiography, blood laboratory analysis, bedside spirometry, bicycle stress-
electrocardiography, and echocardiography.
Inclusion criteria for participation were age ≥65 years and ability to give informed consent. 
Exclusion criteria were: history or signs of myocardial infarction, stable or unstable angina pectoris, 
rhythm or conduction abnormalities, cardiomyopathy, congestive heart failure, moderate or severe 
valve stenosis or regurgitation, left ventricular hypertrophy (all according to ACC/AHA Practice 
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Guidelines); history of hypertension, defined as systolic blood pressure (SBP) in rest >140 mmHg 
and/or diastolic blood pressure (DBP) >90 mmHg or use of anti-hypertensive medication19, onetime 
limits of normal BP were 160/90 mmHg at screening; any other serious disease; and use of medication 
with cardiovascular effects. All subjects gave written informed consent. The study was approved by 
the Ethics Committee for Research on Human Subjects of the University Medical Center Nijmegen, 
The Netherlands, and conformed to the principles outlined in the Declaration of Helsinki20.
Protocol
Subjects refrained from caffeine and nicotine for at least 12 hours prior to the experiment. In the 
catheterisation-laboratory, the anti-G garment was applied and the subject assumed a supine 
position at the catheterisation table; consecutively, the Finapres was applied. A Swan-Ganz catheter 
was inserted into the basilic or cephalic vein by an experienced cardiologist (W.R.M.A.) and 
positioned in the left or right pulmonary artery under fluoroscopic guidance.
With the catheter left in non-occlusive position, the subject was transported to the adjacently 
located coronary care unit. After a five-minute rest period in supine position, mean PCWP was 
measured before, immediately after, and at four minutes after inflation of the anti-G garment. Just 
prior to each determination of PCWP, PAP was measured. After deflation, the subject was placed in 
semi-recumbent position. Following a five-minute rest period, an identical procedure was performed 
as in the supine position. Two hours after removal of the catheter, the subject was released from the 
hospital. In the evening, a research-nurse performed a follow-up by telephone to evaluate late post-
procedural complications.
Materials and measurements
The PCWP and PAP (in mmHg) were determined by right-sided catheterisation, using a 7.5 French 
Swan Ganz CCO/VIP 139HF75 catheter (Baxter, Irvine, USA), connected to a Perceptor Compensator 
Morse Manifold pressure transducer (Boston Scientific, Maple Grove, USA). The pressure 
measurement system was calibrated with a mercury column and pressures were measured with the 
zero level fixed at the intersection of the fourth intercostal space and the mid-axillary line. Pressures 
were measured at the end of expiration.
Continuous invasive cardiac output (CO, in l/min) was obtained with the above-mentioned 
catheter, connected to a Baxter Edwards critical-care Vigilance Monitor (Baxter). This method of 
measuring CO is based on thermodilution; a thermal filament located at the proximal port of the 
catheter produces heat to the blood and temperature is measured with a thermistor close to the 
catheter-tip. Continuous CO has been reported to be a reliable alternative to bolus thermodilution 
CO21. Reproducibility was better in continuous CO than in thermodilution CO22. As displayed CO 
is updated every 30 seconds reflecting an average of the previous 3 minutes of data, only values 
displayed at baseline and at four minutes after inflation were used for analysis to ensure that 
the effect of anti-G garment inflation on continuous CO was truly reflected. In order to assess 
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reproducibility of continuous CO, Bland Altman analysis23 was performed on CO at baseline in 
supine and semi-recumbent position.
Blood pressure (in mmHg) was measured beat to beat with Finapres (Ohmeda 2300, Englewood, 
USA) on the fore- or middle finger at the non-catheterised arm. Total peripheral resistance (TPR, in 
dyne�s�cm-5) was calculated as mean arterial pressure times 80 divided by continuous CO24.
The anti-G suit, a standard Air Force anti-gravity suit (Anti-G Garment Cutaway CSU-13B/P), 
consisted of five interconnected bladders (calves, thighs, and lower abdomen). In 30 seconds, the 
suit was inflated with air to a pressure of 52 mmHg (1 psi) using a manual pump. Previous studies 
showed that this level of pressure was well tolerated while it was sufficient to induce substantial 
cardiovascular changes14, 18, 25, 26. Complaints experienced by the subject during anti-G garment 
inflation and complications during inflation and catheterisation were noted in the subject’s research 
file for safety assessment.
Data analysis
Data were recorded using a personal computer and sampled with the MID TestOrganizer, version 5.3 
(Department of Biomedical Engineering, University Medical Center, Nijmegen, The Netherlands). BP 
and heart rate were analysed offline from the Finapres signal, lasting 20 consecutive beats ending five 
seconds prior to each PCWP determination, with the software programme BeatScope, version 1.0 
(TNO-TPD Biomedical Instrumentation, Amsterdam, The Netherlands).
Statistics
Statistical analysis was performed with SPSS, version 10.0 (SPSS Inc, 2000, Chicago, USA). Values 
are expressed as mean±SD. Repeated measurement ANOVA was used to compare group means of 
variables that were measured at more than two time-points. Paired t-tests were used to compare 
variables in supine and semi-recumbent position. A two-sided p-value ≤0.05 was taken as the level 
of significance.
We assumed a standard deviation of PCWP in healthy elderly subjects of 3.0 mmHg and regarded 
3.0 mmHg as a clinically relevant increase. We calculated that a sample size of 20 subjects would be 
sufficient to detect a difference of 2.7 mmHg at a power of 80%.
Results
Patient enrolment
Twenty subjects (17 males, 3 females) were enrolled in the study. The mean age (±SD) was 70±4 
years. None of the subjects used medication. BP was assessed sphygmanometrically and was in the 
(high-) normal range (SBP 138±14, range 115-160 mmHg, DBP 82±5, range 70-90 mmHg). At the 
bicycle stress electrocardiography, all subjects performed well, reaching more than the predicted 
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maximal heart rate and workload. Echocardiographic findings were all in the normal age-adjusted 
range27 (E/A ratio 0.86±0.20, left ventricular ejection fraction 52±6%). The measurements were 
performed between 22 March 2000 and 6 October 2000.
Pulmonary Capillary Wedge Pressure
Figure 1 presents PCWP of individual subjects in supine and semi-recumbent position. Except for 
one subject in supine position, inflation of the anti-G garment resulted in an increase in PCWP in all 
subjects in both positions. Mean values are shown in Table 1. In supine position, PCWP increased 
significantly immediately after inflation, a relative increase of 59±29%. After four minutes, PCWP 
had decreased but was still 35±24% higher than before inflation. In semi-recumbent position, PCWP 
showed a relative increase of 100±27% and was 67±18% higher at four minutes after inflation than 
before inflation.
Inflation of the anti-G garment caused a larger absolute increase in PCWP in semi-recumbent 
position than in supine position, 8.6±1.9 mmHg versus 5.7±2.7 mmHg (p<0.001). In addition, the 
absolute level of PCWP was significantly higher in semi-recumbent position compared to supine 
position, 2.0±2.4 mmHg (p=0.002) immediately after inflation, while before inflation PCWP did not 
differ significantly in both postural positions.
Figure 1  Individual (n=20) mean PCWP, pulmonary capillary wedge pressure, in mmHg, before inflation, immediately after, 
and at four minutes after inflation of the anti-G garment in supine position (left panel) and in semi-recumbent position 
(right panel).
PC
W
P,
 m
m
 H
g
4
8
12
20
24
PC
W
P,
 m
m
 H
g
before  
inflation
immediately            4 min  
                 after inflation 
16
4
8
12
20
24
16
before  
inflation
immediately            4 min  
                 after inflation 
74
Chapter 5 Lower body positive pressure by anti-G garment inflation
75
Table 1  Haemodynamic variables in response to inflation of an anti-G garment in 20 healthy elderly subjects. Data are 
presented as mean±SD. PCWP, pulmonary capillary wedge pressure; SPAP, systolic pulmonary artery pressure; DPAP, 
diastolic pulmonary artery pressure; MPAP, mean pulmonary artery pressure; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; MAP, mean arterial pressure; HR, heart rate; CO, cardiac output; TPR, total peripheral resistance. * p<0.05, 
** p<0.001 vs. before inflation, repeated measurement ANOVA.
Baseline Immediately after Inflation 4 min after Inflation
Supine position
PCWP (mmHg) 9.9 ± 2.1 15.5 ± 3.9** 13.4 ± 3.7**
SPAP (mmHg) 26.6 ± 4.0 31.3 ± 5.8** 30.2 ± 5.2**
DPAP (mmHg) 12.9 ± 2.1 17.6 ± 4.2** 16.2 ± 3.7**
MPAP (mmHg) 16.9 ± 2.3 22.3 ± 4.6** 20.6 ± 3.9**
SBP (mmHg) 150.4 ± 17.1 155.1 ± 18.9* 151.7 ± 21.1
DBP (mmHg) 69.5 ± 10.0 75.7 ± 12.2** 74.6 ± 9.4**
MAP (mmHg) 96.0 ± 11.3 101.4 ± 13.4** 100.5 ± 12.7*
HR (min-1) 62 ± 9 62 ± 9 62 ± 9
CO (l·min-1) 5.94 ± 1.40 (n=18) 5.93 ± 1.47
TPR (d·s·cm-5) 1346 ± 299 (n=18) 1441 ± 384
Semi-recumbent position 
PCWP (mmHg) 8.9 ± 2.0 17.5 ± 3.3** 14.7 ± 2.9**
SPAP (mmHg) 24.1 ± 3.9 32.9 ± 5.6** 31.9 ± 4.2**
DPAP (mmHg) 12.5 ± 2.1 20.2 ± 4.5** 18.8 ± 3.1**
MPAP (mmHg) 15.7 ± 2.8 24.3 ± 5.1** 22.5 ± 3.5**
SBP (mmHg) 153.6 ± 16.1 160.2 ± 19.2* 156.6 ± 17.5
DBP (mmHg) 76.6 ± 7.7 82.5 ± 9.6** 80.6 ± 9.1*
MAP (mmHg) 102.0 ± 8.9 108.3 ± 11.4** 106.0 ± 11.3*
HR (min-1) 61 ± 7 63 ± 8* 61 ± 8
CO (l·min-1) 5.81 ± 1.30 (n=19) 5.86 ± 1.51
TPR (d·s·cm-5) 1461 ± 341 (n=19) 1532 ± 406
Due to technical problems, in one subject CO could not be measured in supine position and in one subject CO could not 
be measured in both postural positions. 
Pulmonary artery pressure, arterial blood pressure, cardiac output, and total 
peripheral resistance
Table 1 presents hemodynamic variables measured before and after inflation of the anti-G garment in 
supine position and in semi-recumbent position. Systolic pulmonary artery pressure (SPAP), diastolic 
pulmonary artery pressure (DPAP), and mean pulmonary artery pressure (MPAP) all increased 
significantly immediately after inflation and were still elevated significantly at four minutes. In supine 
position, MPAP increased by 32±15% immediately and by 22±14% at four minutes after inflation. In 
semi-recumbent position, MPAP increased by 55±17% immediately and by 45±22% at four minutes 
after inflation. Inflation of the anti-G garment caused a larger absolute increase in MPAP in semi-
recumbent position than in supine position, 8.6±3.0 mmHg versus 5.4±2.9 mmHg (p<0.001). The 
absolute level of MPAP was significantly higher in semi-recumbent position compared to supine 
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position, 2.0±2.4 mmHg (p=0.001) immediately after inflation, while before inflation MPAP was 
significantly smaller in semi-recumbent position, -1.1±1.6 mmHg (p=0.004).
The SBP increased after inflation, though only immediately after inflation this increase was 
significant. In both positions, DBP and MAP increased significantly immediately after inflation. At 
four minutes after inflation, DBP and MAP had attenuated but were still significantly higher than 
before inflation. Both DBP and MAP were significantly higher in semi-recumbent position compared 
to supine position, both before and after inflation.
Heart rate increased little, yet statistically significantly, in semi-recumbent position immediately 
after inflation. Cardiac output, and total peripheral resistance did not change significantly after 
inflation in either position. Bland Altman analysis of CO in supine and semi-recumbent position is 
shown in Figure 2. The mean difference between CO in supine and semi-recumbent (bias) was 0.036 
/min, with a SD (precision) of 0.84 l/min, a SEM of 0.20 l/min, and with 95% limits of agreement of 
-1.60 to +1.67 l/min.
Figure 2  Bland Altman plot: The difference between cardiac output (CO) in supine (sup) position and in semi-recumbent 
position (semi-rec) plotted against their mean. The broken lines represent the 95% limits of agreement.
Safety
No complications occurred during or after the catheterisation. No subject experienced any 
discomfort, dyspnoea, or any sign of acute congestive heart failure during or after inflation of the 
anti-G garment.
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Discussion
The main finding of this study in healthy elderly subjects is that anti-G garment inflation induces a 
significant increase in PCWP in supine and semi-recumbent position, without complications.
The increase in PCWP by anti-G garment inflation may be explained by more than one underlying 
mechanisms. The first mechanism is an increase in preload caused by a shift of venous blood from 
the peripheral to the central circulation. A strong indication for this is the fact that with inflation of 
the anti-G garment the pulmonary artery pressure increases as well. Furthermore, the absolute and 
the relative increases of both PCWP and MPAP were larger in the semi-recumbent position than in 
the supine position, which is indicative for blood volume shift as well. In a semi-recumbent position, 
blood pools into the lower abdomen and legs due to gravity. Because of this pooling, inflation of 
the anti-G garment causes a larger shift of venous blood volume resulting in a larger increment of 
PCWP. 
The shift of venous blood to the central circulation seems a plausible explanation for the increase 
in PCWP by anti-G garment inflation, yet may not be the only explanation. We might expect that an 
increased PCWP reflects an increased left end-diastolic pressure and ventricular preload, resulting 
in an increase in cardiac output. The fact that cardiac output did not increase while PCWP did 
increase suggests an additional effect of inflation of the anti-G garment. The inflated anti-G garment 
presumably compresses the vascular bed in the lower body mechanically, causing an increase in left 
ventricular afterload. In our study, this was illustrated by the fact that MAP increased significantly 
by inflation. TPR tended to increase at four minutes after inflation, though not significantly. Isolated 
increase in afterload, by means of incomplete occlusion of the ascending aorta, was reported to 
increase end-diastolic left ventricular pressure in a study on open-chest rabbits28. Nevertheless, it 
remains difficult to compare the effect of eventual occlusion of very distal arterioles with experiments 
of total occlusion of larger vessels. Subjects did not have ischaemia-related complaints, which may 
lead to the conclusion that that small arterioles were not occluded. On the other hand, the garment 
was only inflated for four minutes, which we believe is too short to result in ischaemia.
To what degree the increase in MAP was accounted for by the Frank-Starling mechanism, where 
the better filling results in more powerful cardiac contraction, remains unknown. Furthermore, in 
the formula of TPR, central venous pressure is not present, in contrary to the formula of peripheral 
vascular resistance (PVR = (MAP - right atrial pressure)/continuous CO24. In this setting, where 
venous pressure is raised from baseline to inflation, the absence of central venous pressure is of 
importance. By anti-G garment inflation, MAP increases, but so does venous pressure. Since we 
did not measure right atrial pressure, it is questionable whether also peripheral vascular resistance 
increased by anti-G garment inflation. 
The possibility of a combined effect of anti-G garment inflation on left ventricular preload 
and afterload has been suggested by previous reports13, 18, 26, 29, 30. In a study using isotope-labelled 
erythrocytes, less than 5% of the total blood volume was displaced from the lower to the upper 
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body with inflation medical anti shock trousers (which resemble anti-G garments) in healthy male 
subjects, suggesting increase in afterload besides shift of venous blood to the central circulation29. 
Echocardiographic end-systolic and end-diastolic left ventricular volume increased after anti-G 
garment inflation, also suggesting increase in both preload and afterload13, 26. In healthy young men, 
central venous pressure increased after both anti-G garment inflation and saline infusion. However, 
MAP increased solely by means of anti-G garment inflation and remained unchanged after saline 
infusion30.
Interestingly, while MAP was increased significantly, heart rate did not decrease by inflation of 
the anti-G garment. Arterial pulse pressure remained unchanged by inflation of the garment and 
heart rate is probably controlled by changes in pulse pressure. Illustrative for the latter may be that in 
patients with heart failure, heart rate remains unchanged during the straining phase of the Valsalva 
manoeuvre while MAP increases and pulse pressure remains unchanged. In healthy subjects, heart 
rate increases during the straining phase of the Valsalva manoeuvre as pulse pressure decreases, even 
while MAP increases in the second part of the straining phase10, 31.
Whether artificial elevation of PCWP in healthy elderly subjects by inflation of an anti-G 
garment resembles the patho-physiological elevation of PCWP seen in the situation of heart 
failure is uncertain. In heart failure, compensatory mechanisms increase heart rate, cardiac muscle 
mass, blood volume, and cardiac filling pressures causing redistribution of blood flow in order to 
maintain the pumping function of the heart32. In our study, subjects did not suffer from any cardiac 
abnormality; the echocardiographic data were in accordance with echo data of 980 healthy elderly 
subjects in the Cardiovascular Health Study27. While inflation of the anti-G garment resulted in an 
increase in MAP and TPR, heart rate and cardiac output remained unchanged. These findings do not 
resemble the above-mentioned situation of heart failure.
As far as safety is concerned, inflation of the anti-G garment did not lead to any complaints or 
clinical signs of pulmonary congestion or any other complications and thus appears to be a safe 
method to increase PCWP.
The present study was subject to certain limitations. Since continuous cardiac output 
measurement only provides a summary of the previous three minutes, it was not possible to evaluate 
the immediate effects of anti-G garment inflation on cardiac output and total peripheral resistance. 
At four minutes after inflation however, continuous measurement of cardiac output provided useful 
information, since at that moment the effect of inflation on cardiac output had already been taken 
into account while PCWP was still significantly increased compared to before inflation. Still, small 
changes in CO could have been undetected. Bland Altman analysis on baseline CO measurements 
in supine and semi-recumbent showed a small bias, yet the 95% limits of agreement were large. The 
threshold to ascertain that changes in cardiac output were not because of internal variability was 
0.59 l/min (3 x SEM of mean difference22).
As we did not measure intrathoracic pressure by an oesophageal pressure transducer, it is not 
exactly known to what part the significant increase in PCWP measured is a true transmural increase 
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in pressure. Inflation of the abdominal part of the anti-G garment may push the diaphragm upwards 
resulting in an increase in intrathoracic pressure. Therefore, the increase in PCWP is probably not 
entirely caused by increase in transmural left atrial pressure alone but is at least partially caused by 
an increase in intrathoracic pressure as well. In patients who underwent coronary bypass surgery, an 
anti-shock garment caused a significant increase in PCWP. When intrathoracic pressure, measured 
with an oesophageal pressure tube, was subtracted from the PCWP, the increase in PCWP was not 
significant anymore, yet with eight subjects, this study was not powered to detect differences of 
several mmHg17. On the other hand, end-diastolic left ventricular volume26 was reported to increase 
by anti-G garment inflation, supporting an increase in transmural pressure. 
Conclusion
In healthy elderly subjects, anti-G garment inflation is a safe, non-invasive, method to induce a 
significant increase in PCWP in both supine and semi-recumbent position. Our findings justify its 
application in future studies in which a non-invasive temporary increase in PCWP is required.
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Abstract
The blood pressure response to the Valsalva manoeuvre is related to pulmonary capillary wedge 
pressure (PCWP) and can be used to diagnose heart failure. However, this has never been studied 
specifically in the elderly, in whom the prevalence of heart failure is highest. Furthermore, normal 
values of the Valsalva manoeuvre are lacking. We aimed to obtain normal values of PCWP and the 
blood pressure response to the Valsalva manoeuvre in elderly subjects. Therefore, 28 healthy subjects, 
aged 70±4 years, performed Valsalva manoeuvres before and after anti-G garment inflation, which 
was used for temporary increase of PCWP. Before inflation, PCWP was 9.8±1.9 mmHg in supine and 
8.9±2.1 in semi-recumbent position. From the blood pressure response, measured with Finapres, 
the systolic blood pressure ratio (SBPR), pulse pressure ratio (PPR), stroke volume ratio (SVR), and 
heart rate ratio (HRR) were calculated. In supine position, SBPR was 0.76±0.11, PPR 0.51±0.16, SVR 
0.42±0.11, and HRR 1.17±0.12. Semi-recumbently, SBPR was 0.74±0.10, PPR 0.46±0.14, SVR 0.41±0.10, 
and HRR 1.24±0.23. After inflation of the anti-G garment, the areas under the ROC curves of SBPR, 
PPR, and SVR for elevated (≥15 mmHg) PCWP were >0.85 in supine position. In conclusion, this is 
the first study to obtain normal values of the blood pressure response to the Valsalva manoeuvre 
and PCWP in healthy elderly subjects, which is essential for the interpretation of patient data. The 
Valsalva manoeuvre showed significant discriminatory power in the detection of elevated PCWP, 
which underscores its potential in the non-invasive diagnosis of heart failure.
Introduction
The prognosis of patients with heart failure is poor with a five-year mortality of 59% in men and 
45% in women1, but can be improved with early diagnosis and treatment2, 3, which emphasises the 
importance of early diagnosis. However, in elderly patients, physical examination and radiographic 
methods are not accurate in the diagnosis of heart failure. Therefore, heart failure can be missed 
easily4, 5. A simple, safe, and non-invasive bedside technique for diagnosis of heart failure could 
contribute to early detection and improved treatment of heart failure.
Heart failure can be defined as the pathophysiological state in which the heart is unable to pump 
blood at the rate needed by the metabolising tissues or can do so only with elevated filling pressure6. 
Pulmonary capillary wedge pressure (PCWP) provides a clinically useful estimate of left atrial pressure 
and left ventricular filling pressure and can be used to diagnose heart failure7. However, PCWP can 
only be assessed invasively through pulmonary artery catheterisation, which is not without risks of 
morbidity and mortality8, 9. Since the blood pressure response to the Valsalva manoeuvre is related 
to PCWP, it might be used to diagnose heart failure10-14.
While the prevalence of heart failure increases rapidly with age15, 16, the relation between PCWP 
and blood pressure response to the Valsalva manoeuvre has never been investigated specifically 
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in patients aged 65 years and older. In order to understand and interpret data of elderly cardiac 
patients, the blood pressure response to the Valsalva manoeuvre and its relation to PCWP should be 
assessed in healthy elderly subjects. With increasing age, the left atrium slightly enlarges as a result 
of ventricular myocardial stiffness caused by increased arterial stiffening and impaired relaxation 
of the left ventricle17, suggesting that PCWP increases with increasing age. However, little is known 
about normal values of PCWP in the elderly18, 19. Furthermore, normal values of the blood pressure 
response to the Valsalva manoeuvre subjects have never been reported. Therefore, we sought to 
obtain normal values of PCWP and of the blood pressure response to the Valsalva manoeuvre in 
healthy elderly subjects. In addition, we studied whether elevated PCWP (≥15 mmHg), which was 
effectuated by anti-Gravity garment inflation, could be diagnosed in these subjects by using the 
blood pressure response to the Valsalva manoeuvre.
Methods
Subjects
Inclusion criteria for participation were age ≥65 years and ability to give written informed consent. 
Exclusion criteria were: history or signs of myocardial infarction, stable or unstable angina pectoris, 
rhythm or conduction abnormalities, cardiomyopathy, congestive heart failure, moderate or severe 
valve stenosis or regurgitation, left ventricular hypertrophy (all according to ACC/AHA Practice 
Guidelines); history of hypertension, defined as systolic blood pressure in rest >140 mmHg and/or 
diastolic blood pressure >90 mmHg or use of anti-hypertensive medication (at the screening visit, 
limits of normal blood pressure were 160/90 mmHg); any other serious disease; use of medication 
with cardiovascular effects.
Suitable volunteers were invited to the outpatient clinic to undergo a screening programme 
consisting of medical history, physical examination, electrocardiography, blood laboratory analysis, 
bedside spirometry, bicycle stress-electrocardiography, and echocardiography. The recruitment of the 
subjects was described in a previous report20. In brief, this report described that it was possible to recruit 
healthy elderly volunteers for cardiovascular research, which included cardiac catheterisation, and that 
the main motive for participation was the cardiovascular screening prior to inclusion in the actual 
study. All subjects gave written informed consent. The study was approved by the Ethics Committee 
for Research on Human Subjects of the University Medical Center Nijmegen, The Netherlands, and 
conformed to the principles outlined in the World Medical Association Declaration of Helsinki21.
Materials and measurements
All measurement devices were connected to a personal computer through a data-acquisition box 
and an AD converter. Signals were recorded and sampled with the MID TestOrganizer for Windows 
95, version 5.3 (Department of Biomedical Engineering, University Medical Center, Nijmegen, the 
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Netherlands). The entire measurement system was placed on a mobile handcart, which enabled easy 
bedside monitoring.
PCWP was determined by right-sided catheterisation, using a 7.5 French Swan Ganz CCO/VIP 
139HF75 catheter (Baxter, Irvine, USA), connected to a Perceptor Compensator Morse Manifold 
pressure transducer (Boston Scientific, Maple Grove, USA). The pressure measurement system 
was calibrated with a mercury column. Pressures were measured with the zero level fixed at the 
intersection of the fourth intercostal space and the mid-axillary line and were measured at the end 
of expiration.
Non-invasive continuous arterial blood pressure and heart rate (HR) were measured beat-to-
beat using a Finapres device (Ohmeda 2300, Englewood, CO, USA) on the index- or middle finger 
of the arm that was not catheterised. Finapres has been reported to be an accurate method for 
assessing blood pressure non-invasively22 and assessing blood pressure changes during the Valsalva 
manoeuvre23. A height detector (Department of Biomedical Engineering, University Medical Center, 
Nijmegen, the Netherlands), comparing finger level and heart level at the fourth intercostal space in 
the mid-axillary line, corrected the blood pressure signal for hydrostatic pressure artefacts. 
Finapres blood pressure was analysed offline with the software programme BeatScope, version 
1.0 (TNO-TPD Biomedical Instrumentation, Amsterdam, The Netherlands), which incorporates the 
Modelflow programme, which computes aortic flow from pressure in humans, using a nonlinear 
three-element model. This model represents aortic characteristic impedance, arterial compliance, 
and systemic vascular resistance24. Although Modelflow does not supply reliable absolute cardiac 
output values in the elderly without invasive calibration25, Modelflow has been reported to be 
suitable for assessing relative changes in cardiac output26, 27.
A standard Air Force anti-gravity suit (Anti-G Garment Cutaway CSU-13B/P), consisting of 
five interconnected bladders (calves, thighs, and lower abdomen) was used to increase PCWP 
temporarily. In elderly subjects, anti-G garment inflation has been reported to increase PCWP 
significantly as a result of increase in both cardiac preload and afterload28. The suit was inflated with 
air to a pressure of 52 mmHg (1 psi) using a manual pump, in 30 seconds.
The Valsalva manoeuvre
The Valsalva manoeuvre consisted of a normal inspiration followed by forced expiration for 
15 seconds aiming at a pressure of 40 mmHg, but of at least 30 mmHg, into a tube which was 
connected to a disposable pressure transducer (Baxter, Irvine, USA). The expiratory pressure was 
displayed to the subject on a small monitor for biofeedback. A tiny hole in the tube ensured that 
the pressure was generated in the thorax and not in the mouth by closing the glottis. During the 
screening programme prior to the measurement, the Valsalva manoeuvre was practiced to ensure 
that the subject was able to perform the manoeuvre.
A normal blood pressure response to the Valsalva manoeuvre consists of four typical phases 
(see Figure 1): Phase one represents an initial rise in arterial pressure, caused by transmission of the 
86
Chapter 6 Normal values of pulmonary capillary wedge pressure and the blood pressure response to the Valsalva manoeuvre
87
increased intra-thoracic pressure to the peripheral arteries. Phase two is characterised by reduction 
of systolic, diastolic, and pulse pressure, accompanied by a reflex increase in heart rate caused by 
reduction of venous return. Due to sympathetic reflex activity, in some subjects arterial pressure 
increases in the second part of phase two, while pulse pressure remains decreased, resulting in a 
U-shaped blood pressure curve. Phase three begins with release of the strain when arterial pressure 
drops suddenly due the fall of intra-thoracic pressure. Phase four is characterised by an overshoot 
of arterial pressure accompanied by reflex-bradycardia; this is due to the combination of the inrush 
into the heart of blood which has been dammed up in the venous bed and reflex vasoconstriction 
and tachycardia secondary to the low perfusion pressure of the carotid and baroreceptors during 
phase three10, 29.
Figure 1  Registration of the blood pressure response to the Valsalva manoeuvre. The upper registration is Finapres blood 
pressure. The four typical phases of the blood pressure can be clearly distinguished. See the text for further explanation. 
The lower registration is the expiratory pressure during the Valsalva manoeuvre.
Valsalva ratios were calculated from the blood pressure response to the Valsalva manoeuvre. The 
pulse pressure ratio (PPR) was calculated as the ratio of the mean of the three lowest successive pulse 
pressures in phase two and the mean of the highest three successive pulse pressures in phase 1 (A/B, 
see Figure 1). The systolic blood pressure ratio (SBPR), the diastolic blood pressure ratio (DBPR), 
and stroke volume ratio (SVR) were calculated in the same way. The heart rate ratio (HHR) was the 
ratio of the highest heart rate, calculated as the inverse of the mean of the three successive shortest 
inter-beat intervals during phase two, and the lowest heart rate, the inverse of the mean of the three 
successive longest inter-beat intervals during phase one.
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Protocol
Subjects refrained from caffeine and nicotine for at least 12 hours prior to the experiment. In the 
catheterisation-laboratory, the anti-G garment was applied and the subject assumed a supine 
position at the catheterisation table; after this, the Finapres was applied. A Swan Ganz catheter was 
inserted into the basilic or cephalic vein by an experienced cardiologist (W.R.M.A.) and positioned 
in the left or right pulmonary artery under fluoroscopic guidance. The catheter was left in a non-
occlusive position and the subject was transported to the coronary care unit.
After a five-minute rest period in supine position, mean PCWP was measured before, immediately 
after, and at four minutes after inflation of the anti-G garment. After each determination of PCWP, 
a Valsalva manoeuvre was performed. After deflation, the subject was placed in a semi-recumbent 
position. Following a five-minute rest period, a procedure identical to that performed in the supine 
position was carried out. Two hours after removal of the catheter, the subject was released from the 
hospital. In the evening, a research-nurse performed follow-up by telephone to evaluate late post-
procedural complications.
Statistical analysis
Statistical analysis was performed with SPSS, version 10.0 (SPSS Inc, 2000, Chicago, USA). A two-
sided p-value of 0.05 was taken as the level of significance. Values are expressed as mean with 
the standard deviation. Within-group variables at different time points were compared using 
repeated measurement ANOVA. Variability of a variable during different Valsalva manoeuvres 
was expressed as the within-subject standard deviation, calculated as the square root of the mean 
variance of a variable during three Valsalva manoeuvres30. The coefficient of variation was the 
within subject standard deviation of a variable expressed as percentage of the group mean of that 
variable. Correlation between the blood pressure response to the Valsalva manoeuvre and PCWP 
was computed by calculating Pearson’s correlation coefficient. Multi-variable, stepwise, linear 
regression analysis was performed to assess the importance of baseline variables on the blood 
pressure response to the Valsalva manoeuvre. Assessment of the discriminatory power of the blood 
pressure response to the Valsalva manoeuvre to detect elevated PCWP was performed with Receiver 
Operator Characteristics (ROC) analysis31.
Results
Patient enrolment
The flow diagram in Figure 2 shows the enrolment of healthy elderly subjects in the study protocol. 
More men (85%) than women (15%) completed the protocol: more men (74%) responded to the 
advertisement and since respondents were invited to the screening in order of response, more men 
(74%) than women (16%) were included. In addition, due to spasms of the antecubital veins, the 
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insertion of the catheter failed in three women. The data of the 28 elderly subjects who completed 
the study protocol were suitable for analysis. Subject characteristics are presented in Table 1. The age 
ranged from 65 to 81 years. None of the subjects used medication. At the screening visit, blood pressure 
was assessed sphygmanometrically and was in the (high-) normal range, with systolic blood pressure 
ranging from 110 to 160 mmHg and diastolic blood pressure from 70 to 90 mmHg. On the bicycle 
stress electrocardiography, all subjects performed well, reaching more than the predicted maximal 
heart rate and workload. Echocardiographic findings were all in the normal, age-adjusted range32, 33.
Figure 2  Flow diagram of enrolment of subjects. Between brackets numbers of (male/female); γgt, gamma-glutamyl-
transferase; CCU, coronary care unit; SVT, supra-ventricular tachycardia.
Responded to
advertisement
n=180 (134/46)
Included
n=38 (24/14)
Protocol completed
n=28 (22/6) 
Excluded n=14 (9/5):
Reason for exclusion:
Hypertension n=3 (1/2)
Left/right bundle branch block n=5 (3/2)
Ectopic atrial rhythm n=1 (1/0)
Previous myocardial infarction n=2 (1/1)
Positive stress-electrocardiography n=2 (2/0)
Alcohol abuse with elevated γgt n=1 (1/0) 
Did not complete protocol n=10 (2/8):
Subjects withdrew n=1 (0/1)
Catheter induced SVT n=1 (0/1)
Failed insertion of catheter n=5 (0/5)
Catheter dislocation at CCU n=3 (2/1)
Invited to screening
n=52 (33/19)
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Table 1  Subject characteristics at screening 
Parameter subjects, n=28
Sex (male/female) 22/6
Age (years) 70 ±4
Systolic blood pressure (mmHg) 137  ±14
Diastolic blood pressure (mmHg) 82  ±4
Heart rate (min-1) 64  ±6
Length (cm) 175  ±8
Weight (kg) 77  ±10
Body mass index (kg/m2) 25  ±3
Bicycle stress-electrocardiography
 Maximum heart rate (% of predicted)
 Maximum workload (% of predicted)
106  ±9
141  ±19
Echocardiography
 Left ventricular mass (g)
 Left ventricular mass/length (g/m)
 Peak Velocity early diastolic rapid filling wave (E, m/s)
 Peak Velocity late diastolic atrial contraction wave (A, m/s)
 E/A ratio
 Deceleration time (DT, ms)
 Ejection fraction (Simpson, %)
152 ±32
87 ±17
0.63 ±0.16
0.74 ±0.16
0.86 ±0.18
233 ±51
52 ±7
Data are expressed as mean±SD.
Normal values of PCWP
In supine position, mean PCWP was 9.8±1.9 mmHg, ranging from 6.7 to 14.0 mmHg, 5th – 95th 
percentiles: 6.7-13.3 mmHg. In semi-recumbent position, mean PCWP was 8.9±2.1 mmHg, ranging 
from 4.6 to 12.5 mmHg, 5th – 95th percentiles: 5.1-12.4 mmHg.
The Valsalva manoeuvre and normal values of the blood pressure response
All subjects were able to achieve an expiratory pressure of at least 30 mmHg. Group mean values of 
the systolic blood pressure, diastolic blood pressure, pulse pressure, and heart rate during the four 
phases of the Valsalva manoeuvre, are shown in Figure 3. For each phase of the Valsalva manoeuvre 
compared to the preceding phase, the changes in blood pressure and heart rate were significant, 
except for diastolic blood pressure in phase two versus phase one in the supine position, and for 
pulse pressure in phase one compared to baseline in the semi-recumbent position.  Per subject, the 
mean values of the three subsequent Valsalva manoeuvres were used. Table 2 shows the mean values 
and percentiles of the SBPR, DBPR, PPR, SVR, and HRR in supine and semi-recumbent position. In 
supine position, the coefficient of variation of SBPR was 9%, of DBPR 9%, of PPR 14%, of SVR 13%, 
and of HRR 9%. In semi-recumbent position, the coefficient of variation of SPR was 9%, of DBPR 9%, 
of PPR 19%, of SVR 18%, and of HRR 15%.
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Figure 3  Group mean values with standard deviations (brackets) of the systolic blood pressure (SBP), diastolic blood 
pressure (DBP), pulse pressure (PP), and heart rate, during baseline (0) and the four phases (1-4) of the Valsalva manoeuvre, 
in supine position (n=28, panel a) and in semi-recumbent position (n=27, panel b). Due to dislocation of the catheter 
during the study protocol, in one subject values were obtained in supine position only.
Table 2  Mean and percentile values of Valsalva ratios in supine and semi-recumbent position 
Variable percentiles (%)
Supine n=28 mean±SD 5 10 25 50 75 90 95
Systolic blood pressure ratio (SBPR) 0.76±0.11 0.57 0.60 0.67 0.76 0.83 0.89 0.98
Diastolic blood pressure ratio (DBPR) 0.98±0.11 0.80 0.84 0.88 0.99 1.04 1.18 1.23
Pulse pressure ratio (PPR) 0.51±0.16 0.22 0.26 0.42 0.51 0.59 0.65 0.90
Stroke volume ratio (SVR) 0.42±0.11 0.23 0.29 0.32 0.42 0.49 0.54 0.67
Heart rate ratio (HRR) 1.17±0.12 1.01 1.04 1.07 1.16 1.24 1.36 1.41
semi-recumbent n=27 mean±SD
Systolic blood pressure ratio (SBPR) 0.74±0.10 0.57 0.64 0.68 0.71 0.79 0.88 0.97
Diastolic blood pressure ratio (DBPR) 0.96±0.12 0.76 0.86 0.88 0.93 0.99 1.10 1.29
Pulse pressure ratio (PPR) 0.46±0.14 0.27 0.31 0.38 0.43 0.56 0.61 0.83
Stroke volume ratio (SVR) 0.41±0.10 0.26 0.29 0.33 0.41 0.46 0.55 0.66
Heart rate ratio (HRR) 1.24±0.23 0.95 1.04 1.14 1.18 1.32 1.43 1.95
Relation between the Valsalva ratios and PCWP
Table 3 shows the correlation coefficients of the Valsalva ratios and PCWP. PPR and SVR showed a 
significant correlation with PCWP. HRR did not correlate significantly with PCWP. In semi-recumbent 
position, the correlation of PPR and SVR with PCWP was stronger than in supine position. Figure 4 
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shows a scatter plot of PCWP and PPR in semi-recumbent position, with the regression line, and the 
regression equation. 
Of all baseline variables, PCWP only correlated significantly with the body mass index: in supine 
position r=0.47, p=0.01 and in semi-recumbent position r=0.49, p=0.01. In the supine position, 
stepwise multi-variable regression identified SVR and BMI as the strongest independent predictors 
for PCWP, equation: PCWP = -1.4 + 7.8*SVR + 0.32*BMI, r=0.65, p=0.001. In semi-recumbent position, 
PPR and BMI were the strongest independent predictors for PCWP, equation: PCWP = -3.6 + 7.9*PPR 
+ 0.35*BMI, r=0.71, p<0.001.
Table 3  Correlation coefficients of the Valsalva Ratios and PCWP in supine and semi-recumbent position
Variable supine semi-recumbent
Baseline n=28 n=27
PCWP range, mmHg 7 – 14 5 – 13 
r p r p
SBPR 0.31 NS 0.35 NS
DBPR 0.10 NS 0.14 NS
PPR 0.40 0.04 0.51 <0.01
SVR 0.44 0.02 0.51 <0.01
HRR 0.31 NS 0.20 NS
PCWP = pulmonary capillary wedge pressure, SBPR = systolic blood pressure ratio, DBPR = diastolic blood pressure ratio, 
PPR = pulse pressure ratio, SVR = stroke volume ratio, HRR = heart rate ratio. r = correlation coefficient, NS = not significant.
Figure 4  Scatterplot of PCWP and PPR of 27 subjects in semi-recumbent position. The line is the regression line.
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The influence of inflation of an Anti-G garment on the PCWP and the blood pressure response 
to the Valsalva manoeuvre is shown in Figure 5. PCWP increased significantly immediately after 
inflation, and declined slightly after four minutes, yet was still significantly elevated compared to 
baseline. In supine position, SBPR, PPR and SVR, increased significantly immediately after inflation, 
compared to baseline. After four minutes, the increase was not statistically significant compared to 
baseline. In semi-recumbent position, only the increase of SVR was significant.
Figure 5  Effect of inflation of an anti-gravity (anti-G) garment in supine (panel a) and in semi-recumbent position (panel 
b), at baseline (0), immediately after inflation (1), and at four minutes after inflation (2), on the systolic blood pressure ratio 
(SBPR, black circles), pulse pressure ratio (PPR, white circles), stroke volume ratio (SVR, grey circles), heart rate ratio (HHR), 
and on pulmonary capillary wedge pressure (PCWP). The brackets indicate the 95% confidence interval of the mean. 
* p<0.05, ** p<0.01, compared to baseline.
In order to assess the discriminatory power of the blood pressure response to the Valsalva 
manoeuvre to detect elevated PCWP (≥15 mmHg), ROC analysis was performed. In supine position, 
immediately after inflation, the area under the curve was only significantly greater than 0.5 for SVR, 
namely 0.77; 95% CI: 0.56-0.98, p=0.020. However, at four minutes after inflation, the area under the 
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curve of SVR was 0.87; 95% CI: 0.71-1.03, p=0.012; also for SBPR and PPR, the area under the curve 
was larger than 0.5: 0.85; 95% CI: 0.62-1.08, p=0.017, and 0.86; 95% CI: 0.64-1.08, p=0.014, respectively. 
In semi-recumbent position, for SBPR, PPR, and SVR, the area under the curve was not significantly 
larger than 0.5. For HRR, the area under the curve was not above 0.5 in any position.
There was no significant correlation between PCWP and echocardiographic variables, which 
were not assessed at the same day: peak velocity early diastolic rapid filling wave (E) (r=0.05, NS), 
peak velocity late diastolic atrial contraction wave (A) (r=0.19, NS), E/A ratio (r=0.17, NS), and 
deceleration time (DT) (r=0.08, NS).
Discussion
To our knowledge, this is the first study reporting normal values of the blood pressure response to 
the Valsalva manoeuvre in the elderly. While the relationship of the blood pressure response to the 
Valsalva manoeuvre in patients has been described extensively, data of healthy subjects are lacking. 
In the elderly, in whom the prevalence of heart failure is highest, normal values of the blood pressure 
response have never been reported. Normal values for the blood pressure response to the Valsalva 
manoeuvre in healthy subjects, including measures of variability, are essential in interpreting patient 
data. The data from this study enable correct interpretation of data on the relationship between 
cardiac filling pressures and the blood pressure response to the Valsalva manoeuvre in elderly 
patients, in not only studies already performed but also in future studies.
In the normal range of PCWP, the PPR and SVR correlated significantly with PCWP, however 
these correlations were moderate. The SBPR did not correlate significantly with PCWP. The 
moderate correlation of the blood pressure response to the Valsalva manoeuvre and PCWP is not 
in accordance with previous reports describing a stronger correlation12, 34. In these reports, the range 
of PCWP was large, from 2 to 32 mmHg. This range is much larger than in our healthy subjects, 
in whom PCWP was in the normal range. In the physiological range of PCWP, there may be no 
evident linearity between the blood pressure response to the Valsalva manoeuvre and PCWP; at 
least the natural scatter of variables appears to be larger than their correlation. This is supported by 
a study performed in patients undergoing diagnostic catheterisation, with preserved left ventricular 
function and left ventricular end-diastolic pressure (LVEDP) below 25 mmHg. The PPR, derived 
from intra-aortal blood pressure, showed no relationship with LVEDP35. In addition, with increasing 
age, variability increases36, which might explain the modest correlation between the blood pressure 
response to the Valsalva manoeuvre and PCWP. 
We found that the correlation between PPR and PCWP and SVR and PCWP was stronger than 
between SBPR and PCWP. An explanation might be that, in contrary to SBPR, PPR is not influenced 
by the U-shaped phenomenon in the blood pressure response. The U-shaped phenomenon, which 
was described previously in healthy subjects29, is characterised by a simultaneous increase of DBP 
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and SBP in the second part of phase two of the blood pressure response, resulting in a decreased 
but steady pulse pressure. SBPR will be influenced by this, but PPR will remain unchanged. A 
disadvantage of using PPR to assess PCWP might be the large coefficient of variance. An important 
aspect of diagnostic testing is the reproducibility of the results. The coefficient of variation of the PPR 
is around 15%, larger than that of SBPR, which could be a disadvantage of using PPR versus SBPR.
In phase two of the Valsalva manoeuvre, heart rate was significantly higher than in phase one. 
While we found no correlation between the HRR and PCWP, the change in heart rate could still have 
influenced our results. It has been reported that with increasing heart rate, central systolic pressure 
and pulse pressure decrease significantly while peripheral systolic pressure and pulse pressure remain 
unchanged, due to a change in the shape of the central pressure wave form as a result of reduced 
wave reflection37. This could mean that in patients with low PCWP, the PPR measured at the finger 
is higher than when the PPR would be derived from pulse pressure measured in the aorta. Our 
study was designed to obtain normal values of blood pressure response to the Valsalva manoeuvre 
measured with non-invasive measurement of blood pressure at the finger and our results may 
therefore not used as a reference to Valsalva ratios derived from central aortal blood pressures.
Since the decrease of blood pressure during the straining phase of the Valsalva manoeuvre can be 
explained by hampered filling of the right and, later, the left ventricle, resulting in reduction of stroke 
volume, we expected that the relative reduction of stroke volume also would be related to PCWP. 
Indeed, SVR correlated with PCWP but not stronger than PPR did. An explanation for this might 
be that stroke volume was derived from the blood pressure curve with pulse contour analysis, as it 
cannot be measured directly.
Though the blood pressure response to the Valsalva manoeuvre correlates only moderately, 
based on ROC analyses, PPR, SBPR and SVR appear to be good diagnostic instruments for detection 
of PCWP higher than 15 mmHg, which is considered to be to high. For example, in the supine 
position at four minutes after inflation, for a PPR cut-off level of 0.6 for elevated PCWP, sensitivity 
was 0.8 and specificity was 0.9. In heart failure, filling pressure is elevated6 and because PCWP is an 
estimate of left ventricular filling pressure7, elevated PCWP is highly suggestive for the (subclinical) 
presence of heart failure. Therefore, the blood pressure response to the Valsalva manoeuvre might 
be a valuable tool in the non-invasive diagnosis of heart failure.
With the changing properties of the aging heart, one might expect that cardiac filling pressure 
increases in the elderly. However, we found in a relatively large group of subjects that all mean PCWP 
values were in the normal range of 6 to 15 mmHg38, which is in accordance with the limited data of 
two previous studies in small groups of 11 and 14 healthy elderly subjects, respectively18, 19. With the 
availability of normal values of PCWP, in addition to the scarce data on normal PCWP in the elderly, 
this report may be of interest for future studies.
We acknowledge that echocardiography is the method for assessment of cardiac function and is 
an important tool in the diagnosis of heart failure39. However, cardiac dysfunction and heart failure 
are not synonyms. Based on the definition of heart failure as the state in which the heart is unable 
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to pump blood at the rate needed by the metabolising tissues or can do so only with elevated 
filling pressures6, assessment of left ventricular filling pressure or PCWP seems mandatory. Several 
echocardiographic approaches to assess PCWP have been proposed, but it is not clear if any of these 
methods provides the precision and accuracy needed for the evaluation of patients40. In our study, 
we found no correlation between echocardiographic variables and PCWP, which were not assessed 
on the same day. However, as mentioned before, PCWP was in the normal range in all subjects, which 
could partly explain the poor correlation. Furthermore, we did not use tissue Doppler imaging, 
which has been reported to be promising in the assessment of PCWP41. Therefore, we cannot 
conclude that the Valsalva ratios are superior to echocardiography or vice versa, but the Valsalva 
manoeuvre may give information additional to echocardiography. Furthermore, echocardiography is 
not immediately accessible for dyspnoeic patients who visit a General Physician and in that case, the 
Valsalva manoeuvre might be more easily available for the diagnosis of heart failure.
This study was subject to some limitations: only 15% of our subjects were female, while most 
of the elderly cardiac patients are female. Therefore, our data may not be representative for female 
cardiac patients.
Conclusion
This is the first study to obtain normal values of the blood pressure response to the Valsalva 
manoeuvre and PCWP in healthy elderly subjects, which is essential for the correct interpretation of 
patient data on PCWP and the Valsalva manoeuvre. In supine position, the blood pressure response 
to the Valsalva manoeuvre showed significant discriminatory power in the detection of elevated 
PCWP, which underscores its potential in the non-invasive diagnosis of heart failure.
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Abstract
In the present study, we assessed whether elevated (≥15 mmHg) pulmonary capillary wedge pressure 
(PCWP) can be detected using the blood pressure response to the Valsalva manoeuvre in a group of 
elderly patients with various cardiac disorders, including atrial fibrillation and valvular heart disease, 
and healthy elderly controls. The Valsalva manoeuvre was performed in 93 patients, 71±4 years 
and 28 healthy controls, aged 70±4, undergoing right-sided cardiac catheterisation. Blood pressure 
was measured non-invasively with Finapres. Pulse pressure ratio (PPR), the ratio of minimum pulse 
pressure during phase 2 and maximum pulse pressure during phase 1 of the Valsalva manoeuvre, 
was correlated to PCWP, r=0.63, p<0.001. The area under the receiver operator characteristic curve 
of PPR with elevated PCWP was 0.85 (p<0.001). For PPR=0.62, sensitivity for elevated PCWP was 80%, 
specificity 79%, positive predictive value 76%, negative predictive value 83%. Correlation of PPR with 
PCWP and the ability of PPR to detect elevated PCWP was present in atrial fibrillation, heart failure, 
and valvular heart disease. In conclusion, the PPR is a sensitive and specific instrument to diagnose 
elevated PCWP non-invasively in a large group of elderly patients with various cardiac disorders. This 
makes the Valsalva manoeuvre a useful non-invasive tool for diagnosing heart failure, applicable in 
elderly patients with common cardiac disorders, such as atrial fibrillation and valvular heart disease.
Introduction
The prognosis of heart failure can be improved with early diagnosis and treatment1. However, 
physical examination and radiographic methods are not very sensitive for detection of heart failure 
and heart failure can be missed easily, especially in the elderly2, 3. Therefore, a simple, non-invasive 
bedside technique for diagnosis of heart failure could be useful.
Heart failure can be defined as the pathophysiological state in which the heart is unable to pump 
blood at a rate needed by the metabolising tissues or can do so only from elevated filling pressure4. 
Since the blood pressure response to the Valsalva manoeuvre is related to pulmonary capillary wedge 
pressure (PCWP), which is a measure of left ventricular filling pressure, it may be used to diagnose 
heart failure. An abnormal blood pressure response to the Valsalva manoeuvre in the presence of 
heart failure was reported over six decades ago5. From 1989, reports have quantitatively described 
the relationship between the blood pressure response to the Valsalva manoeuvre and cardiac filling 
pressures6-10. These reports all described small numbers of patients, with only few patients with 
valvular heart disease being reported, and only two patients were reported to have atrial fibrillation7. 
Furthermore, these studies were not restricted to the elderly in whom the prevalence of heart failure 
is highest3.
Valvular heart disease and arrhythmias are often present in the elderly and can lead to heart 
failure or worsening of heart failure3. A method to diagnose heart failure should not only be 
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applicable in the elderly, but should also be applicable in common cardiac disorders such as atrial 
fibrillation and valvular heart disease. Therefore, the present study sought to assess whether elevated 
PCWP (≥15mmHg) can be detected in a large heterogeneous group of elderly cardiac patients with 
various cardiac disorders, including atrial fibrillation and valvular heart disease, and healthy elderly 
controls.
Materials and methods
Patients
Between March 2000 and April 2002, consecutive elderly patients (n=104), aged 65 years and 
older, who were scheduled to undergo right-sided cardiac catheterisation at the catheterisation 
laboratory or the coronary care unit of the University Medical Center Nijmegen, The Netherlands, 
were evaluated to take part in the present study. The indication for catheterisation was determined 
by the treating physician at the outpatient clinic or during hospitalisation, and was not performed 
for research purposes. Reasons for hospital admission were congestive heart failure or an acute 
coronary syndrome. Reasons for right-sided catheterisation (either with or without left-sided cardiac 
catheterisation) were diverse including as part of the preparation for surgery for valvular heart 
disease and/or coronary artery bypass grafting, as part of the diagnostic process for the cause of 
heart failure, and for hemodynamic monitoring of patients with acute heart failure.
Severe chronic obstructive lung disease has a marked influence on the blood pressure response to 
the Valsalva manoeuvre11 and was reason for exclusion. Baseline characteristics were recorded from 
the patient’s medical file at the time of the catheterisation. Echocardiography or nuclear cardiac 
imaging, before or after catheterisation, was performed at the discretion of the treating physician 
and was not part of the study protocol. All subjects gave written informed consent. The study was 
approved by the Ethics Committee for Research on Human Subjects of the University Medical 
Center Nijmegen, The Netherlands, and conformed to the principles outlined in the Declaration of 
Helsinki12.
Controls
Data were used of 28 healthy elderly subjects, aged 70±4 years, who participated in a study on normal 
values of the blood pressure response to the Valsalva manoeuvre and PCWP, which was published 
recently13. The recruitment of these subjects was described in a previous report14. In brief, this report 
described that it was possible to recruit healthy elderly volunteers for cardiovascular research, which 
included cardiac catheterisation, and that the main motive for participation was the cardiovascular 
screening prior to inclusion in the actual study.
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Materials
Measurement devices were connected to a personal computer through a data-acquisition box and 
an AD converter. Signals were recorded and sampled with the MID TestOrganizer for Windows 
95, version 5.3 (Department of Biomedical Engineering, University Medical Center, Nijmegen, the 
Netherlands). The entire measurement system was placed on a mobile handcart, which enabled easy 
bedside monitoring.
Right-sided cardiac catheterisation
PCWP and pulmonary artery pressure (PAP) were determined by right-sided catheterisation using a 
7 French Swan Ganz catheter (Baxter, Irvine, USA). PCWP and PAP were measured with the zero level 
fixed at the intersection of the fourth intercostal space and the mid-axillary line and were measured 
at the end of expiration. In cases where coronary angiography or ventriculography was planned, 
pressure measurements were performed before administration of contrast medium.
Measurement of blood pressure and heart rate
Non-invasive continuous arterial blood pressure and heart rate were measured beat-to-beat using a 
Finapres device (Ohmeda 2300, Englewood, USA) on the index- or middle finger. Finapres has been 
reported to be an accurate method of assessing blood pressure non-invasively15 and for assessing 
blood pressure changes during the Valsalva manoeuvre16.
Finapres blood pressure was analysed offline with the software programme BeatScope, version1.0 
(TNO-TPD Biomedical Instrumentation, Amsterdam, The Netherlands), which computes aortic 
flow from pressure in humans, using a nonlinear three-element model. This model represents 
aortic characteristic impedance, arterial compliance, and systemic vascular resistance17. Although 
Modelflow does not supply reliable absolute cardiac output values in the elderly without invasive 
calibration18, Modelflow has been reported to be suitable for assessing relative changes in cardiac 
output19.
The Valsalva manoeuvre
The Valsalva manoeuvre consisted of a normal inspiration followed by forced expiration for 15 
seconds with the aim of reaching a pressure of 40 mmHg in a tube, which was connected to a 
disposable pressure transducer (Baxter, Irvine, USA). A tiny hole in the tube ensured that the 
pressure was generated in the thorax and not in the mouth by closing the glottis.
A normal blood pressure response to the Valsalva manoeuvre consists of four typical phases 
as shown in the upper panel of Figure 1. Phase one represents an initial rise in arterial pressure, 
caused by transmission of the increased intra-thoracic pressure to the peripheral arteries; Phase 
two is characterised by reduction of systolic, diastolic, and pulse pressure, accompanied by a reflex 
increase in heart rate, caused by reduction of venous return; Phase three begins with release of the 
strain when arterial pressure falls suddenly due the fall of intra-thoracic pressure; and phase four is 
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characterised by an overshoot of arterial pressure to above control levels accompanied with reflex-
bradycardia.
Figure 1  Upper panel: Registration of the blood pressure response to the Valsalva manoeuvre. The upper registration 
is Finapres blood pressure. The four typical phases can clearly be distinguished (see text for explanation). The lower 
registration is the expiratory pressure during the Valsalva manoeuvre. An abnormal blood pressure response, which is seen 
in heart failure, is characterised by absence of decrease in blood pressure during phase two, as shown in the lower panel.
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An abnormal blood pressure response, which is seen in heart failure, is characterised by absence 
of decrease in blood pressure during Phase two, as shown in the lower panel of Figure 1. The 
absence of a decrease in blood pressure during phase two is caused by elevation of central venous 
and pulmonary venous pressure, which enables filling of the heart in spite of the increase in intra-
thoracic pressure5, 20. The decrease in blood pressure was also reported to depend on the slope and 
the position on the left-ventricular function curve20. On this curve, stroke work, of which pulse 
pressure and mean arterial pressure are approximate indices, is plotted against filling pressure. With 
high filling pressures, at the flattened part of the curve, a fall in filling pressure will affect stroke work 
only minimally. The slope of the curve is dependent on the severity of the heart disease. In patients 
with elevated left ventricular filling pressures, a decrease in filling pressure due to straining will not 
result in a decrease in arterial blood pressure.
Before catheterisation, the Valsalva manoeuvre was practiced to make the patient familiar with 
the manoeuvre. Immediately after measurement of PCWP and PAP, the Valsalva manoeuvre was 
performed in supine position, preferably three times but at least once, depending on the patient’s 
ability. Between two successive manoeuvres, a two-minute rest period was applied. The expiratory 
pressure was displayed to the subject at a small monitor for biofeedback. The patient was encouraged 
to achieve an expiratory pressure of 40 mmHg or, if not possible, as high as possible, for at least 12 
seconds. A minimum cut-off level of expiratory pressure of 20 mmHg was chosen since this level still 
induces a significant decrease in pulse pressure in normal subjects21.
Valsalva ratios
Valsalva ratios were calculated from the blood pressure response to the Valsalva manoeuvre. The pulse 
pressure ratio was calculated as the ratio of the mean of the three lowest successive pulse pressures in 
phase two and the mean of the highest three successive pulse pressures in phase one (A/B, see Figure 
1). In atrial fibrillation, the mean of the five lowest successive pulse pressures in phase two and the 
mean of the five highest successive pulse pressures in phase one were used. The systolic blood pressure 
ratio, the diastolic blood pressure ratio, and stroke volume ratio were calculated in the same way. The 
heart rate ratio was the ratio of the highest heart rate, calculated as the inverse of the mean of the 
three successive shortest inter-beat intervals during phase two, and the lowest heart rate, the inverse 
of the mean of the three successive longest inter-beat intervals during phase one. For all ratios, the 
mean of the Valsalva manoeuvres performed by a single patient was used for further analysis. 
Data analysis and statistics
Statistical analysis was performed with SPSS 10.0 for Windows (SPSS Inc, 2000, Chicago, USA). 
Values are expressed as mean±SD. A two-sided p-value ≤0.05 was considered to indicate statistical 
significance.
Variability of a variable during different Valsalva manoeuvres was expressed as the within-
subject standard deviation, calculated as the square root of the mean variance of a variable during 
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three Valsalva manoeuvres. The coefficient of variation was the within subject standard deviation 
expressed as percentage of the group mean22. Linear regression modelling was used to estimate 
the univariate and multivariate relation of the blood pressure response to the Valsalva manoeuvre 
with PCWP. Stepwise forward selection was performed with a value of p<0.05 as the criterion to 
remain in the model. Assessment of the discriminatory power of the blood pressure response to the 
Valsalva manoeuvre to detect elevated PCWP (≥15 mmHg) was performed with Receiver Operator 
Characteristics (ROC) analysis. Chi-Square or Fischer’s exact tests were used for dichotomous 
data, and Mantel-Haenszel Chi-Square tests for ordinal data. For comparison of continuous data, 
independent samples T-tests were used.
Results
Characteristics of the patients
During the study period, 104 patients undergoing right-sided catheterisation were initially included 
in the study. The data of five patients were discarded because we were not able to get a stable 
Finapres signal (n=4), and one patient developed non-sustained ventricular tachycardia during the 
Valsalva manoeuvre, caused by the Swan-Ganz catheter or by the Valsalva manoeuvre itself. Of the 
remaining 99 patients, 6 patients (5 female, 1 male) were not able to achieve an expiratory pressure 
of at least 20 mmHg and thus their data were excluded from analysis.
The baseline characteristics of the remaining 93 patients are shown in Table 1. Left ventricular 
ejection fraction (LVEF) data were available in all patients. In 87 patients, LVEF was assessed by 
echocardiography. Of the remaining 6 patients, ventriculographic LVEF was used in 5 patients, and 
scintigraphic LVEF was used in one patient. Of 93 patients, 21 (23%) were known with a history of 
heart failure and 26 (28%) were admitted because of heart failure. In 63 (68%) patients, suspected 
heart failure was a reason for the right-sided catheterisation. In 40 patients (43%), diagnosis of heart 
failure was mentioned in the patient’s medical file. ACE-inhibitors were used by 46%, beta blockers 
by 68%, calcium channel blockers by 17%, digoxin by 23%, and diuretics by 49% of patients. Of the 
93 patients, 10 patients performed one Valsalva manoeuvre, 22 performed two, and 61 performed 
three Valsalva manoeuvres. The coefficient of variation of the systolic blood pressure ratio was 8%, 
of the diastolic blood pressure ratio 8%, of the pulse pressure ratio 17%, of the stroke volume ratio 
17%, and of the heart rate ratio 12%.
Of the 28 controls, 6 were females. None of the controls used medication. All controls performed 
three Valsalva manoeuvres. The coefficient of variation of the systolic blood pressure ratio was 9%, 
of the diastolic blood pressure ratio 9%, of the pulse pressure ratio 14%, of the stroke volume ratio 
13%, and of the heart rate ratio 9%. Hemodynamic data of the catheterisation and Valsalva ratios of 
patients and controls are shown in Table 2.
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Table 1  Baseline characteristics of the patients
n=93
Variable No. (%)
Age (yr) 71±5 (range: 65-83)
Male/Female sex 55/38 (59/41)
Length (cm) 169±9
Weight (kg) 76±14
Smoking 13 (14)
Malignancy 11 (12)
Diabetes Mellitus 22 (24)
Hypertension 41 (44)
Previous myocardial infarction 20 (22)
Previous coronary artery bypass grafting 15 (16)
Atrial fibrillation 16 (17)
Aortic regurgitation 18 (19)
Aortic stenosis 34 (37)
Mitral regurgitation 26 (28)
Mitral stenosis 6 (7)
Left ventricular ejection fraction (%) 49±16
Heart failure in medical history 21 (23)
Heart failure at admission 26 (28)
CKMB or troponin I positive at admission 12 (13)
Plus-minus values are means±SD.
Table 2  Hemodynamic data and Valsalva ratios 
Patients Controls
Variable n=93 n=28
Invasively assessed pressures
Right atrial pressure 8 ± 5 (n=88) -
Systolic pulmonary artery pressure 41 ± 16 27 ± 4***
Diastolic pulmonary artery pressure 20 ± 8 13 ± 2***
Mean pulmonary artery pressure 28 ± 10 17 ± 2***
Pulmonary capillary wedge pressure 17 ± 8 10 ± 2***
End diastolic left ventricular pressure 20 ± 7 (n=63) -
Valsalva ratios
Systolic pressure ratio 0.84 ± 0.17 0.76 ± 0.11**
Diastolic pressure ratio 1.00 ± 0.13 0.99 ± 0.11
Pulse pressure ratio 0.65 ± 0.25 0.51 ± 0.16**
Stroke volume ratio 0.58 ± 0.20 0.42 ± 0.11***
Heart rate ratio 1.09 ± 0.18 1.17 ± 0.12*
Data are expressed as mean±SD. Pressures are expressed in mmHg. Valsalva ratios are means of 1 to 3 Valsalva 
manoeuvres performed by each patient. All controls performed 3 manoeuvres. * p<0.05, ** p<0.01, *** p<0.001 controls 
versus patients.
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Correlation between the blood pressure response to the Valsalva manoeuvre and 
PCWP
In the patients, pulse pressure ratio was significantly correlated to PCWP with a correlation 
coefficient (r) of 0.62, p<0.001, as were systolic blood pressure ratio, r=0.54, p<0.001, diastolic blood 
pressure ratio, r=0.35, p=0.001, and stroke volume ratio, r=0.58, p<0.001. The heart rate ratio was 
not correlated to PCWP. Using stepwise forward analysis with systolic blood pressure ratio, pulse 
pressure ratio, diastolic blood pressure ratio, and stroke volume ratio, pulse pressure ratio was 
related most strongly to PCWP. Therefore, only pulse pressure ratio was used in further regression 
modelling. Figure 2 displays a scatter plot of PCWP and pulse pressure ratio and the regression lines 
of PWCP regressed on pulse pressure ratio in patients, controls, and patient and controls together. 
In the group of patients and controls together, the correlation coefficient of pulse pressure ratio and 
PCWP was 0.63, p<0.001. 
The discriminatory power of the blood pressure response to the Valsalva manoeuvre to detect 
elevated (≥15 mmHg) PCWP in patients and controls was performed by plotting an ROC-curve, 
see Figure 3. The area under the ROC curve was 0.85; 95% CI: 0.78–0.92 (p<0.001). For a cut-off 
value of pulse pressure ratio of 0.62, sensitivity for elevated PCWP was 80%, specificity 79%, positive 
predictive value was 76%, and negative predictive value was 83%. 
Figure 2  Scatter plot of pulmonary capillary wedge pressure (PCWP) and pulse pressure ratio (PPR) in study patients 
(n=93, black circles). The dashed line is the regression line: PCWP = 4.7 + (19.4 x PPR), r=0.62, p<0.001. Data of healthy 
elderly controls, who participated in a previous study on PCWP and the Valsalva manoeuvre13, are also shown (n=28, open 
circles). The dotted line is the regression line: PCWP = 7.4 + (4.8 x PPR), r=0.40, p=0.036. The solid line is the regression line 
of patients and controls together (n=121): PCWP = 3.2 + (20.1 x PPR), r=0.63, p<0.001.
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Figure 3  Receiver Operating Characteristic curve of the pulse pressure ratio (PPR) on elevated (≥15 mmHg) pulmonary 
capillary wedge pressure in patients and controls (n=121). The area under the curve is 0.85; 95% CI: 0.78 – 0.92, p<0.001.
Influence of cardiac disorders and use of medication
Of the baseline variables, heart failure (in medical history or as reason for hospital admission), 
presence of pulmonary rales, and mitral stenosis were significantly related to PCWP. Stepwise 
regression modelling identified pulse pressure ratio as the strongest predictor of PCWP, with heart 
failure and mitral stenosis as other independent predictors of PCWP.
In Table 3, patients are grouped by the presence or absence of various cardiac disorders. If patients 
with atrial fibrillation are excluded from analysis, the correlation coefficient remains unchanged in 
the remaining patients. In patients with atrial fibrillation (n=16), the correlation coefficient was 
significant. The area under the ROC curve for diagnosis of elevated PCWP was around 0.80 in all 
subgroups. For the small group of patients with mitral valve stenosis (n=6), PCWP was elevated and 
pulse pressure ratio was equal or above 0.6 in all patients.
In Table 4, patients are grouped according to the use of beta-blockers, ACE inhibitors, calcium 
channel blockers, digoxin, and diuretics. The correlation between the pulse pressure ratio and PCWP 
was significant in all subgroups, and the area under the ROC curve for diagnosis of elevated PCWP 
was above 0.80 in all subgroups.
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Table 3  Coefficients of regression analysis of PCWP on PPR, and areas under the ROC-curves for PCWP ≥15 mmHg, in 
patients grouped by the presence or absence of cardiac disorders
n PCWP range PPR range r p ROC-AUC 95% CI p
All patients 93 0.8-44.1 0.16-1.16 0.62 <0.001 0.84 0.76-0.92 <0.001
Atrial fibrillation 16 8.4-27.8 0.41-1.07 0.50 0.048 0.84 0.63-1.04 0.036
No atrial fibrillation 77 0.8-44.1 0.16-1.16 0.64 <0.001 0.85 0.76-0.93 <0.001
Aortic regurgitation 18 4.1-31.5 0.20-1.16 0.71 0.001 0.99 0.95-1.03 0.001
Aortic stenosis 34 4.1-39.9 0.20-1.16 0.58 <0.001 0.81 0.67-0.96 0.002
Mitral regurgitation 26 2.3-34.7 0.19-1.07 0.57 0.002 0.81 0.63-0.99 0.010
Mitral stenosis 6 16.1-39.9 0.60-1.01 0.46 NS - - -
Any valvular heart disease 58 2.3-39.9 0.19-1.16 0.59 <0.001 0.83 0.72-0.94 <0.001
No valvular heart disease 35 0.8-44.1 0.16-1.09 0.66 <0.001 0.86 0.73-0.98 <0.001
Heart failure 40 0.8-44.1 0.20-1.16 0.70 <0.001 0.90 0.81-1.00 <0.001
No heart failure 53 2.3-28.8 0.16-1.02 0.45 0.001 0.78 0.66-0.91 <0.001
LVEF <40% 24 7.1-44.1 0.24-1.09 0.74 <0.001 0.92 0.80-1.03 0.003
LVEF ≥40% 69 0.8-34.7 0.16-1.16 0.56 <0.001 0.81 0.71-0.91 <0.001
PCWP = pulmonary capillary wedge pressure, in mmHg, PPR = pulse pressure ratio, ROC = Receiver Operating 
Characteristic, AUC = area under the curve, LVEF = left ventricular ejection fraction, r = coefficient of regression, 
CI = confidence interval. More than one disorder can be present in one patient.
Table 4  Coefficients of regression analysis of PCWP on PPR, and areas under the ROC-curves for PCWP ≥15 mmHg, in 
patients grouped by use of medication
n PCWP range PPR range r p ROC-AUC 95% CI p
All patients 93 0.8-44.1 0.16-1.16 0.62 <0.001 0.84 0.76-0.92 <0.001
Beta blockers 63 0.8-44.1 0.20-1.16 0.62 <0.001 0.85 0.76-0.95 <0.001
No beta blockers 30 2.3-39.9 0.16-1.07 0.63 <0.001 0.82 0.65-0.98 0.004
ACE inhibitors 43 0.8-30.0 0.20-1.07 0.52 <0.001 0.83 0.69-0.96 0.001
No ACE inhibitors 50 2.3-44.1 0.16-1.16 0.69 <0.001 0.85 0.74-0.95 <0.001
Calcium channel blockers 16 9.5-34.7 0.20-1.02 0.62 0.010 0.84 0.60-1.08 0.023
No calcium channel 
blockers
77 0.8-44.1 0.16-1.16 0.62 <0.001 0.84 0.75-0.93 <0.001
Digoxin 21 0.8-31.5 0.20-1.16 0.77 <0.001 0.87 0.71-1.02 0.007
No digoxin 72 2.3-44.1 0.16-1.09 0.55 <0.001 0.83 0.73-0.93 <0.001
Diuretics 46 0.8-44.1 0.20-1.16 0.66 <0.001 0.85 0.73-0.98 <0.001
No diuretics 47 2.3-31.5 0.16-1.03 0.55 <0.001 0.83 0.72-0.95 <0.001
PCWP = pulmonary capillary wedge pressure, in mmHg, PPR = pulse pressure ratio, ROC = Receiver Operating 
Characteristic, AUC = area under the curve, r = coefficient of regression, CI = confidence interval.
Influence of expiratory pressure
Of 93 patients, 9 patients (10%) were able to achieve an expiratory pressure during the Valsalva 
manoeuvre of 40 mmHg; 68 patients (73%) were able to achieve 30 mmHg. The expiratory pressure 
was not significantly correlated to PCWP, r=0.14, NS. The expiratory pressure was correlated to the 
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pulse pressure ratio, r=0.39, p<0.001. The higher the expiratory pressure achieved, the higher the 
correlation coefficient was of PCWP on pulse pressure ratio. Of the patients not able to achieve an 
expiratory pressure of 30 mmHg, more patients were female, of shorter length, less on beta-blockers, 
and in higher NYHA classes, compared to those who were able to achieve 30 mmHg. All controls 
were able to achieve an expiratory pressure of at least 30 mmHg.
Relationship between pulse pressure ratio and other measures of cardiac filling 
pressure in patients
Pulse pressure ratio was correlated to: right atrial pressure (n=88), r=0.34, p=0.001; diastolic 
pulmonary artery pressure (n=93), r=0.49, p<0.001; mean pulmonary artery pressure (n=93), r=0.54, 
p<0.001; systolic pulmonary artery pressure (n=93), r=0.50, p<0.001, and left ventricular end-
diastolic pressure (n=63), r=0.35, p=0.005. 
Correlation between echocardiographic variables and PCWP
Echocardiography was not performed as part of the study protocol but data, though not complete, 
were available in 87 patients and presented in Table 5. Data were used from echocardiography 
performed before or after the study. Mean duration between echocardiography and the study in 
patients was 138±250 days, ranging between 1480 days before and 312 days after the study; 90% 
of all echo studies was performed between 356 days before and 4 days after the Valsalva study. Of 
the available data, only peak velocity early diastolic rapid filling wave (E), r=0.29, p=0.022, and the 
E/A ratio, r=0.29, p=0.043, correlated with PCWP. LVEF, peak velocity late diastolic atrial contraction 
wave (A), E velocity deceleration time, and pulmonary vein peak systolic and diastolic velocity did 
not correlate with PCWP.
Table 5  Echocardiographic variables of patients (n=93) and controls (n=28)
Variable available in (n) Patients available in (n) Controls
LVEDD (mm) (n=74) 53 ± 8.8 (n=28) 48 ± 5.6**
LVESD (mm) (n=69) 36 ± 10.3 (n=28) 29 ± 4.5***
LVEF (%) (n=87) 49 ± 15.3 (n=4) 52 ± 7.4
E (m/sec) (n=63) 0.97 ± 0.42 (n=28) 0.63 ± 0.16***
A (m/sec) (n=47) 0.91 ± 0.31 (n=28) 0.74 ± 0.16**
E/A ratio (n=50) 1.04 ± 0.47 (n=28) 0.86 ± 0.18*
DT (msec) (n=58) 245 ± 89.5 (n=28) 233 ± 50.7
PVS (m/sec) (n=17) 0.48 ± 0.22 (n=0) -
PVD (m/sec) (n=17) 0.58 ± 0.20 (n=0) -
PVS/PVD (n=17) 0.96 ± 0.52 (n=0) -
Data are expressed as mean±SD. LVEDD = left ventricular end diastolic diameter; LVESD = left ventricular end systolic 
diameter; LVEF = left ventricular ejection fraction; E = peak velocity early diastolic rapid filling wave; A = peak velocity 
late diastolic atrial contraction wave; DT = E velocity deceleration time; PVS = pulmonary vein peak systolic velocity; PVD 
= pulmonary vein peak diastolic velocity. * p<0.05, ** p<0.01, *** p<0.001 controls versus patients. 
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Discussion
The main finding in the present study is that the blood pressure response to the Valsalva manoeuvre, 
in terms of pulse pressure ratio, is a reasonably accurate method of predicting elevated PCWP in 
a heterogeneous group of elderly patients with various cardiac disorders. The diagnostic feature 
of pulse pressure ratio in predicting elevated PCWP is not influenced by the presence or absence 
of various common cardiac disorders. This makes the blood pressure response to the Valsalva 
manoeuvre a non-invasive tool for diagnosis of heart failure, applicable in elderly patients with 
various cardiac disorders, like atrial fibrillation and valvular heart disease.
In most of the reports describing the relation between the blood pressure response to the Valsalva 
manoeuvre and cardiac filling pressures, patients with arrhythmias were excluded8, 10, and only two 
patients were reported to have atrial fibrillation7. In the general population, the prevalence of atrial 
fibrillation in the elderly is around 6%23. In heart failure patients, the prevalence varies from 10% in 
NYHA class II to 50% in NYHA class IV patients23. The exclusion of patients with atrial fibrillation 
would therefore be a serious limitation of a tool for diagnosing heart failure. In the present study, we 
were able to assess PCWP in patients with atrial fibrillation using the blood pressure response to the 
Valsalva manoeuvre.
In studies on the quantitative relationship of the blood pressure response to the Valsalva 
manoeuvre, only 11 patients were reported to suffer from cardiac valve abnormalities. In our study, 
58 patients (62%) had any kind of valvular heart disease. The discriminatory power of the blood 
pressure response to the Valsalva manoeuvre to detect elevated PCWP in patients with valvular 
heart disease was high. In the elderly population, the prevalence of valvular heart disease is high; in 
randomly selected subjects from 55 to 86 years old, the prevalence of severe aortic valve calcification 
was reported 13%, and of (mild) aortic regurgitation it was 29%24. Therefore, the results of the 
present study are essential, especially since previous data of elderly patients suffering from common 
cardiac disorders are scarce.
Importantly, the discriminatory power of the pulse pressure ratio to detect elevated PCWP was 
present in all subgroups of patients grouped by the use of medication. This is an important finding 
since many elderly cardiac patients use one or more cardiovascular drugs, which makes this method 
applicable in elderly patients with multiple drug therapy.
Although the pulse pressure ratio correlated significantly with PCWP, the correlation was 
moderate, which impedes exact assessment of PCWP. The correlation of the blood pressure response 
to PCWP is in concordance with one report6 but is less strong than in other reports7, 10. Several 
mechanisms could account for this. First, many of our elderly patients were not able to achieve an 
expiratory pressure of 40 mmHg during the Valsalva manoeuvre. Therefore, the expiratory pressures 
achieved by our patients deviated between 20 and 40 mmHg, which must have influenced our 
results. It became clear that the higher the expiratory pressure, the stronger was the correlation 
between pulse pressure ratio and PCWP. However, in particular, small females in high NYHA class 
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were not able to achieve the expiratory pressure. In future studies, this should be accounted for. 
Secondly, the method used for continuous blood pressure measurement could have played a role. We 
used Finapres, instead of the Vericor system, which was used in a study reporting a strong correlation 
between the blood pressure response and PCWP7. On the other hand, Finapres was also used in a 
study reporting a stronger correlation than we found10, and a study reporting a similar correlation 
used intra-aortal blood pressure measurement with fluid-filled catheters6. Thirdly, we assessed 
PCWP with fluid-filled catheters, which are not as reliable as high-fidelity catheters. Interestingly, 
in one study, pulse pressure ratio, which was derived from intra-aortal blood pressure using high-
fidelity catheters, showed no significant relationship with left ventricular end-diastolic pressure9. 
However, this study was performed solely in patients with preserved left ventricular function, and 
relatively low cardiac filling pressures. Finally, with increasing age, variability of biological variables 
increases25, which might explain the less strong correlation of the blood pressure response to the 
Valsalva manoeuvre and PCWP.
Serious doubts concerning the safety of the Valsalva manoeuvre have been reported because of 
a supposed accompanying fall in coronary blood flow26. On the other hand, the Valsalva manoeuvre 
was reported as a non-pharmacological method to relief angina pectoris, suggesting that the Valsalva 
manoeuvre reduces cardiac oxygen demand, relieving acute ischaemia rather than aggravating it27. In 
more than 2100 patients with severe heart disease, no complications were observed during carefully 
monitored Valsalva manoeuvres7. In the present study, a broad-complex tachycardia occurred during 
the Valsalva manoeuvre in one patient, probably caused by mechanical irritation by the Swan-Ganz 
catheter during the manoeuvre. Therefore, we conclude that the Valsalva manoeuvre can be used 
safely in elderly cardiac patients.
Though echocardiography was not performed for research purposes in our present study, 
echocardiographic data were available in most patients. However, echocardiography and 
catheterisation were not performed on the same day. Regrettably, most of the echocardiographic 
studies were incomplete and tissue Doppler imaging data were not available. As expected, peak 
velocity early diastolic rapid filling wave and the E/A ratio correlated with PCWP, but not as strongly 
as between the pulse pressure ratio and PCWP. The limited correlation between echocardiographic 
parameters and PCWP might be related to the wide time lag between echocardiography and 
performance of the Valsalva manoeuvre. We acknowledge that echocardiography is the method for 
assessment of cardiac function and is an important tool in the diagnosis of heart failure3. However, 
cardiac dysfunction and heart failure are not synonymous. Based on the definition of heart failure 
as the state in which the heart is unable to pump blood at the rate needed by the metabolising 
tissues or can do so only with elevated filling pressures4, assessment of left ventricular filling pressure 
or PCWP seems mandatory. Several echocardiographic approaches to assess PCWP have been 
proposed, but it is not clear if any of these methods provides the precision and accuracy needed 
for the evaluation of patients28. A correlation coefficient between PCWP and early transmittal 
velocity/tissue Doppler mitral annular early diastolic velocity of 0.69 has been reported in a study 
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by Dokainish, which, notably, excluded patients with atrial fibrillation, mitral valvular disease, or 
unstable angina29. We cannot conclude that the Valsalva ratios are superior to echocardiography or 
vice versa. Whether the Valsalva manoeuvre may give information additional to echocardiography 
will need to be assessed in further study.
We did not measure natriuretic peptides in our study patients. Natriuretic peptides have been 
reported to be promising in the diagnosis of heart failure, which was confirmed by independent 
cardiologists based on clinical symptoms30. However, the correlation between PCWP and natriuretic 
peptides has been reported to be poor29, as was the diagnostic accuracy to detect elevated PCWP31. 
Though the area under the ROC curve of the pulse pressure ratio for elevated PCWP was high in 
our study, above 0.80, one has to bear in mind that this still means that with a cut-off value of 0.62, 
and a sensitivity of 80% and specificity of 79%, 12% of the subjects will be diagnosed incorrectly as 
having elevated PCWP and 9% will be diagnosed incorrectly as having a normal PCWP. However, 
the pulse pressure ratio in our study performed better than B-type natriuretic peptide (BNP) did 
in the study by Dokainish with a sensitivity of 91% and a specificity of 56%, but slightly worse than 
echocardiographic early transmitral velocity/tissue Doppler mitral annular early diastolic velocity 
with a sensitivity of 85% and a specificity of 88%29. Therefore, further studies on the detection of 
elevated PCWP should be performed, combining and comparing the blood pressure response to the 
Valsalva manoeuvre, natriuretic peptides, and echocardiography.
Limitations
The decrease in pulse pressure is related to expiratory pressure21, meaning that, if the expiratory 
pressure is low, the decrease in pulse pressure is small regardless of cardiac filling pressure or cardiac 
function. In our group of elderly subjects, the maximum expiratory pressure during the Valsalva 
manoeuvre differed among the subjects and not all subjects were able to achieve an expiratory 
pressure of 40 mmHg. This might have attenuated the correlation between the pulse pressure ratio 
and PCWP. The difficulty to achieve a preset expiratory pressure may be a serious limitation of the 
assessment of PCWP by the blood pressure response to the Valsalva manoeuvre.
Conclusions
The blood pressure response to the Valsalva manoeuvre, in terms of pulse pressure ratio, is a 
reasonably accurate method to predict elevated PCWP in a group of elderly patients with various 
cardiac disorders and healthy elderly controls. The diagnostic feature of pulse pressure ratio in 
predicting elevated PCWP is not influenced by the presence or absence of various common cardiac 
disorders or by cardiovascular drug therapy. This makes the blood pressure response to the Valsalva 
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manoeuvre a useful non-invasive tool for diagnosis of heart failure, which is applicable in elderly 
patients with common cardiac disorders, like atrial fibrillation and valvular heart disease.
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Abstract
Introduction: Assessment of pulmonary capillary wedge pressure (PCWP), which reflects left 
ventricular filling pressure, is important for diagnosing heart failure. The blood pressure response to 
the Valsalva manoeuvre correlates with PCWP. Recently, we described the relationship between the 
pulse pressure ratio of the Valsalva manoeuvre in 93 elderly cardiac patients. In seven patients, PCWP 
measurements were performed on more than one occasion. In this report, we studied whether 
changes in PCWP can be assessed using the pulse pressure ratio.
Methods: In 7 patients, PCWP was measured with a pulmonary artery catheter on several occasions, 
varying from one to six, over a period up to one year. Blood pressure was measured non-invasively 
with Finapres. Pulse pressure ratio was calculated as the ratio of minimum pulse pressure during 
phase 2 and maximum pulse pressure during phase 1 of the Valsalva manoeuvre.
Results: The pulse pressure ratio was significantly correlated to PCWP, r=0.62, p=0.003. The change 
in pulse pressure ratio was significantly correlated to the change in PCWP, r=0.64, p<0.001.
Conclusion: Change in PCWP is reflected by the change in pulse pressure ratio of the Valsalva 
manoeuvre. The blood pressure response to the Valsalva manoeuvre may therefore play a role in the 
monitoring of heart failure patients. This has to be confirmed in further study, preferably also taking 
account of echocardiographic data and natriuretic peptides.
Introduction
In order to diagnose heart failure, assessment of left ventricular filling pressure, or pulmonary 
capillary wedge pressure (PCWP) as its approximate derivative, is essential. This is in accordance 
with both the definition “Heart failure is the pathophysiological state in which the heart is unable 
to pump blood at a rate needed by the metabolising tissues or can do so only from elevated filling 
pressure”1, as with the latest guidelines for the diagnosis and treatment of chronic heart failure by 
the European Society of Cardiology2. These guidelines state that elevated PCWP at rest is of great 
importance in supporting the diagnosis of heart failure, while normal PCWP is of great importance 
in opposing the diagnosis of heart failure.
The blood pressure response to the Valsalva manoeuvre has been reported to correlate with 
PCWP3-7. Furthermore, changes in PCWP have been reported to correlate with changes in the blood 
pressure response to the Valsalva manoeuvre3, 7, however these studies were not confined to the 
elderly, in whom the prevalence of heart failure is highest2.
In a recent report, we described the relationship between the blood pressure response to the 
Valsalva manoeuvre in 93 elderly cardiac patients8. In seven of these patients, measurements were 
performed on several occasions, varying from one to six, over a period up to one year. In the present 
study, we studied whether changes in PCWP can be assessed using the blood pressure response to 
the Valsalva manoeuvre.
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Methods
Patients
Between March 2000 and April 2002, a study in 93 elderly cardiac patients undergoing right-sided 
cardiac catheterisation was conducted to assess the relationship between PCWP and the blood 
pressure response to the Valsalva manoeuvre. Details of this study were published recently8. The 
indication for catheterisation was determined by the treating physician at the outpatient clinic 
or during hospitalisation, and was not performed for research purposes. Reasons for right-sided 
catheterisation (either with or without left-sided cardiac catheterisation) were diverse: as part of the 
preparation for surgery for valvular heart disease and/or coronary artery bypass grafting, as part of 
the diagnostic process for the cause of heart failure, and for hemodynamic monitoring of patients 
with acute heart failure.
In seven of the 93 study patients, PCWP and the blood pressure response to the Valsalva 
manoeuvre were assessed on more than one occasion, which gave us the opportunity to study 
whether changes in PCWP could be assessed using the blood pressure response to the Valsalva 
manoeuvre.
All subjects gave written informed consent. The study was approved by the Ethics Committee 
for Research on Human Subjects of the University Medical Center Nijmegen, The Netherlands, and 
conformed to the principles outlined in the Declaration of Helsinki9.
Materials
Measurement devices were connected to a personal computer through a data-acquisition box and 
an AD converter. Signals were recorded and sampled with the MID TestOrganizer for Windows 
95, version 5.3 (Department of Biomedical Engineering, University Medical Center, Nijmegen, the 
Netherlands). The entire measurement system was placed on a mobile handcart, which enabled easy 
bedside monitoring.
Right-sided cardiac catheterisation
Pulmonary capillary wedge pressure (PCWP) and pulmonary artery pressure (PAP) were determined 
by right-sided catheterisation using a 7 French Swan Ganz catheter (Baxter, Irvine, USA). PCWP and 
PAP were measured with the zero level fixed at the intersection of the fourth intercostal space and 
the mid-axillary line and were measured at the end of expiration. In case coronary angiography or 
ventriculography was planned, pressure measurements were performed before administration of 
contrast medium.
Measurement of blood pressure and heart rate
Non-invasive continuous arterial blood pressure and heart rate were measured beat-to-beat using 
a Finapres device (Ohmeda 2300, Englewood, USA) on the index- or middle finger. Finapres was 
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reported to be an accurate method to assess blood pressure non-invasively10 and to assess blood 
pressure changes during the Valsalva manoeuvre11.
Finapres blood pressure was analysed offline with the software programme BeatScope, version1.0 
(TNO-TPD Biomedical Instrumentation, Amsterdam, The Netherlands).
The Valsalva manoeuvre
The Valsalva manoeuvre consisted of a normal inspiration followed by forced expiration for 15 
seconds aiming at a pressure of 40 mmHg in a tube, which was connected to a disposable pressure 
transducer (Baxter, Irvine, USA). A tiny hole in the tube ensured that the pressure was generated in 
the thorax and not in the mouth by closing the glottis.
A normal blood pressure response to the Valsalva manoeuvre consists of four typical phases. 
Phase one represents an initial rise in arterial pressure, caused by transmission of the increased 
intra-thoracic pressure to the peripheral arteries; Phase two is characterised by reduction of systolic, 
diastolic, and pulse pressure, accompanied by a reflex increase in heart rate, caused by reduction of 
venous return; Phase three begins with release of the strain when arterial pressure drops suddenly 
due the fall of intra-thoracic pressure; Phase four is characterised by an overshoot of arterial pressure 
to above control levels accompanied with reflex-bradycardia.
An abnormal blood pressure response, which is seen in heart failure, is characterised by absence of 
decrease in blood pressure during phase two. The absence of decrease in blood pressure during phase 
two is caused by elevation of central venous and pulmonary venous pressure, which enables filling 
of the heart in spite of the increase in intra-thoracic pressure12, 13. The decrease in blood pressure was 
also reported to depend on the slope and the position on the left-ventricular function curve13. On 
this curve, stroke work, of which pulse pressure and mean arterial pressure are approximate indices, 
is plotted against filling pressure. With high filling pressures, at the flattened part of the curve, a fall 
in filling pressure will affect stroke work only minimally. The slope of the curve is dependent on the 
severity of the heart disease. In patients with elevated left ventricular filling pressures, a decrease in 
filling pressure due to straining will not result in a decrease in arterial blood pressure.
Before the catheterisation, the Valsalva manoeuvre was practiced to make the patient familiar 
with the manoeuvre. Immediately after measurement of PCWP and PAP, the Valsalva manoeuvre was 
performed in supine position, preferably three times but at least once, depending on the patient’s ability. 
Between two successive manoeuvres, a two-minute rest period was applied. The expiratory pressure 
was displayed to the subject at a small monitor for biofeedback. The patient was encouraged to achieve 
an expiratory pressure of 40 mmHg or, if not possible, as high as possible, for at least 12 seconds.
The pulse pressure ratio was calculated as the ratio of the mean of the three lowest successive 
pulse pressures in phase two and the mean of the highest three successive pulse pressures in phase 
one. In atrial fibrillation, the mean of the five lowest successive pulse pressures in phase two and the 
mean of the five highest successive pulse pressures in phase one were used. The mean of the Valsalva 
manoeuvres performed by a single patient was used for further analysis. 
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Data Analysis and Statistics
Statistical analysis was performed with SPSS 10.0 for Windows (SPSS Inc, 2000, Chicago, USA). 
Values are expressed as mean±SD. A two-sided p-value ≤0.05 was considered to indicate statistical 
significance.
Linear regression was used to describe the relation of the blood pressure response to the Valsalva 
manoeuvre with PCWP and Pearson correlation coefficients were calculated. 
Results
Patients
Table 1 presents the characteristics of the patients. The blood pressure response to the Valsalva 
manoeuvre and PCWP are plotted for each patient in Figure 1. PCWP and the blood pressure 
response to the Valsalva manoeuvre
Figure 1  Pulmonary capillary wedge pressure (PCWP) and pulse pressure ratio (PPR) plotted for each measurement for 
patient A, B, C, D, E, F, and G.
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Table 1  Characteristics of the study patients (n=7)
Reason for right-sided Measurements
Patient Gender Age catheterisation time-period number Comments
A Male 67 Acute HF 5 days 6 Severe mitral regurgitation due to mitral 
valve prolapse. Initial clinical recovery 
with diuretics, ACE inhibitors, and 
nitroglycerin. Recovered completely after 
mitral valve replacement and CABG.
B Male 68 HF/Sepsis 2 days 2 Known with CABG, myocardial infarction 
and chronic HF. Treated with antibiotics, 
dobutamin, and diuretics. Discharged in 
good condition after four weeks.
C Male 68 Aortic valve stenosis 1 year 2 Underwent aortic valve replacement. 
One year after the initial measurement, 
right-sided catheterisation was 
performed because of suspected 
constrictive pericarditis, which was not 
confirmed by catheterisation.
D Male 73 Angina/dyspnoea 2 days 2 Known with ischemic dilated 
cardiomyopathy. After catheterisation, 
he was monitored at the coronary care 
unit because of hemodynamic instability 
and transient AV-block. He was treated 
with a temporary pacemaker. Discharged 
in good condition.
E Male 71 Worsening of HF 4 days 4 Known with CABG, heart failure with 
severely impaired systolic left ventricular 
function, and atrial fibrillation. He was 
treated with inotropics and diuretics. He 
was discharged in good condition.
F Female 69 Shock/severe AoVR 3 days 2 Admitted into the coronary care unit 
because of forward failure and treated 
with inotropics. After replacement of the 
ascending aorta and aortic valve, she was 
discharged in good condition.
G Female 69 Endocarditis/severe 
AoVR
4 days 3 Known with right-sided mastectomy and 
radiotherapy because of breast cancer. 
Treated with inotropics and antibiotics. 
After replacement of the aortic valve, she 
was discharged in good condition
HF = heart failure; CABG = coronary artery bypass grafting; AoVR = aortic valve regurgitation.
PCWP was significantly correlated to the pulse pressure ratio, r=0.62, p=0.003 when all PCWP and 
pulse pressure ratio measurements were pooled together.
The change in PCWP and the change in pulse pressure ratio per patient, for two different time 
points, were plotted, as shown in Figure 2. The change in PCWP was significantly correlated to the 
change in pulse pressure ratio, r=0.64, p<0.001. In 24 of 26 cases (93%), the direction of the change 
in pulse pressure and the direction of change in PCWP corresponded.
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Figure 2  Scatter plot of change in pulmonary capillary wedge pressure (delta PCWP) and the change in pulse pressure ratio 
(delta PPR) regression line: delta PCWP = -2.0 + (20.0 x delta PPR), r=0.64, p<0.001.
Discussion
The main finding of this study is that change in PCWP is reflected by change in the pulse pressure 
ratio of the Valsalva manoeuvre. To our knowledge, only two studies have described a correlation 
between the change in PCWP and the change in blood pressure response to the Valsalva manoeuvre 
in 15 and 11 patients, respectively3, 7. Our data are in accordance with these reports, and underscore 
the potential of the blood pressure response to the Valsalva manoeuvre as a tool to monitor heart 
failure patients over time.
The role of assessment of cardiac filling pressure in heart failure patients has been an issue of 
debate14, 15. It has been stated that elevated cardiac filling pressure is a result of impaired cardiac 
function rather than the primary cause of the symptoms of heart failure and reduction of cardiac 
filling pressure should not be the primary therapeutic target14. Furthermore, while careful monitoring 
of PCWP with a pulmonary artery catheter in patients, who were hospitalised because of heart failure, 
improved quality of life, it did not improve prognosis16. However, in heart failure patients, reduction of 
filling pressures improves ventricular function while relieving congestive symptoms. After resolution of 
resting dyspnoea and oedema, substantial elevation in filling pressure may cause exertional limitation 
and further reduction of filling pressure will lead to improvement of exercise capacity15. Therefore, we 
conclude that assessment of cardiac filling pressure is clinically relevant, whether it is a measure of the 
primary goal to reduce cardiac filling pressure or a measure of cardiac function.
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We acknowledge that echocardiography is the method for assessment of cardiac function and is 
an important tool in the diagnosis of heart failure2. However, several echocardiographic approaches 
to assess PCWP have been proposed, but it is not clear if any of these methods provides the precision 
and accuracy needed for the evaluation of patients17. A correlation coefficient between change in 
PCWP and change in early transmittal velocity/tissue Doppler mitral annular early diastolic velocity 
of 0.87 has been reported18. Notably, in this study, patients with atrial fibrillation, mitral valvular 
disease, or unstable angina were excluded. Whether the Valsalva manoeuvre may give information 
additional to echocardiography in the monitoring of heart failure patients has to be assessed in 
further study.
Echocardiography is not always easily available in the outpatient clinic or in the practice of the 
General Practitioner. The blood pressure response to the Valsalva manoeuvre could be an easily 
available, feasible tool to diagnose heart failure non-invasively and to monitor heart failure patients 
in the outpatient clinic or in the practice the General Practitioner. However, only under the condition 
that a device that can assess the blood pressure response to the Valsalva manoeuvre becomes 
available at low costs. Otherwise, this method will only be used in those (teaching) hospitals that 
have the ability to non-invasive continuous blood pressure measurement. 
We did not measure natriuretic peptides in our study patients. Natriuretic peptides are promising 
in the diagnosis of heart failure19 and are important as prognostic predictor in heart failure20, 21 but 
also in subjects without heart failure22. However, in clinical practice today, the place of natriuretic 
peptides is as mainly as “rule out” test to exclude significant cardiac disease2. Yet, a normal level of 
natriuretic peptide can not completely exclude cardiac disease2. Though treatment of heart failure 
guided by measurement of natriuretic peptides may reduce cardiovascular events23, at present there 
are not enough data to support serial measurement of natriuretic peptides in patients with heart 
failure14. The correlation between PCWP and natriuretic peptides has been reported to be poor and 
the change in natriuretic peptide did not correlate significantly with change in PCWP18.
The blood pressure response to the Valsalva manoeuvre might play an important role in the serial 
assessment of cardiac filling pressure. However, one has to bear in mind that small alterations may 
not be detected because of measurement error. In healthy elderly subjects a coefficient of variation 
was reported of 9% for the systolic pressure ratio, of 14% for the pulse pressure ratio and 13% for the 
stroke volume ratio24. These data are comparable with those reported of B-type natriuretic peptide 
with a coefficient of variation varying from 10 to 16%25.
Limitations
The number of study patients was small. Furthermore, the number of measurements was not equal 
in each patient. Therefore, our data are hypothesis generating and should be confirmed in further 
study.
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Conclusion
Change in PCWP is reflected by the change in pulse pressure ratio of the Valsalva manoeuvre. The 
blood pressure response to the Valsalva manoeuvre may therefore play a role in the monitoring of 
heart failure patients. This has to be confirmed in further study, preferably also taking account of 
echocardiographic data and natriuretic peptides.
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Abstract
Objective: To assess whether the blood pressure response to the Valsalva manoeuvre, which is 
related to cardiac filling pressures, is a non-invasive prognostic marker for mortality. 
Design: Observational retrospective study.
Setting: University hospital.
Patients: A heterogeneous group of 93 elderly cardiac patients, aged 71±5 years, undergoing right-
sided catheterisation.
Interventions: The Valsalva manoeuvre was performed while continuous blood pressure was 
measured non-invasively with Finapres. From the blood pressure response to the Valsalva manoeuvre, 
the pulse pressure ratio (PPR) was calculated as ratio of the lowest and highest pulse pressure.
Main outcome measures: All cause mortality.
Results: Median follow-up was 396 days (range 1-815). Survival differed in patients divided by PPR 
tertiles: survival was 94% (SE 4%) in the first, 80% (SE 7%) in the second, and 60% (SE 9%) in the 
third tertile (p=0.007). Cox regression identified PPR as independent predictor of mortality; (Hazard 
Ratio: 1.52, per 0.1; 95% CI: 1.12-2.07, p=0.008), in a model with age, gender, left ventricular ejection 
fraction, admission for heart failure, myocardial infarction, heart rate, presence of pulmonary rales, 
and New York Heart Association class.
Conclusions: In a heterogeneous group of elderly cardiac patients, undergoing right-sided cardiac 
catheterisation, the PPR of the Valsalva manoeuvre was an independent non-invasive prognostic 
marker for mortality. These hypothesis-generating findings warrant further studies on the prognostic 
implications of the Valsalva manoeuvre.
Introduction
Heart failure is primarily a disorder of the elderly. The prevalence of heart failure increases with age to 
about 10% in persons over 75 years1. The prognosis of patients with heart failure in a general population 
is poor with a five-year mortality of approximately 50%2. Estimation of life expectancy of an individual 
patient could contribute to the well being of the patient, either by trying to improve prognosis by 
medical interventions3 or, in individual cases, by refraining from medical intervention4. Therefore, a 
simple, safe, and non-invasive bedside technique to estimate the risk for mortality could be a useful.
The blood pressure response to the Valsalva manoeuvre might be such a technique. The blood 
pressure response to the Valsalva manoeuvre is related to cardiac filling pressures5, 6, which are 
elevated in heart failure7. Since elevated cardiac filling pressures are related to increased mortality8, 9, 
the blood pressure response to the Valsalva manoeuvre could have prognostic significance itself.
In this study, we examined the relationship between the blood pressure response to the Valsalva 
manoeuvre and mortality in a heterogeneous group of elderly cardiac patients undergoing right-
sided cardiac catheterisation.
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Methods
Patients
Between March 2000 and April 2002, consecutive elderly patients (n=104), aged 65 years or older, 
who were scheduled to undergo right-sided cardiac catheterisation, were invited to take part in this 
study. The indication for the catheterisation was determined by the attending physician. Reasons 
for admission into the hospital were (suspected) congestive heart failure or an acute coronary 
syndrome. Reasons for right-sided catheterisation (either with or without left-sided cardiac 
catheterisation) were diverse: as part of the diagnostic process in case of suspected heart failure, as 
part of the preparation for cardiac surgery, and for hemodynamic monitoring of patients, with or 
without suspected heart failure.
Severe chronic obstructive lung disease, which has a marked influence on the blood pressure 
response to the Valsalva manoeuvre10, was the only reason for exclusion. Baseline characteristics 
were recorded from the patient’s medical file at the time of the catheterisation. Echocardiography 
or nuclear cardiac imaging was performed at the discretion of the attending physician and was not 
part of the study protocol.
All subjects gave written informed consent. The study was approved by the Ethics Committee 
for Research on Human Subjects of the University Medical Center Nijmegen, The Netherlands, and 
conformed to the principles outlined in the Declaration of Helsinki11.
Right-sided cardiac catheterisation
Pulmonary capillary wedge pressure (PCWP) and mean pulmonary artery pressure (MPAP) were 
determined by right-sided catheterisation performed at the catheterisation laboratory or the 
coronary care unit, using a 7-French Swan Ganz catheter (Baxter, Irvine, USA).
The Valsalva manoeuvre
A normal blood pressure response to the Valsalva manoeuvre consists of four typical phases and is 
shown in the upper panel of Figure 1. An abnormal blood pressure response is shown in the lower 
panel of Figure 1 and is characterised by absence of decrease of blood pressure due to persistent 
filling of the left ventricle during the straining phase of the Valsalva manoeuvre, which is thought to 
be caused by elevated left- and/or right-sided filling pressures5.
Prior to the catheterisation, the Valsalva manoeuvre was practiced to make the patient familiar 
with the manoeuvre. Immediately after measurement of PCWP and MPAP, the Valsalva manoeuvre 
was performed in supine position, preferably three times but at least once, depending on the patient’s 
ability. Between successive manoeuvres, a two-minute rest period was applied. The expiratory 
pressure was displayed to the subject for biofeedback. The patient was encouraged to achieve an 
expiratory pressure of 40 mmHg or as high as possible, for at least 12 seconds. A tiny hole in the tube 
ensured that the pressure was generated in the thorax and not in the mouth by closing the glottis. 
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A minimum of 20 mmHg was required since this pressure still induces a significant decrease of pulse 
pressure in normal subjects12.
From the blood pressure response to the Valsalva manoeuvre, the pulse pressure ratio (PPR) 
was calculated as the ratio of the mean of the three lowest successive pulse pressures in phase 2 
and the mean of the three highest successive pulse pressures in phase 1 (A/B, see Figure 1). In atrial 
fibrillation, the mean of the five lowest successive pulse pressures in phase 2 and the mean of the five 
highest successive pulse pressures in phase 1 were used. Per patient, the lowest PPR of all Valsalva 
manoeuvres performed was considered the PPR. The systolic pressure ratio (SPR), the mean pressure 
ratio (MPR), and the diastolic pressure ratio (DPR) were calculated in the same way.
Non-invasive continuous arterial blood pressure and heart rate were measured beat-to-beat 
using a Finapres device (Ohmeda 2300, Englewood, CO, U.S.A.) on the index- or middle finger. 
Finapres has been reported to be an accurate method to assess blood pressure non-invasively13 
and to assess blood pressure changes during the Valsalva manoeuvre14. Data were recorded using a 
personal computer and sampled with the MID TestOrganizer, version 5.3 (Department of Biomedical 
Engineering, University Medical Center, Nijmegen, The Netherlands).
Follow-up
Survival was assessed by the research-fellow (J.J.R.) at four months after inclusion of the last patient. 
Survival data were acquired from the hospital’s (digital) medical files or by telephone contact with 
the patient or with the patient’s general physician. Cause of death, admissions into the hospital due 
to heart failure, coronary bypass surgery, and cardiac valve surgery were recorded.
Data analysis and statistics
Statistical analysis was performed with SPSS 10.0 for Windows (SPSS Inc, 2000, Chicago, USA). Values 
are expressed as mean±SD, unless stated otherwise. Criterium for statistically significant difference 
was set off at α=0.05. Primary outcome was death from all causes. Survival curves were constructed 
using the Kaplan Meier method and survival between patient groups was compared using the 
Log rank test. To determine the strongest predictors of mortality, co-variables were entered into a 
stepwise Cox-regression model. Backward stepwise analysis was performed with a value of p<0.05 as 
the criterion to remain in the model. The pressure ratios of the Valsalva manoeuvre were analysed per 
step of 0.1, whereas PCWP and MPAP were analysed per mmHg. The following other variables were 
used: age, sex, left ventricular ejection fraction (LVEF), hospital admission because of heart failure, 
elevation of cardiac markers (Troponin I or Creatin Kinase MB), heart rate, presence of pulmonary 
rales, and New York Heart Association (NYHA) functional classification. 
For continuous data, differences were assessed with paired samples T-tests, independent samples 
T-tests or One-way ANOVA when appropriate, and with Chi-Square or Fisher’s exact tests for 
dichotomous and ordinal data.
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Figure 1  Upper panel: Registration of the blood pressure response to the Valsalva manoeuvre. The upper registration 
is Finapres blood pressure. Phase 1 represents an initial rise in arterial pressure, caused by transmission of the increased 
intra-thoracic pressure to the peripheral arteries; Phase 2 is characterised by reduction of systolic, diastolic, and pulse 
pressure, accompanied by a reflex increase in heart rate, caused by reduction of venous return; Phase 3 begins with release 
of the strain when arterial pressure drops suddenly due the fall of intra-thoracic pressure; Phase 4 is characterised by an 
overshoot of arterial pressure to above control levels accompanied with reflex-bradycardia. The lower registration is the 
expiratory pressure during the Valsalva manoeuvre. An abnormal blood pressure response, which is seen in heart failure, 
is characterised by absence of decrease of blood pressure during Phase 2, as shown in the lower panel. The pulse pressure 
ratio is calculated as the ratio of the mean of the three lowest successive pulse pressures in phase 2 and the mean of the 
three highest successive pulse pressures in phase 1 (A/B, see Figure 1). The systolic pressure ratio, the mean pressure ratio, 
and the diastolic pressure ratio are calculated in the same way.
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Results
Characteristics of the patients
During the study period, 104 patients undergoing right-sided catheterisation were initially included 
in the study. The data of five patients were discarded: in four patients we were not able to get a stable 
Finapres signal for indefinite reasons, and one patient developed non-sustained ventricular tachycardia 
during each Valsalva manoeuvre. Of the remaining 99 patients, 6 patients (5 female, 1 male) were not 
able to achieve an expiratory pressure of 20 mmHg; their data were excluded from analysis.
The baseline characteristics of the remaining 93 patients are shown in Table 1. No patients had 
clinical signs of Parkinson’s disease, primary autonomic failure or multiple system atrophy. LVEF 
data were available in all patients; in 87 patients, LVEF was assessed by echocardiography, in five by 
ventriculography, and in one by scintigraphy. Of 93 patients, 21 (23%) were known with a history of 
heart failure; 23 (25%) were admitted because of heart failure. In 63 (68%) patients, suspected heart 
failure was a reason for performance of right-sided catheterisation.
The Valsalva manoeuvre and hemodynamic data
Hemodynamic data obtained during catheterisation and the blood pressure response to the Valsalva 
manoeuvre are shown in Table 2. With the onset of straining, systolic pressure increased 16±11 mmHg; 
95% CI: 14-18 mmHg, diastolic pressure increased 16±7 mmHg; 95% CI: 14-17 mmHg, mean arterial 
pressure increased 14±8; 95% CI: 12-16 mmHg, and pulse pressure increased 4±8 mmHg; 95% CI: 3-6 
mmHg, all 92 degrees of freedom (df) and p<0.001. The increase in systolic, diastolic and pulse pressure 
did not correlate with PPR. The increase in mean arterial pressure correlated moderately with PPR, 
r=0.22, p=0.32. Expiratory pressure during Valsalva and PPR were correlated (r=- 0.44, p<0.001). 
Follow-up
No patients were lost to follow-up. Median duration of follow-up was 396 days (range 1-815). Of 93 
patients, 20 (22%) died. Pulse pressure ratio was significantly higher in the patients who died, mean 
0.70±0.17; 95% CI: 0.62-0.78, compared to those who did not, 0.55±0.20; 95% CI: 0.50-0.60, df=91, 
p=0.004. PPR correlated significantly with survival time, r=-0.28, p=0.007.
Of the 20 patients who died, 7 patients (35%) died of heart failure, 9 patients (45%) died of cardiac 
complications following cardiac surgery, and 4 patients (20%) died of non-cardiac complications 
following cardiac surgery. Of the 73 survivors, after discharge from the hospital following the 
catheterisation, 4 (6%) patients were re-admitted into the hospital because of heart failure.
During follow up, 45 (48%) patients underwent cardiac surgery. Mortality was 29% in those who 
underwent surgery and 17% in those who did not, which was not significantly different. PPR was not 
significantly different between both groups. LVEF was higher in those who underwent cardiac surgery, 
53%±14%; 95% CI: 49-57, compared to in those who did not, 45%±16%; 95% CI: 41-50, df=91, p=0.015. 
No other baselines differed significantly between those who underwent surgery and those who did not.
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Table 1  Baseline characteristics of the patients
Total PPR, 1st tertile PPR, 2nd tertile PPR, 3rd tertile
Variable n=93 95% CI n=31 95% CI n=31 95% CI n=31 95% CI
Age (yr) 71 ±5 70 - 72 71 ±5 69 - 73 71 ±5 70 - 73 72 ±4 70 - 73
Female sex 38 (41) 8 (26) 15 (49) 15 (49)
Length (cm) 169 ±9 167-171 170 ±8 167-177 168 ±9 164-171 169 ±9 166-172
Weight (kg) 76 ±14 73-79 78 ±12 74-83 78 ±14 73-83 71 ±14 66-77
BMI (kg/m2) 26.7 ±4.4 25.7-27.5 27.0 ±4.1 25.5-28.6 27.8 ±4.6 26.1-29.5 24.9 ±4.1 23.4-26.4*
Smoking 13 (14) 5 (16) 4 (13) 4 (13)
Malignancy 11 (12) 2 (7) 4 (13) 5 (16)
Diabetes Mellitus 22 (24) 8 (26) 7 (23) 7 (23)
Hypertension 41 (44) 15 (48) 15 (48) 11 (36)
History of heart failure 21 (23) 6 (19) 5 (16) 10 (31)
Previous MI 20 (22) 7 (23) 7 (23) 6 (19)
Previous CABG 15 (16) 5 (16) 5 (16) 5 (16)
Atrial fibrillation 16 (17) 5 (16) 5 (16) 6 (19)
Aortic regurgitation 18 (19) 6 (19) 3 (10) 9 (29)
Aortic stenosis 34 (37) 11 (36) 13 (42) 10 (32)
Mitral regurgitation 26 (28) 7 (23) 7 (23) 12 (39)
Mitral stenosis 6 (7) 0 (0) 3 (10) 3 (10)
LVEF (%) 49 ±16 46-52 50 ±16 44-56 50 ±15 44-56 47 ±16 41-53
Admitted for heart failure 23 (25) 4 (13) 8 (26) 11 (35)
CKMB/Troponin positive 12 (13) 3 (10) 4 (13) 5 (16)
Reason for catheterisation
Suspected heart failure 63 (68) 20 (65) 15 (48) 28 (90)**
Valvular disease 52 (60) 15 (48) 17 (55) 20 (65)
Hemodynamic monitoring 7 (8) 2 (7) 1 (3) 4 (13)
Coronary artery disease 53 (57) 18 (58) 21 (68) 14 (45)
Medical condition
Pulmonary rales present 18 (19) 2 (7) 4 (13) 12 (39)**
NYHA class  I 9 (10) 2 (7) 4 (13) 3 (10)
   II 29 (31) 12 (39) 11 (36) 6 (19)
   III 42 (45) 15 (48) 11 (36) 16 (52)
   IV 13 (14) 2 (7) 5 (16) 6 (19)
Medication
ACE inhibitor 43 (46) 11 (36) 13 (42) 19 (61)
Beta blocker 63 (68) 21 (67) 22 (71) 20 (65)
Diuretic 46 (50) 14 (45) 15 (48) 17 (55)
Continuous data are means±SD and 95% confidence interval, dichotomous or ordinal data are n (%); BMI, Body Mass 
Index; MI, myocardial infarction; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; CKMB / 
Trop positive, Creatin Kinase MB or Troponin positive indicating recent myocardial infarction; NYHA, New York Heart 
Association functional classification; * p<0.05, ** p<0.01, between tertiles, Chi square for dichotomous data, 2 degrees 
of freedom (df), Chi square for ordinal data, 6 df, and One-way ANOVA for continuous data, 2 df between groups, 90 df 
within groups.
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Table 2   Hemodynamic data and pressure ratios of the Valsalva manoeuvre
Total PPR, 1st tertile PPR, 2nd tertile PPR, 3rd tertile
Variable n=93 95% CI n=31 95% CI n=31 95% CI n=31 95% CI
PCWP 17 ±8 16-19 13 ±6 11-15 17 ±6 15-19 22 ±9 19-25***
MPAP 28 ±10 25-30 24 ±8 21-26 26 ±8 23-29 34 ±12 29-38***
Heart rate (/min) 70 ±14 67-72 67 ±11 63-71 70 ±15 64-75 72 ±15 66-77
SBP 158 ±31 151-164 150 ±27 140-160 162 ±31 150-173 161 ±34 149-174
DBP 75 ±16 72-79 76 ±18 69-83 78 ±15 72-83 72 ±15 67-77
MAP 102 ±19 98-106 101 ±21 93-108 106 ±19 99-112 100 ±18 94-107
PP 83 ±25 77-88 75 ±19 67-81 84 ±25 74-93 89 ±28 79-100
Expiratory pressure and Valsalva pressure ratios
PVal 33 ±6 32-35 37 ±6 34-39 34 ±5 32-35 30 ±7 28-33***
SPR 0.78 ±0.13 0.75-0.81 0.64 ±0.10 0.60-0.67 0.81 ±0.05 0.79-0.83 0.90 ±0.06 0.88-0.92***
DPR 0.87 ±0.08 0.86-0.89 0.83 ±0.08 0.80-0.86 0.90 ±0.06 0.88-0.92 0.89 ±0.08 0.86-0.92**
MPR 0.83 ±0.10 0.81-0.85 0.75 ±0.09 0.71-0.78 0.86 ±0.05 0.84-0.88 0.90 ±0.07 0.87-0.92***
PPR 0.58 ±0.20 0.54-0.63 0.34 ±0.09 0.31-0.38 0.60 ±0.06 0.58-0.62 0.81 ±0.08 0.78-0.84***
Data are means±SD and 95% CI (confidence interval); PCWP, pulmonary capillary wedge pressure; MPAP, mean pulmonary 
artery pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; 
PVal, expiratory pressure during Valsalva manoeuvre; SPR, systolic pressure ratio; DPR, diastolic pressure ratio; MPR, mean 
pressure ratio; PPR, pulse pressure ratio; Pressures in mmHg; Blood pressure measured with Finapres. ** p<0.01, *** p<0.001, 
between tertiles, One-way ANOVA, 2 degrees of freedom between groups, 90 within groups.
Relation between the Valsalva manoeuvre and mortality
SPR (Hazard Ratio: 1.57; 95% CI: 1.04-2.38, p=0.033) and PPR (Hazard Ratio: 1.43; 95% CI: 1.12-1.84, 
p=0.005) were related to mortality in univariate Cox regression analysis; MPR and DPR were not 
(Hazard Ratios: 1.27; 95% CI: 0.78-2.05 and 0.96; 95% CI: 0.56-1.65, respectively). Using backward 
stepwise analysis with SPR and PPR, PPR appeared to be the strongest predictor for mortality. 
Therefore, only PPR was used in further Cox regression modelling.
Figure 2 displays Kaplan Meier curves of cumulative survival for each tertile of the PPR. In the 
first tertile, 2 patients died, in the second tertile, 6 patients, and in the third tertile 12 patients 
died. Survival differed significantly between the tertiles, Log rank score 9.91, p=0.007. In Table 1, 
the baseline characteristics of all patients and for groups divided by tertiles of the PPR are shown. 
In Table 2, the hemodynamic data before and during the Valsalva manoeuvre are shown for the 
complete group of patients, as for the group divided by tertiles of the PPR. PCWP and MPAP were 
significantly higher in the third tertile compared to the first and second tertiles.
The increase in blood pressure with the onset of straining was not related to mortality, nor 
was the expiratory pressure during the Valsalva manoeuvre. Figure 3 shows the results of a Cox 
survival regression model with PPR and non-invasive baseline variables. Pulse pressure ratio was an 
independent predictor of mortality, as was age. Using backward stepwise analysis, only PPR remained 
as an independent predictor of death.
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Figure 2  Kaplan Meier survival for tertiles of the pulse pressure ratio (PPR). In each tertile were 31 patients. Log rank for 
survival pooled over all tertiles.
Figure 3  Risk of death and non-invasive variables. Univariate and multivariate Cox proportional Hazard analysis. PPR, pulse 
pressure ratio (per step of 0.10); LVEF, left ventricular ejection fraction; HF, heart failure; CKMB / Trop +, Creatin Kinase MB or 
Troponin positive indicating recent myocardial infarction; NYHA, New York Heart Association functional classification I-IV.
Of the non-invasive baseline variables not mentioned in Figure 3, no variable was a univariate 
predictor of mortality, nor was the use of any medication or blood pressure at baseline. The invasive 
variables PCWP and MPAP were both univariate predictors of mortality: Hazard Ratio per mmHg: 
1.07; 95% CI: 1.02-1.13, p=0.008, and Hazard Ratio: 1.05; 95% CI: 1.01-1.08, p=0.017, respectively. If 
corrected for PWCP, PPR was not an independent predictor for mortality, Hazard Ratio: 1.32; 95% CI: 
0.99-1.78, p=0.061. If corrected for MPAP, PPR was a significant predictor, Hazard Ratio: 1.35; 95% CI: 
1.03-1.78, p=0.030. Using backward analysis in a model with PCWP and MPAP, PPR appeared to be 
the strongest predictor of mortality.
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Variable  (95% CI) p Value
PPR (0.10) 1.43 (1.12-1.84) 0.005
Age (yr) 1.10 (1.00-1.20) 0.061
Female gender 0.78 (0.31-1.96) 0.595
LVEF (%) 1.00 (0.97-1.03) 0.895
Admitted for HF 1.57 (0.63-3.94) 0.336
CKMB/Trop + 2.29 (0.75-6.77) 0.146
Heart rate (/min) 1.01 (0.99-1.04) 0.351
Pulmonary rales 2.84 (1.13-7.15) 0.026
NYHA II vs I 0.44 (0.11-1.86) 0.264
NYHA II vs I 0.49 (0.13-1.84) 0.290
NYHA II vs I 0.98 (0.22-4.33) 0.965
Univariate  
Hazard Ratio for death
Multivariate  
Hazard Ratio for death
 (95% CI) p Value
1.52 (1.12-2.07) 0.008
1.14 (1.01-1.29) 0.030
0.37 (0.13-1.08) 0.068
1.02 (0.99-1.05) 0.274
0.72 (0.17-3.10) 0.664
2.54 (0.56-11.55) 0.229
1.03 (0.99-1.06) 0.195
2.01 (0.52-7.78) 0.312
0.39 (0.09-1.83) 0.234
0.26 (0.06-1.14) 0.074
0.23 (0.04-1.35) 0.103
Hazard Ratio Hazard Ratio 
0.25          0.5            1              2             4 0.25          0.5            1              2             4
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For patients not undergoing cardiac surgery (n=48), PPR was a univariate predictor of mortality: 
Hazard Ratio: 2.06; 95% CI: 1.18-3.59, p=0.011, and an independent predictor in a model with age 
and presence of pulmonary rales: Hazard Ratio: 1.95; 95% CI: 1.06-3.59, p=0.031. In patients who 
underwent cardiac surgery (n=45), PPR tended to be a univariate predictor of mortality.
Figure 4  Univariate Cox proportional Hazard Ratios of PPR in subgroups. PPR, pulse pressure ratio (per step of 0.10); atrial 
fib, atrial fibrillation; Adm for HF, admission for heart failure; LVEF, left ventricular ejection fraction; valv dis, valvular heart 
disease; CKMB / Trop +, Creatin Kinase MB or Troponin positive indicating recent myocardial infarction; NYHA, New York 
Heart Association functional classification I-IV.
Subgroups (total n=93)  (95% CI) p Value
Male (n=55) 1.49 (1.10-2.00) 0.008
Female (n=38) 1.38 (0.86-2.23) 0.185
Atrial fib (n=16) 2.03 (0.52-7.96) 0.312
No atrial fib (n=77) 1.40 (1.09-1.79) 0.008 
Hypertension (n=41) 1.78 (1.21-2.63) 0.004
No hypertension (n=52) 1.28 (0.90-1.81) 0.166
Adm for HF (n=23) 1.25 (0.77-2.04) 0.371
Not adm for HF (n=70) 1.54 (1.12-2.11) 0.008
LVEF <40%  (n=24) 1.17 (0.76-1.79) 0.484
LVEF ≥40% (n=69) 1.57 (1.15-2.15) 0.005
Valv dis (n=58) 1.27 (0.97-1.67) 0.088
No valv dis (n=35) 1.88 (1.10-3.21) 0.022
CKMB / Trop + (n=12) 1.47 (0.79-2.74) 0.224
CKMB / Trop - (n=81) 1.42 (1.07-1.87) 0.014
Rales (n=18) 1.26 (0.76-2.08) 0.373
No rales (n=75) 1.40 (1.02-1.92) 0.035
NYHA I-II (n=38) 1.58 (0.90-1.91) 0.158
NYHA III-IV (n=55) 1.57 (1.10-2.23) 0.012
Surgery (n=45) 1.40 (0.93-1.66) 0.140
No surgery (n=48) 2.06 (1.18-3.59) 0.011
Hazard Ratio of PPR for death
Hazard Ratio
0.5                        1                            2                          4
Discussion
The main finding in this study is that the PPR of the Valsalva manoeuvre is related to the risk of 
mortality in a heterogeneous group of elderly cardiac patients, undergoing right-sided cardiac 
catheterisation. The PPR appeared to be a prognostic marker in addition to variables that already 
have been established as predictors for mortality. The PPR might therefore be of use in the assessment 
of the life expectancy of a patient.
The blood pressure response to the Valsalva manoeuvre has been reported to be related to left 
ventricular ejection fraction (LVEF)15, right atrial pressure16, pulmonary artery pressure17, pulmonary 
capillary wedge pressure6, left ventricular end diastolic pressure17, NYHA class18, and natriuretic 
peptides18. Of all these variables, a relation with survival has been reported8, 9, 19-21. In our study, 
PPR appeared to be the strongest predictor of mortality, together in a model with PCWP and 
MPAP, which could mean that the PPR has prognostic value additional to cardiac filling pressures. 
Therefore, the PPR might be a measure of cardiovascular integrity in whole, integrating different 
measures of cardiac dysfunction. 
The absence of decrease in blood pressure, during a bedside Valsalva manoeuvre, was reported 
to be highly predictive of future sudden death in survivors myocardial infarction15. The authors 
attributed the prognostic value of the Valsalva manoeuvre to its correlation with an impaired LVEF. 
Interestingly, we found no relation between LVEF and survival. Furthermore, the blood pressure 
response was not related to LVEF, which might indicate that LV filling pressure is a more important 
prognostic marker than LVEF.
The absence of decrease in blood pressure during phase two is probably caused by elevation of 
venous pressure, which enables filling of the heart in spite of the increase in intra-thoracic pressure 
during the straining phase of the Valsalva maneuver22. However, the decrease in blood pressure also 
depends on the slope and the position on the left-ventricular function curve5. On this curve, stroke 
work, or pulse pressure or mean arterial pressure, is plotted against filling pressure. The slope of 
this curve depends on the severity of the heart disease. With high filling pressures, at the flattened 
part of the curve, a fall in filling pressure, caused by straining, will affect stroke work only minimally 
resulting in an absence of decrease in blood pressure. The absence of decrease in blood pressure 
may also be caused by alteration of the autonomic system. In heart failure, the autonomic system is 
altered, with an increase in sympathetic activity, associated with increased plasma noradrenalin, and 
a reduction in vagal activity23. Because of these changes, baroreflex sensitivity (BRS), assessed with 
phenylephrine, is decreased in heart failure and associated with increased mortality8. Importantly, 
the agreement between phenylephrine BRS and Valsalva manoeuvre is poor, especially in patients 
with impaired left ventricular function24, and BRS assessed with the Valsalva manoeuvre in heart 
failure patients was not a prognostic predictor20. We might however speculate that, though the BRS 
can not be properly assessed using the Valsalva manoeuvre, the impaired decrease in blood pressure 
is not only caused by elevated filling pressure but also by increased sympathetic activity and elevated 
noradrenalin levels, which impedes decrease of blood pressure in the straining phase of the Valsalva 
manoeuvre. 
A substantial number of our patients died after surgery, which might have influenced our finding 
that PPR is a predictor of mortality. In those not undergoing surgery, all patients died of heart failure 
and PPR was strongly related to mortality. In those undergoing surgery, the predictive value of PPR 
was less manifest. Yet, patients with a high PPR may still be at increased risk of mortality when they 
undergo cardiac surgery. Apparently, in cardiac surgery, other factors than reflected by the Valsalva 
manoeuvre may cause mortality and cannot be predicted by the Valsalva manoeuvre.
Maximum expiratory pressure during the Valsalva manoeuvre differed among the subjects, 
which could have influenced our findings. Expiratory pressure and PPR were correlated, which 
can be explained by the physiological mechanisms occurring during the Valsalva manoeuvre. Low 
expiratory effort may be due to unrelated things, like general weakness or compliance, meaning 
that if expiratory pressure is low, the decrease of pulse pressure is small, regardless of cardiac filling 
pressures, and cardiac or autonomic function. 
Since we studied elderly patients who underwent right-sided catheterisation, the study group 
was very heterogeneous and highly selected, with a high mortality rate. Therefore, our findings may 
not be extrapolated to other, more specific groups of patients. Analysis of several subgroups of 
patients uniformly showed a Hazard Ratio of PPR larger than one in all subgroups, however in several 
groups this was not significant and confidence intervals were wide, probably due to the low number 
of patients. Therefore, a prospective study should be performed in a large cohort of patients, with 
clearly described subgroups and perhaps with a lower expected mortality rate, to reconfirm the 
prognostic ability of the blood pressure response to the Valsalva manoeuvre. If so, a device that can 
assess the blood pressure response to the Valsalva manoeuvre and provides the PPR should become 
widely available, preferably at low costs. Otherwise, this method will only be used in (teaching) 
hospitals that have the ability to non-invasive continuous blood pressure measurement. Therefore, 
also the prognostic value of sphygmanometrical (cuff) blood pressure changes during the Valsalva 
manoeuvre should be assessed in future studies. High sensitivity and specificity of detecting elevated 
PCWP has been described using cuff blood pressure changes during the Valsalva manoeuvre25. This 
could mean that this method might have prognostic significance as well, which would make the 
Valsalva manoeuvre a more feasible prognostic instrument in daily clinical practice.
Conclusion
The PPR of the Valsalva manoeuvre was related to the risk of mortality in a heterogeneous group of 
elderly cardiac patients undergoing right-sided cardiac catheterisation. Therefore, the PPR might be 
a non-invasive prognostic marker in addition to established invasive and non-invasive prognostic 
variables. These hypothesis-generating findings fuel the interest to large prospective studies on the 
prognostic implications of the Valsalva manoeuvre.
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Summary
Heart failure is primarily a disorder of the elderly. Particularly in the elderly, diagnosis of heart failure 
is difficult1. However, early diagnosis is important, since mortality and symptoms can be reduced 
with carefully tailored therapy2, 3. Heart failure can be defined as the state in which the heart is unable 
to pump blood at the rate needed by the metabolising tissues or can do so only with elevated filling 
pressures4. Therefore, assessment of left ventricular filling pressure or pulmonary capillary wedge 
pressure (PCWP) is of great importance for diagnosing heart failure, however PCWP has to be 
assessed invasively, which is not without risk5, 6. The availability of a simple, safe, repeatable, and non-
invasive technique for determining left ventricular filling pressure could greatly contribute to the 
early detection and improved treatment of heart failure. In the last five decades, correlation between 
cardiac filling pressures, i.e. PCWP, and the blood pressure response to the Valsalva manoeuvre has 
been described7-9. However, these studies were small and not restricted to the elderly, in whom the 
prevalence of heart failure is highest. Furthermore, the blood pressure response to the Valsalva 
manoeuvre was only examined scarcely in patients with atrial fibrillation and cardiac valvular 
disease, disorders that are highly prevalent in the elderly10, 11. The general aim of this thesis was to 
study whether the blood pressure response to the Valsalva manoeuvre can be used to assess PCWP 
in elderly subjects.
In chapter 2, the literature about the Valsalva manoeuvre as a diagnostic instrument for heart 
failure was reviewed. During the last five decades, a multitude of reports has described a relationship 
between the blood pressure response to the Valsalva manoeuvre and cardiac filling pressures. In broad 
outlines, a normal blood pressure response with the typical four phases in healthy subjects and a 
square wave response in patients with clinically manifest heart failure has been reported consistently. 
According to most studies, the square wave response is due to an increased intrathoracic volume, 
though studies conflict regarding the correlation of this response with increases in right-sided or left-
sided intra-cardiac pressures. All reports are, however, consistent in the fact that a square wave blood 
pressure response to the Valsalva manoeuvre is seen in severely ill patients and is a sign of severely 
impaired circulation. It is unclear whether an intermediate response to the Valsalva manoeuvre has 
clinical and perhaps prognostic implications. Furthermore, the inter-individual and intra-individual 
variability of the blood pressure response to the Valsalva manoeuvre could hamper exact estimation 
of cardiac filling pressures. The manoeuvre is influenced by a multitude of variables such as patient 
age, the use of cardiovascular drugs, and the presence of pulmonary emphysema or autonomic 
dysfunction. These difficulties might trouble a correct interpretation of the Valsalva blood pressure 
response. Further research is clearly needed to investigate the utility of the Valsalva manoeuvre in 
diagnosing and monitoring heart failure, with particular attention to the factors mentioned before.
In chapter 3, the recruitment of healthy elderly subjects to participate in the study protocol, 
which included right-sided cardiac catheterisation, was described. It appeared to be easily possible 
to recruit healthy elderly volunteers for cardiovascular research that includes cardiac catheterisation. 
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The cardiovascular screening was the main motive for participation, while the allowance played 
no significant role. Custom-made information, coaching and care throughout the entire study by a 
specialised research nurse resulted in satisfaction and commitment of the study subjects.
In chapter 4, Modelflow pulse contour analysis of the Finapres blood pressure was compared 
to thermodilution cardiac output as gold standard, in healthy elderly subjects. Modelflow cardiac 
output differed significantly from and showed no significant correlation with invasively determined 
thermodilution cardiac output. While relative changes in Modelflow cardiac output have been 
reported to a give a correct reflection of cardiac output changes, Modelflow pulse contour analysis 
was inaccurate for reliable assessment of absolute cardiac output values without initial invasive 
calibration.
Chapter 5 described lower body positive pressure by anti-gravity (anti-G) garment inflation as a 
method to temporarily increase PCWP in healthy elderly subjects. Anti-G garment inflation induced 
a significant increase in PCWP in supine and semi-recumbent position. The increase in PCWP by anti-
G garment inflation may be explained by an increase in preload caused by a shift of venous blood 
from the peripheral to the central circulation, and by an increase in left ventricular afterload due to 
mechanical compression of the vascular bed in the lower body. Inflation of the anti-G garment did 
not lead to any complaints or clinical signs of pulmonary congestion or any other complications. 
Therefore, anti-G garment inflation was a safe, non-invasive, method to induce a significant increase 
in pulmonary capillary wedge pressure in both supine and semi-recumbent position. These findings 
justify its application in studies in which a non-invasive temporary increase in pulmonary capillary 
wedge pressure is required.
In chapter 6, the first study reporting normal values of the blood pressure response to the Valsalva 
manoeuvre and in the elderly was described. Normal values for the blood pressure response to the 
Valsalva manoeuvre in healthy subjects, including measures of variability, are essential in interpreting 
patient data. Normal data of PCWP in the elderly were acquired, in addition to the scarce data on 
normal values of PCWP that already exist. In the normal range of PCWP, the pulse pressure ratio of 
the Valsalva manoeuvre correlated significantly with PCWP, however this correlation was moderate. 
Stroke volume ratio correlated with PCWP but not stronger than the pulse pressure ratio did. The 
systolic blood pressure ratio did not correlate significantly with PCWP. Based on Receiver Operating 
Characteristics (ROC) analyses, pulse pressure ratio, systolic blood pressure ratio and stroke volume 
ratio appeared to be good diagnostic instruments for detection of elevated PCWP, which was 
effectuated by anti-G garment inflation. Therefore, the blood pressure response to the Valsalva 
manoeuvre might be a valuable tool in the non-invasive diagnosis of heart failure.
Chapter 7 described a study on the detection of elevated pulmonary capillary wedge pressure 
in elderly patients with various cardiac disorders by the Valsalva manoeuvre. The pulse pressure 
ratio was significantly correlated to PCWP with a correlation coefficient (r) of 0.62, as were systolic 
blood pressure ratio, r=0.54, diastolic blood pressure ratio, r=0.35, and stroke volume ratio, r=0.58. 
The heart rate ratio was not correlated to PCWP. Using stepwise forward analysis, the pulse pressure 
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ratio was related most strongly to PCWP. The pulse pressure ratio was an accurate method to 
predict elevated PCWP, based on ROC analysis. The presence or absence of various common cardiac 
disorders, like atrial fibrillation and valvular heart disease, did not influence the diagnostic feature 
of pulse pressure ratio in predicting elevated PCWP. This makes the blood pressure response to the 
Valsalva manoeuvre a non-invasive tool for diagnosis of heart failure, applicable in elderly patients 
with various cardiac disorders, like atrial fibrillation and valvular heart disease.
Chapter 8 described a study in a small group of patients (n=7), in whom the blood pressure 
response to the Valsalva manoeuvre and pulmonary capillary wedge pressure was assessed 
sequentially. The change in pulmonary capillary wedge pressure was reflected by change in the blood 
pressure response to the Valsalva manoeuvre, in terms of the pulse pressure ratio. This underscores 
the potential of the blood pressure response to the Valsalva manoeuvre as a tool to monitor heart 
failure patients.
Chapter 9 described a retrospective study on the prognostic implications of the blood 
pressure response to the Valsalva manoeuvre in elderly cardiac patients. The pulse pressure ratio 
of the Valsalva manoeuvre was related to the risk of mortality independently of age, gender, left 
ventricular ejection fraction, admission for heart failure, myocardial infarction, heart rate, presence 
of pulmonary rales, and New York Heart Association functional class. The pulse pressure ratio 
appeared to be the strongest predictor of mortality, in a model with PCWP and mean pulmonary 
artery pressure. Therefore, the pulse pressure ratio might be a non-invasive prognostic marker in 
addition to established invasive and non-invasive prognostic variables. Large prospective studies 
have to reconfirm the prognostic implications of the Valsalva manoeuvre.
General discussion
The blood pressure response to the Valsalva manoeuvre appeared to be a good diagnostic tool 
for the detection of elevated PCWP in elderly subjects and it can therefore be used as a tool to 
diagnose heart failure. One could argue that echocardiography is the method for assessment of 
cardiac function and therefore an important tool in the diagnosis of heart failure1. However, cardiac 
dysfunction and heart failure are not synonyms. Based on the definition of heart failure as the state 
in which the heart is unable to pump blood at the rate needed by the metabolising tissues or can do 
so only with elevated filling pressures4, assessment of left ventricular filling pressure or pulmonary 
PCWP seems mandatory to diagnose heart failure. After all, elevated PCWP greatly supports the 
diagnosis of heart failure, whereas normal PCWP strongly opposes the diagnosis of heart failure1. 
However, PCWP can only be assessed invasively through pulmonary artery catheterisation, which is 
not without risks5, 6. Several echocardiographic approaches to assess PCWP have been proposed, but 
it is not clear if any of these methods provides the precision and accuracy needed for the evaluation 
of patients12.
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The studies in this thesis were designed before the era of the appearance of the natriuretic peptides. 
Natriuretic peptides have been reported to be promising in the diagnosis of heart failure, with the 
opinion of independent cardiologists, based on clinical symptoms, as gold standard for the presence 
or absence of heart failure13. In the very elderly, natriuretic peptides have shown to be promising in the 
detection of left ventricular systolic and diastolic function14. However, the correlation between PCWP 
and natriuretic peptides has been reported to be poor15, as was the diagnostic accuracy to detect 
elevated PCWP16. We can not claim that the blood pressure response is superior to echocardiography 
or natriuretic peptides to diagnose heart failure. Yet, the blood pressure response can be of value, 
additional to other variables like echocardiographically assessed (left) ventricular function and 
natriuretic peptides, to diagnose heart failure, which has to be proven in future studies.
Until now, normal data of the blood pressure response have never been reported, not in younger 
subjects, or in the elderly. The acquirement of normal values of the blood pressure response is 
essential in the interpretation of patient data.
An absence of decrease in blood pressure during the Valsalva manoeuvre appeared to be related 
to a poor prognosis in a retrospective analysis of our patients. Importantly, the prognostic value of 
the blood pressure response was independent of other, acknowledged prognostic variables, as age, 
New York Heart Association functional class en left ventricular ejection fraction. Yet, new prognostic 
markers like B-type natriuretic peptide (BNP), which recently have been described to have prognostic 
value in elderly heart failure patients17, were not assessed. Therefore, prospective studies, which also 
consider BNP, have to be performed in order to reconfirm the prognostic value of the blood pressure 
response to the Valsalva manoeuvre.
In conclusion, the blood pressure response to the Valsalva manoeuvre is an easy, safe, non-invasive 
tool to assess PCWP in elderly healthy subjects and cardiac patients. Therefore, the blood pressure 
response can be used to diagnose heart failure in the elderly, irrespective of rhythm disturbances 
and valvular heart disease. In addition, this method can be used to monitor heart failure patients. 
Furthermore, the blood pressure response to the Valsalva manoeuvre might serve as a prognostic 
marker. However, in order to make this method widely and easily applicable, devices that provide 
non-invasive continuous blood pressure during the Valsalva manoeuvre should be available at 
low costs. In order to assess the role of the blood pressure response to the Valsalva manoeuvre 
in addition to natriuretic peptides and echocardiography in the diagnosis of heart failure and as 
prognostic marker, further research has to be performed. 
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Samenvatting
Hartfalen is primair een ziekte van de oudere mens. Vooral bij ouderen is het vaststellen van 
hartfalen moeilijk1. Een vroege diagnose van hartfalen is echter belangrijk omdat zowel symptomen 
bij en de prognose van patiënten met hartfalen verbeterd kunnen worden met op maat gesneden 
therapie2, 3. Hartfalen kan gedefinieerd worden als die toestand waarbij het hart niet in staat is 
om voldoende bloed rond te pompen bij normale vullingsdrukken of dat alleen kan doen bij 
verhoogde vullingsdrukken4. Daarom is het meten van de vullingsdruk van de linker hartkamer, of 
van de pulmonale capillaire wiggedruk (PCWP), belangrijk om hartfalen vast te stellen. Echter het 
meten van de PCWP gebeurt invasief wat niet zonder risico is5, 6. Een simpele veilige methode om de 
vullingsdruk van de linker hartkamer of de PCWP niet invasief te meten zou belangrijk bijdragen aan 
de vroege diagnostiek en verbeterde behandelingsmogelijkheden van hartfalen. In de laatste vijftig 
jaar is meerdere malen een relatie beschreven tussen cardiale vullingsdrukken zoals PCWP en de 
bloeddrukreactie op de Valsalva manoeuvre7-9. Deze studies waren echter klein en beperkten zich niet 
slechts tot ouderen bij wie hartfalen het meest voorkomt. Verder is de bloeddrukreactie nauwelijks 
onderzocht bij boezemfibrilleren en bij kleplijden wat beide frequent voorkomt bij ouderen10, 11. Het 
algemene doel van dit proefschrift was derhalve om te onderzoeken of de bloeddrukreactie op de 
Valsalva manoeuvre gebruikt kan worden om de PCWP, als maat voor linkerkamer vullingsdruk, te 
meten bij ouderen.
In hoofdstuk 2 werd een overzicht gegeven van de literatuur over de Valsalva manoeuvre als 
diagnostisch instrument voor hartfalen. Gedurende de laatste vijftig jaar zijn er meerdere rapporten 
verschenen die de relatie beschrijven tussen de bloeddrukreactie op de Valsalva manoeuvre en 
cardiale vullingsdrukken. Een normale bloeddrukreactie met het typische vier fasepatroon wordt 
consistent beschreven in de literatuur, net als een blokvormig bloeddrukpatroon bij patiënten 
met evident hartfalen. Het blokvormige bloeddrukpatroon wordt gekenmerkt door een initiële 
stijging van de bloeddruk met het begin van de Valsalva manoeuvre die niet gevolgd wordt door 
een bloeddruk daling, zoals dat bij gezonden het geval is. Volgens de meeste studies wordt het 
blokvormige bloeddrukpatroon veroorzaakt door dat het thoracale bloed volume is vergroot. 
Echter in de literatuur is er geen eenduidigheid over of de bloeddrukreactie samenhangt met de 
hoogte van de linkszijdige dan wel rechtszijdige drukken. Alle rapporten melden echter consistent 
dat een blokvormige bloeddrukreactie een teken is van een gestoorde circulatie en voorkomt bij 
ernstig zieke patiënten. Het is niet duidelijk of een matig afwijkend bloeddrukpatroon, dat wil zeggen 
wel bloeddruk daling maar onvoldoende, klinische en misschien wel prognostische waarde heeft. De 
intra-individuele variabiliteit zorgt er voor dat het moeilijk is om een exacte voorspelling te doen van 
de cardiale vullingsdrukken met behulp van de Valsalva manoeuvre.
De Valsalva manoeuvre wordt beïnvloed door vele factoren, waaronder leeftijd, het gebruik 
van medicatie met invloed op het cardiovasculaire systeem, ernstig longemfyseem en autonome 
dysfunctie. Dit kan een correcte interpretatie van de bloeddrukreactie op de Valsalva manoeuvre 
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verstoren. Verder onderzoek is nodig naar de Valsalva manoeuvre als diagnosticum voor hartfalen, 
met inachtneming van de bovengenoemde factoren.
In hoofdstuk 3, werd de werving besproken van oudere gezonde proefpersonen om deel te nemen 
aan wetenschappelijk onderzoek waarbij ook een rechtszijdige hartcatheterisatie hoorde. Het bleek 
heel wel mogelijk om daar proefpersonen voor te werven. Het uitgebreide cardiovasculaire onderzoek 
voorafgaand aan de eigenlijke studie was voor de meeste proefpersonen de voornaamste reden om 
mee te doen. De vergoeding voor deelname speelde geen belangrijke rol. Uitgebreide informatie 
verstrekking aan de proefpersoon, met persoonlijke ondersteuning en zorg door een gespecialiseerde 
onderzoeksverpleegkundige, resulteerden in enorme betrokkenheid en tevredenheid van de 
proefpersonen.
In hoofdstuk 4, werd de het hartminuutvolume middels Modelflow drukgolf analyse van de 
Finapres bloeddruk vergeleken met thermodilutie hartminuutvolume als goudstandaard, bij 
gezonde oudere proefpersonen. Het Modelflow hartminuutvolume verschilde significant van het 
thermodilutie hartminuutvolume. Bovendien correleerde beide methoden niet met elkaar. Hoewel 
beschreven is dat met de Modelflow methode relatieve veranderingen in het hartminuutvolume 
kunnen worden bepaald, is de Modelflow methode niet geschikt om zonder calibratie betrouwbaar 
het hartminuutvolume te meten.
Hoofdstuk 5 beschrijft het opblazen van een anti-zwaartekracht (anti-G) broek, ofwel een 
pilotenbroek, als methode om de PCWP te verhogen bij gezonde oudere proefpersonen. Het 
opblazen van de anti-G broek veroorzaakt positieve druk op het onderlichaam met stijging van de 
PCWP als gevolg. Deze stijging van de PCWP is enerzijds een gevolg van verhoogde “preload”, oftewel 
vulling voorafgaand aan de contractie, en anderzijds een gevolg van verhoogd “afterload”, een maat 
voor de weerstand van het hart tijdens de contractie. Dit laatste wordt veroorzaakt doordat met 
de anti-G broek het vaatbed in de onderste lichaamshelft wordt samengedrukt. Er werden geen 
klachten van de proefpersonen tijdens het opblazen van de anti-G broek en er deden zich geen 
complicaties voor. Geconcludeerd werd dat het opblazen van een anti-G broek een veilige methode 
is om een significante stijging van de PCWP te bewerkstelligen. Bij studie waarbij een stijging van de 
PCWP gewenst is, kan deze methode dan ook gebruikt worden.
In hoofdstuk 6 werd de eerste studie beschreven naar de normaalwaarden van de bloeddrukreactie 
op de Valsalva manoeuvre gemeten bij gezonde ouderen. Beschikking over normaalwaarden, inclusief 
de maten van variabiliteit, is essentieel om data van patiënten te kunnen beoordelen. Verder werden 
waarden verkregen van de PCWP gemeten bij gezonde ouderen. Tot nu was nauwelijks iets bekend 
over normaalwaarden van PCWP bij ouderen bekend. Bij normale PCWP correleerde de polsdruk 
ratio van de Valsalva manoeuvre (de laagste polsdruk gedeeld door de hoogste polsdruk) significant 
met de PCWP, echter de correlatie was niet heel sterk. Ook de slagvolume ratio correleerde met 
de PCWP, maar niet sterker dan de polsdruk ratio. De systolische bloeddruk ratio correleerde 
niet met de PCWP. Gebaseerd op Receiver Operating Characteristics (ROC) analysen bleken de 
polsdruk ratio, de systolische bloeddruk ratio en de slagvolume ratio goede diagnostica voor het 
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vaststellen van verhoogde PCWP, welke was bewerkstelligd met de anti-G broek. Dit kan betekenen 
dat de bloeddrukreactie op de Valsalva manoeuvre gebruikt kan worden voor het niet invasief 
diagnosticeren van hartfalen.
Hoofdstuk 7 beschrijft een studie over het vaststellen van verhoogde PCWP met de bloeddrukreactie 
op de Valsalva manoeuvre bij oudere patiënten met verscheidene cardiale aandoeningen. De 
polsdrukratio correleerde significant met de PCWP, met een correlatie coëfficiënt (r) van 0.62, als 
ook de systolische bloeddruk ratio, r=0.54, de diastolische bloeddruk ratio, r=0.35, en de slagvolume 
ratio, r=0.58. De hartfrequentie ratio, de hoogste hartfrequentie gedeeld door de laagste tijdens de 
manoeuvre, correleerde niet met de PCWP. Met stapsgewijze multivariabele regressie analyse bleek 
de polsdruk ratio de sterkste voorspeller voor PCWP. Middels ROC analyse, bleek de polsdruk ratio 
een accurate methode om verhoogd PCWP vast te stellen. De aan- of afwezigheid van verscheidene 
veel voorkomende cardiale aandoeningen zoals boezemfibrilleren en hartklep afwijkingen hadden 
geen invloed op het diagnostische vermogen van de polsdruk ratio. Dit maakt de polsdruk ratio 
van de Valsalva manoeuvre een niet invasief diagnosticum voor hartfalen, toepasbaar in de oudere 
patiënt met veel voorkomende cardiale aandoeningen zoals boezemfibrilleren en klepafwijkingen.
Hoofdstuk 8 beschrijft een studie in een kleine groep patiënten (n=7), waarbij de bloeddrukreactie 
op de Valsalva manoeuvre en de PCWP meerdere malen werden gemeten. De verandering van 
de PCWP werd gereflecteerd door de veranderde bloeddrukreactie op de Valsalva manoeuvre, 
uitgedrukt in polsdruk ratio, systolische druk ratio en slagvolume ratio. Dit onderstreept de potentie 
van de Valsalva manoeuvre om patiënten met hartfalen te vervolgen en te monitoren.
Hoofdstuk 9 beschrijft een retrospectieve studie naar de prognostische betekenis van de 
bloeddrukreactie op de Valsalva manoeuvre bij oudere cardiale patiënten. De polsdruk ratio van de 
Valsalva manoeuvre was gerelateerd aan de kans op overlijden, onafhankelijk van leeftijd, geslacht, 
linker kamer ejectiefractie, opname vanwege hartfalen, myocardinfarct, polsfrequentie, aanwezigheid 
van pulmonale crepitaties, en de New York Heart Association klasse. In een model met PCWP 
en gemiddelde pulmonalis druk, bleek de polsdruk ratio de sterkste prognostische variabele. De 
polsdruk ratio van de Valsalva manoeuvre zou daarmee wel eens een onafhankelijke prognostische 
voorspeller kunnen zijn, onafhankelijk van reeds bekende voorspellers. Grote prospectief opgezette 
onderzoeken zijn nodig om de prognostische waarde van de bloeddrukreactie op de Valsalva 
manoeuvre te bevestigen.
Algemene discussie
De bloeddrukreactie op de Valsalva manoeuvre bleek een goed diagnostisch instrument voor het 
vaststellen van verhoogd pulmonale capillaire wiggedruk (PCWP) en kan daarom gebruikt worden 
om hartfalen vast te stellen. Men zou kunnen stellen dat echocardiografie de methode is om de 
cardiale functie te bepalen en daarmee onmisbaar is voor het diagnosticeren van hartfalen1. Echter, 
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hartfalen en cardiale dysfunctie zijn geen synoniemen. Uitgaande van de definitie van hartfalen 
als die toestand waarin het hart niet in staat is om voldoende bloed rond te pompen bij normale 
vullingsdrukken, of dat alleen kan doen bij verhoogd vullingsdrukken4, is bepaling van de linker 
ventrikel vullingsdruk, of de PCWP als afgeleide daarvan, onontbeerlijk. Zo pleit een verhoogde 
PCWP bijzonder sterk voor de diagnose hartfalen terwijl een verlaagde PCWP de diagnose vrijwel 
uitsluit1. Echter, de PCWP kan alleen maar worden bepaald met rechtszijdige hartcatheterisatie, 
wat niet zonder risico is5, 6. Meerdere echocardiografische methoden om de PCWP te bepalen zijn 
ontwikkeld, echter tot op heden is het niet duidelijk of deze methoden geschikt zijn ter evaluatie van 
de patiënt12.
De studies uit dit proefschrift zijn opgezet voor de opkomst van het natriuretische peptide. 
Natriuretische peptiden lijken veelbelovend voor het diagnosticeren van hartfalen, echter met 
het oordeel van een team van cardiologen als goudstandaard voor de diagnose hartfalen13. Bij 
hoogbejaarden bleek het natriuretische peptide veelbelovend voor het vaststellen van zowel 
systolische als diastolische linker kamer dysfunctie14. Echter, de natriuretische peptiden blijken 
nauwelijks te correleren met de PCWP15 en blijkt het diagnostische vermogen om verhoogde PCWP 
vast te stellen laag16.
We kunnen niet stellen dat de bloeddrukreactie op de Valsalva manoeuvre een beter of 
slechter diagnosticum voor hartfalen is dan echocardiografie of de natriuretische peptiden. De 
bloeddrukreactie op de Valsalva manoeuvre zou echter wel toegevoegde waarde kunnen hebben 
wat in toekomstig onderzoek zal moeten worden bewezen.
De mate van afname van de bloeddruk tijdens de Valsalva manoeuvre bleek een voorspeller 
te zijn voor de dood bij retrospectieve analyse bij oudere cardiale patiënten. Belangrijk is dat deze 
voorspellende waarde onafhankelijk was van andere prognostische factoren. Echter, zoals eerder 
vernoemd zijn geen natriuretische peptiden bepaald, waarvan inmiddels ook prognostische waarde 
is beschreven17. Er zijn dus prospectieve studies nodig die de prognostische waarde van de Valsalva 
manoeuvre, met inachtneming van andere prognostische variabelen als het natriuretische peptide, 
moeten bevestigen.
Samenvattend kan men stellen dat de bloeddrukreactie op de Valsalva manoeuvre een makkelijke 
en veilige methode is om niet invasief de PCWP te meten bij gezonde ouderen en bij oudere 
hartpatiënten. Derhalve kan de bloeddrukreactie op de Valsalva manoeuvre gebruikt worden om 
hartfalen te diagnosticeren bij ouderen, ook bij hartritmestoornissen of hartklepdefecten. Verder 
kan deze methode gebruikt worden om patiënten met hartfalen te vervolgen. Bovendien kan de 
bloeddrukreactie op de Valsalva manoeuvre gebruikt als maat voor de prognose van patiënten. Echter, 
wil deze methode makkelijk beschikbaar zijn en algemeen geaccepteerd worden dan zullen goedkope 
apparaten op de markt moeten komen waarmee men niet invasief de bloeddruk kan meten tijdens de 
Valsalva manoeuvre. Of de bloeddrukreactie op de Valsalva manoeuvre bij de diagnose van hartfalen 
en als prognostische voorspeller toegevoegde waarde heeft in combinatie met echocardiografische 
variabelen en met natriuretische peptiden zal verder onderzocht moeten worden.
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Allereerst gaat mijn dank uit naar alle patiënten maar vooral naar de gezonde proefpersonen die 
bereid waren deel te nemen aan het onderzoek. Zonder hen had het onderzoek dat leidde tot dit 
proefschrift niet plaats gevonden.
René Jansen, mijn co-promotor, als iemand mede verantwoordelijk is voor de totstandkoming 
van dit proefschrift, ben jij het. Je hebt me, ook als ik erg diep in de put zat, altijd aan het werk 
gehouden. We waren het soms oneens, maar altijd was je open en eerlijk, en we spraken al onze 
onenigheden uit.  Heel hartelijk dank voor alles!
Wim Aengevaeren, co-promotor, vanaf het begin was je bij het onderzoek betrokken. Je bracht 
bij bijna alle proefpersonen de catheters in, in alle vroegte, voorafgaand aan de overdracht, en altijd 
kreeg ik mijn manuscripten snel en met kritische maar vooral opbouwende commentaren terug. Het 
moest van jou “sexyer” en daar snapte ik aanvankelijk niets van. Nu wel, je had gelijk en het heeft 
geholpen.
Professor Verheugt, promotor, u zag altijd licht, terwijl het voor mij soms aardedonker was 
in onderzoeksland. U creëerde de mogelijkheden om ons onderzoek uit te voeren en om onze 
resultaten internationaal uit te dragen. Ik ben u daar erg dankbaar voor.
Professor Hoefnagels, promotor, u was als hoofd van de afdeling geriatrie bij mijn onderzoek 
betrokken. Weliswaar wat meer op de achtergrond maar niet minder betrokken. Vooral onze 
beschouwende gesprekken waardeer ik enorm.
Anja Bos, lieve Anja, 1e paasdag 2000, moet ik nog meer zeggen? Je was er altijd, op alle vlakken, 
geweldig! Frank Little, beste Frank, niet alleen heb je me geholpen door achter Anja te staan, maar 
ook je commentaar als native speaker waardeer ik enorm.
Peter Kievit, beste Kief, paranimf en “brother in arms”, in de wetenschap, in de opleiding, in de 
sport, aan de eettafel en achter een goed glas. Wat moet ik je zeggen, je weet genoeg denk ik. En nu 
jij, jongen!
Marc Brouwer, Marrekie, jij hebt me het onderzoek in getrokken en me zoveel geleerd. Ik ben er 
wijzer en kritischer van geworden. Ik dank je, en het betekent veel voor me dat je mijn paranimf wilt 
zijn.
De jongens van “de experimentele”, Etienne, Hendrik-Jan, Nick en Wessel. Het fijne is dat wij met 
zijn allen weten hoe het is. Dank voor jullie nooit aflatende luisterende oor en steun.
Jannet, Lilian en René, mijn onderzoekscollega’s van het eerste uur. We hebben hard gewerkt op 
onze kamer op N40. Ook hebben we heel wat tijd verpraat. Toch denk ik dat dat geen verloren tijd 
was.
Gerard, Truus, Noor, Gabe, ik kwam altijd zo maar langs, vaak omdat ik me verbonden voelde 
met de experimentele. Maar ook vaak, tot bijna de dag van vandaag, had ik digitale problemen en 
had ik jullie hulp nodig. Ik kreeg nooit nee te horen, fantastisch.
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Iedereen van de catheterisatiekamer: “Jaap, we hebben weer een rechtscath morgen, iets voor jou?” 
Het kon, en mocht altijd. Ook iedereen van de functie afdeling, een extra echo, geen probleem. En de 
mensen van de CCU: als ik met mijn karretje de CCU op kwam rijden, kreeg ik altijd alle hulp. Heel 
hartelijk dank voor alles.
Gemma, Tanja, May en Senta, niet alleen in het begin van mijn onderzoeksperiode maar ook 
afgelopen maanden had ik jullie hulp weer veelvuldig nodig. Nooit nee, nooit gemopper en altijd een 
luisterend oor. Geweldig bedankt.
Stef Mientki en Hennie Giesbers, de technici. De laatste jaren hebben we elkaar nauwelijks 
gesproken maar ten tijde van het bouwen van de meetopstelling en van de metingen zelf stonden 
jullie altijd voor me klaar.
Ton Dofferhoff, beste Ton, opleider interne geneeskunde in het CWZ, ik ben jou en je maten zeer 
dankbaar dat ik regelmatig de ruimte kreeg om me toe te leggen op het schrijven van de stukken en 
daarmee eindelijk het proefschrift af te ronden. En beste collega assistenten, jullie moesten daardoor 
wel een stapje harder lopen, en dat altijd zonder een onvertogen woord. Ook aan jullie ben ik 
derhalve veel dank verschuldigd. 
De cardiologen uit het Radboud, dank voor jullie nimmer aflatende belangstelling voor de 
vorderingen van mijn proefschrift en voor de morele en praktische ondersteuning.
De cardiologen uit het CWZ, ook jullie ben ik zeer erkentelijk voor jullie steun en jullie hulp met 
het afronden van mijn proefschrift.
Beste Pieter en Margriet, mijn schoonouders, mijn broer Matthijs, en mijn schoonzussen 
en zwagers, ruim zeven jaren lang waren jullie vol belangstelling voor de vorderingen van mijn 
proefschrift. Ik ben blij dat we nu samen de afronding ervan kunnen vieren.
Lieve mama en pa, zonder basis geen proefschrift. De basis legden jullie met een liefdevolle 
opvoeding, de mogelijkheid te gaan studeren, en enig aandringen de studie af te maken. Het roert 
me jullie zo trots te zien met de voltooiing van dit proefschrift.
Lieve Wouter en Femke, het is af, papa’s boekje is eindelijk af. Wat hebben jullie papa moeten 
missen, meer dan eens. Zo klein als jullie zijn, jullie steun is puur en prachtig. Dank jullie wel.
Clarette, meisje, wat heb je het met me moeten stellen. Ik was niet altijd even makkelijk, niet voor 
mezelf maar ook niet voor jou, zeker niet wanneer de stress maximaal was. Toch steunde je me altijd 
met enorm veel geduld en trouw. Ik bewonder je daar enorm om. Dit boekje is ook jouw prestatie. 
Ik hou van je!
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De auteur van dit proefschrift werd geboren op 12 februari 1969 in Utrecht. In 1987 behaalde hij 
zijn VWO-diploma aan het Maurick College in Vught. Na uitloting voor de studie geneeskunde, 
studeerde hij een jaar tandheelkunde aan de Katholieke Universiteit Nijmegen om in 1988 aan te 
vangen met de studie geneeskunde aan de Katholieke Universiteit Nijmegen. In 1996 behaalde hij het 
artsexamen. Hij werkte een jaar als arts assistent niet in opleiding op de afdeling cardiologie in het 
Slingeland Ziekenhuis in Doetinchem, alwaar zijn belangstelling voor de cardiologie daadwerkelijk 
gestalte kreeg. Vanaf 1997 werkte hij als arts assistent niet in opleiding op de afdeling cardiologie 
van het UMC St Radboud te Nijmegen (hoofd prof. dr. F.W.A. Verheugt). Vanaf juli 1999 werkte hij 
gedurende drie en half jaar als arts-onderzoeker op de afdeling geriatrie van het UMC St Radboud 
(hoofd prof. dr. W.H.L. Hoefnagels), onder leiding van dr. R.W.M.M. Jansen, aan het project dat de 
basis vormde van dit proefschrift. Op 1 januari 2003 startte hij met de opleiding cardiologie in het 
UMC St Radboud te Nijmegen (opleider prof. dr. F.W.A. Verheugt). Vanaf 2004 was hij twee jaar 
werkzaam als arts in opleiding tot specialist op de afdeling interne geneeskunde van het Canisius 
Wilhelmina Ziekenhuis te Nijmegen (opleider dr. A.S. Dofferhoff). Thans is hij als arts in opleiding tot 
specialist werkzaam op de afdeling cardiologie in het Canisius Wilhelmina Ziekenhuis (opleider dr. 
A.J.M. Oude Ophuis).
In 1998 trouwde hij met Clarette Blaauw en samen hebben zij twee kinderen, Wouter (1999) en 
Femke (2000).

